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ABSTRACT 
 Nitrogen functionality is ubiquitous in biologically active molecules, from naturally 
occurring alkaloids and peptides to synthetic pharmaceuticals. However, due to its promiscuous 
reactivity, nitrogen can be challenging to incorporate into molecules and carry through synthetic 
sequences. Traditional methods to introduce nitrogen (e.g. Mannich, reductive amination) often 
rely on pre-existing functionality and require additional transformations such as oxidation state 
changes and/or protecting group maniuplations. C—H amination represents a powerful 
alternative synthetic strategy. This approach involves the direct functionalization of highly robust 
sp
3
 C—H bonds, which allows for the introduction of nitrogen functionality at late stages in 
synthetic sequences, both obviating the requirement for lengthy functional group manipulation 
strategies and enabling rapid access to a diversity of structures.  
Although small molecule iron and manganese catalysts were first explored for 
metallonitrene-mediated C—H amination reactions, the majority of synthetic advances in the 
field have been with noble metal dirhodium carboxylate catalysts. These catalysts are highly 
reactive and have collectively displayed the ability to efficiently aminate benzylic, ethereal, and 
aliphatic C—H bonds. However, they are poorly chemoselective in the presence of π-
functionality such as olefins and alkynes, and direct addition to these π-bonds is often 
competitive with desired C—H amination reactivity. It is likely that rhodium’s concerted 
asynchronous C—H insertion mechanism, which favors functionalization at more electron-rich 
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sites, is responsible for this lack of chemoselectivity. Conversely, first row transition metal 
catalysts like iron and manganese are thought to react through a stepwise homolytic C—H 
abstraction/rebound mechanism. We hypothesized that this different mechanism would lead to 
orthogonal reactivity under first row transition metal catalysis, including the ability to 
functionalize allylic C—H bonds with high chemoselectivity. In addition, iron and manganese 
are highly abundant and non-toxic base metals that have been relatively unexplored. 
The first chapter of this dissertation describes the development of the first synthetically 
useful C—H amination method under iron catalysis. This reaction, which employs the bulk 
commodity complex [Fe
III
Pc], confirms our initial hypothesis, displaying excellent 
chemoselectivity (generally >20:1 ins./azir.) for allylic C—H amination over a range of olefin 
classes and exhibiting site-selectivity trends that are orthogonal to those observed under rhodium 
catalysis. In addition, this bulky, electrophilic catalyst is able to differentiate between allylic C—
H bonds in polyolefinic substrates on the basis of their electronic and steric nature. Mechanistic 
studies support a stepwise mechanism involving discrete electrophilic intermediates. 
 In seeking to expand the scope of this C—H amination methodology, we were struck by a 
clear divergence in the literature between reactivity and selectivity. Existing catalysts for 
C(sp
3
)—H amination, including our [FeIIIPc] catalyst, are either highly reactive or highly 
selective, but not both. We sought to exploit the exquisite chemoselectivity of first row transition 
metals in order to develop a small molecule C—H amination catalyst that was truly general. The 
second chapter of this dissertation describes the discovery and development of [Mn(
t
BuPc)], a 
novel manganese catalyst that for the first time is able to effectively functionalize all types of sp
3
 
C—H bonds with preparative product yields (>50%) even for very strong 2° and 1° aliphatic C—
H bonds, while maintaining excellent chemoselectivity for C—H amination (>20:1) in the 
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presence of readily oxidizable π-bonds. We conduct mechanistic studies to investigate the often 
drastic reactivity differences between [Mn(
t
BuPc)] and our previous [Fe
III
Pc], finding subtle 
changes in the C—H cleavage step that suggest attenuated radical behavior with manganese 
relative to iron. The generality of this method and versatility of the oxathiazinane C—H 
amination product lend it well for application to the diversification of topologically and 
functionally complex bioactive molecules. This is demonstrated for picrotoxinin and isosteviol 
derivatives, which maintain (or magnify) the reactivity and selectivity trends observed with the 
corresponding simple substructural units.  
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CHAPTER 1: IRON-CATALYZED INTRAMOLECULAR ALLYLIC C–H AMINATION 
 
1.1 Introduction 
C—H bonds have long been considered to be the inert scaffold upon which functional 
group chemistry occurs. Indeed, the vast majority of traditional synthetic methods involve the 
use of pre-existing functional groups to introduce new functionality or to build molecular 
complexity. This type of approach often necessitates introducing functional groups at the early 
stages of chemical synthesis, which results in the need for additional steps such as oxidation state 
changes and/or protecting group sequences, in order to carry sensitive functionality throughout a 
synthesis. Over the last three decades, the development of methods to directly functionalize sp
3
 
and sp
2
 C—H bonds with transition metal catalysts has begun to shift the synthetic paradigm to 
one in which C—H bonds are regarded as functional groups in their own right.1 These catalysts 
Figure 1 Synthetic potential of C—H functionalization. (A) FG-based approach vs. C—H 
functionalization approach. (B) Examples of C—H amination in synthesis. 
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have demonstrated the remarkable ability to selectively cleave C—H bonds and generate C—C,2 
C—N,3 C—O,1c,4 C—B,5 C—Si,6 and C—X7 bonds. These direct functionalization methods 
allow for the introduction of functionality at late stages of synthesis, obviating the need to carry 
sensitive functional groups through multiple manipulations and thereby streamlining synthetic 
efforts.
8
 This powerful alternative synthetic approach has already been demonstrated through 
numerous examples in total synthesis.
9
  
Nitrogen functionality is ubiquitous in both bioactive natural products and synthetic 
pharmaceuticals, but can be difficult to incorporate into molecular frameworks and exhibits 
promiscuous reactivity that makes it challenging to carry through lengthy synthetic sequences. 
For this reason, the development of C—H amination methodology is of particular importance. It 
has long been known that azides can be decomposed thermally or photochemically to generate 
free nitrenes capable of directly functionalizing C—H bonds.10 The harsh reaction conditions and 
inability to control and tune the reactivity of free nitrenes precludes their utility as general 
synthetic methods, but free nitrene reactions have nonetheless been employed as key steps in the 
total synthesis of natural products such as garryine
11
 and (-)-agelastatin.
12
 Early studies by Kwart  
Figure 2 Early reports of C—H amination reactions. 
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and Kahn with copper powder and azides illustrated the ability of transition metals to mediate 
nitrene-based C—H amination reactions (Figure 2).13 In this report, the authors postulate the 
formation of a copper nitrene as the reactive intermediate, although the complex product 
mixtures observed are suggestive of multiple mechanistic pathways being operative. The field of 
metal nitrenoid-based C—H amination was pioneered in the early 1980s by Breslow, who 
demonstrated that the small molecule heme model porphyrin Fe(TPP)Cl could aminate aliphatic 
and benzylic C—H bonds (Figure 2).14 Despite these promising early reports, research was 
largely abandoned in this area and no synthetically useful iron-catalyzed C—H amination 
methods emerged.
15
 
Figure 3 Rhodium catalysts for intramolecular C—H amination. 
 
The majority of synthetic advances over the last decade have been accomplished through 
the use of dirhodium catalysts (Figure 3).
16
 These catalysts, which are thought to react via a 
concerted asynchronous mechanism (Figure 4), display intramolecular reactivity trends that 
indicate preferential C—H amination occurring at electron rich C—H bonds (3o > ethereal ~ 
benzylic > 2
o
  >> 1
o
). Collectively, these catalysts have demonstrated efficiency for the 
functionalization of a variety benzylic, ethereal, and aliphatic C—H bonds.17 However, for 
olefin-containing substrates, alkene aziridination usually competes favorably with allylic C—H 
amination, likely due to the relative electron-rich nature of olefins.
18,19
 Conversely, nitrenoid- 
4 
 
Figure 4 Catalytic cycles for nitrene-based C—H amination reactions. 
 
based catalysis with first-row transition metals such as copper, manganese, and iron is thought to 
proceed via single-electron pathways (Figure 4).
20
 We hypothesized that reactivity trends with 
first-row transition metals should follow homolytic bond dissociation energies (BDEs),
 
similar to 
ruthenium-based catalysis,
21 
making orthogonal C—H amination reactivity possible. Under this 
type of reaction manifold, for example, allylic C—H amination should be strongly preferred over 
aziridination due to both resonance stabilization of an allylic radical (via C—H abstraction) and 
energetically disfavoring formation of an aliphatic 2° radical (via aziridination) (Figure 5). 
Figure 5 Potential reaction pathways for stepwise and concerted metallonitrene transfer 
mechanisms. 
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Development of a general, highly selective allylic C—H amination reaction for internal 
olefins would be particularly significant. Attempts to improve chemoselectivity under rhodium 
catalysis have met with limited success (Figure 6A).
19
 Although ruthenium catalysts have 
exhibited higher chemoselectivity in some cases, they are not generally selective for allylic C—
H amination among all olefin classes (Figure 6B).
22
 Palladium(II) bis-sulfoxide catalysts react 
through a palladium π-allyl intermediate followed by nucleophilic attack. As a result, these types 
of reactions undergo allylic C—H amination with excellent chemoselectivity, but their substrate 
scope is limited to terminal olefins (Figure 6C).
23
 Given the abundance and non-toxicity of 
iron,
24
 its emerging use in homogeneous catalysis,
25,26,27
 and the potential for orthogonal 
reactivity, we sought to develop the first synthetically useful C—H amination reaction under iron 
catalysis. 
Figure 6 Chemoselectivity in intramolecular allylic C—H amination reactions. (A) Rhodium-
catalyzed nitrene insertions.
18
 (B) Ruthenium-catalyzed nitrene insertions.
22c
 (C) Palladium-
catalyzed π-allyl functionalizations.23b 
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1.2 Results and Discussion 
1.2.1 Reaction Development 
In initial reaction development, several different ligand classes that have been previously 
shown to support high valent iron oxidants were tested for their ability to catalyze the desired 
transformation (Table 1). The non-heme Fe(PDP) catalyst previously developed by our lab for 
aliphatic C—H hydroxylations26e-h was able to effect C—H amination but the yields were poor 
(entry 1). The heme iron catalyst Fe(TPP)Cl, which was employed in early studies on C—H 
amination, exhibited improved reactivity in this case (entry 2). Interestingly, the iron complex of 
salen, known to be an effective heme ligand mimic for epoxidations, showed no reactivity (entry 
3).
28
 The iron phthalocyanine complex [FePc]Cl, which is a bulk commercial chemical that is 
typically used as a printing additive or vulcanizing agent, was superior to Fe(TPP)Cl in terms of 
reactivity (entry 4). This subtle effect is likely due to the increased electron-withdrawing nature 
of phthalocyanine ligands relative to their porphyrin counterparts, resulting in a more 
Table 1 Reaction optimization. 
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electrophilic metal center.
29
 Notably, for all iron complexes examined that exhibited reactivity, 
excellent chemoselectivities (>20:1 ins./azir.) were observed. 
Optimization of the reaction conditions significantly improved reactivity with [Fe
III
Pc], 
resulting in synthetically useful yields of product. Non-coordinating silver salts (AgPF6, AgOTf, 
AgSbF6) showed an increase in reactivity, presumably by generating a cationic iron complex; 
AgSbF6 provided the most consistent results. Use of a mixed solvent system (entry 6) and 
switching to the more soluble PhI(OPiv)2 oxidant (entry 7) both led to a significant improvement 
in overall reactivity. Under the optimized conditions, 68% yield of allylic functionalized product 
was isolated with excellent chemoselectivity (>20:1 ins./azir.). A silver-free catalyst system may 
be particularly beneficial in large-scale applications where cost and procedural simplicity are key 
considerations. Removing the silver salt from the reaction under the optimized conditions led to 
a minor reduction in reactivity (entry 8). Simply increasing the catalyst loading at the beginning 
of the reaction is not beneficial for poorly converting substrates, but iterative addition of a solid 
mixture of [FePc]Cl and AgSbF6 (3-4 x 3.3 mol%) at 2h intervals does confer a slight 
improvement in reactivity (vide infra). 
Figure 7 Tethers explored for reactivity. 
 
 
During the course of reaction discovery, a variety of tethers were explored for the 
generation of amino alcohol derivatives via allylic C—H amination (Figure 7). Interestingly, the 
sulfamate tether appears to be uniquely effective for this transformation under iron catalysis. A 
phosphoramidate tether afforded only aziridination product for all iron complexes that were 
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explored, and yields were modest. Computational studies have suggested that more electron-rich 
nitrene sources tend to favor aziridination,
20c
 and so attempts were made to substitute the 
phosphorous with more electron-poor amine groups, but these synthetic efforts were 
unsuccessful. This tether has the additional disadvantage of forming diastereomers even for 
substrates that lack biasing groups adjacent to the tether, potentially resulting in complex product 
mixtures. Additionally, carbamate tethers have been shown to be effective for rhodium-catalyzed 
C—H amination reactions.30 However, under iron catalysis, these tethers are unreactive for the 
formation of either five- or six-membered rings, and starting material is fully recovered under 
these conditions. 
 
1.2.2 Reaction Scope 
With optimized reaction conditions in hand, we explored the scope of the reaction (Table 
2). Notably, this iron-catalyzed reaction displays the highest chemoselectivities reported to date 
for metallonitrene-mediated C—H aminations, with strong selectivity for allylic amination 
products with a broad range of olefin classes, such as aliphatic E-olefins, styrenyl, trisubstituted, 
terminal, cyclic olefins, α,β-unsaturated esters, and allylic acetates. The allylic amines in all of 
these cases were obtained in good yields and useful diastereoselectivities. Substitution on the 
sulfamate ester is typically required for reactivity in this system, but branching groups restore 
useful reactivity in the absence of such substitution (3, 53%). Electron-withdrawing functionality 
adjacent to the sulfamate tether is well tolerated, affording the allylic amines in good yields (7, 
61% and 8, 69%). Although the sulfamate ester tether prefers formation of six-membered 
sulfamidates, cyclic olefins in which the sulfamate ester is in the homoallylic position are still 
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viable substrates. For example, the sulfamate ester derivative of β-cholesterol affords the 1,2-
difunctionalized product 6 in 58% yield as a single diastereomer. 
Table 2 Olefin scope. 
 
In particular, the tolerance of terminal olefins is quite notable. This class of olefins is the 
most challenging for nitrene-based C—H aminations, presumably due to the lack of steric 
hindrance for addition across the olefin. Rhodium catalysts exhibit especially poor 
chemoselectivity for these types of substrates even when the olefin is positioned remotely,
18
 and 
ruthenium catalysts, which have demonstrated good chemoselectivity for several olefin classes, 
are still poorly selective for allylic C—H amination of terminal olefin substrates.22c In stark 
contrast to this precedent, high selectivities are achieved for allylic C—H amination product 5 
over aziridination (12:1 ins./azir.) under iron catalysis. Importantly, high chemoselectivity is 
observed even without the bias of the tethered nitrene source in the intramolecular reaction 
10 
 
(Figure 8). When a trisubstituted linear olefin is subjected to intermolecular C—H amination 
with [Fe
III
Pc], allylic amines 9 are isolated exclusively (>20:1 ins./azir.), albeit as a mixture of 
constitutional isomers. Conversely, only aziridination is observed with this substrate under 
rhodium catalysis. 
Figure 8 Intermolecular allylic C—H amination. 
 
[Fe
III
Pc] is also a competent catalyst for other types of C—H bonds (Table 3). For 
example, a secondary sulfamate substrate undergoes efficient benzylic C—H amination to afford 
10 with excellent diastereoselectivity (17:1 syn:anti). Functionalization to form five-membered 
rings occurs smoothly for benzylic C—H bonds, as with the Taxol side-chain model substrate 11, 
albeit with poor diastereoselectivity favoring the epimer of the natural side chain (1:3 syn:anti).  
Table 3 Amination of other C—H bond types. 
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[Fe
III
Pc] catalyzes 3° aliphatic C—H aminations as well, although yields are reduced for these 
more challenging C—H bonds. However, it is significant to note that aliphatic C—H amination 
of a substrate containing a stereochemically defined 3° C—H center proceeds with no loss of 
chiral information, regardless of the relative configuration of the sulfamate tether with the 3° 
C—H bond (12). 
 
1.2.3 Site-Selectivity in C—H Aminations 
Given the large chemoselectivity differences between iron and rhodium, we sought to 
systematically compare these two catalysts through a series of intramolecular competition 
experiments (Table 4). Other studies have employed intramolecular C—H bond competition 
studies to establish reactivity trends for rhodium,
18
 ruthenium,
22c
 and silver
31
 catalysis, although 
a systematic analysis with allylic C—H bonds and a direct comparison of different metals was  
Table 4 Orthogonal reactivity in allylic C—H amination. 
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lacking.  Specifically, we compared amination reactivity toward an allylic C—H bond (β) versus 
another energetically distinct type of C—H bond (β’), including benzylic, ethereal, 3° 
aliphatic,and 2° aliphatic C—H bonds. In all cases, the competing olefin aziridination pathway is 
strongly suppressed in the [Fe
III
Pc]-catalyzed reaction relative to Rh2(OAc)4. The reactivity 
trends also clearly indicate that the preference for allylic C—H amination over functionalization 
of other types of C—H bonds is more pronounced with [FeIIIPc], with synthetically useful 
selectivities obtained under these conditions. In addition, examination of the reactivity trends 
reveals distinct orthogonality between iron and rhodium. For example, allylic C—H amination is 
exclusively preferred over aliphatic 3
o
 C—H amination (β/β’ >20:1, 14). In contrast, rhodium 
nitrenes show essentially no preference for allylic versus 3° C—H bond insertion (β/β’ = 1.3:1). 
Ruthenium
22c
 (β/β’ = 5:1) and silver31 (β/β’ = 4:1) nitrenes are also reported to have a much 
lower preference. Moreover, while iron nitrenes demonstrate synthetically useful levels of 
selectivity for allylic versus ethereal (β/β’ = 7:1, 15) and benzylic (β/β’ = 5:1, 16) C—H bond 
aminations, rhodium nitrenes are less selective for allylic C—H amination in the presence of 
these C—H bonds (ethereal: β/β’ = 4:1, benzylic: β/β’ = 2:1). Overall, the following reactivity 
trend is observed for the iron-catalyzed C—H amination: allylic > benzylic > ethereal > 3° > 2° 
>> 1° (Figure 9). Notably, this trend is different from that observed with rhodium and is in  
Figure 9 C—H bond reactivity trends. 
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agreement with the C—H bond dissociation energies (BDE), with the bond having the lowest 
BDE being the most reactive.
32
 The rhodium-catalyzed C—H amination follows the trend: allylic 
~ 3° > benzylic >ethereal > 2° >> 1°, with reactivity that favors more electron-rich sites and is 
consistent with a mechanism involving an electrophilic transition state in the C—H insertion 
step. 
  We have observed that this catalyst displays sensitivity to the electronic character of the 
reacting allylic C—H bond (Table 5). For example, substrates with electron poor olefins, such as 
α,β-unsaturated esters 17 and allylic acetates 18, showed substantially reduced reactivity relative 
to their electron-neutral counterparts (39% yield and 47% yield, respectively). Our group has 
systematically investigated site-selectivity trends for Fe(PDP)-catalyzed aliphatic C—H 
hydroxylations, finding that the bulky, electrophilic Fe(PDP)-oxo is capable of exploiting subtle 
differences in the steric or electronic environment of C—H bonds in molecules, with the more  
Table 5 Site-selectivity in polyolefinic compounds. 
 
14 
 
electron-rich and sterically accessible sites being preferentially hydroxylated.
26e-g,33
 Based on this 
precendent and the above results, we hypothesized that allylic C—H bonds in polyolefin 
compounds could be similarly differentiated and selectively functionalized by the bulky iron 
nitrene oxidant on the basis of the electronic and steric character of the adjacent olefin. 
Consistent with this, the more electron rich allylic C—H bond of polyolefin-containing substrate 
19 was selectively functionalized to afford mono-aminated product in a preparatively useful 
yield (β/β’ = 14:1, 55%). Similarly, the less sterically hindered allylic C—H bond of a citral-
derived substrate 20 was functionalized with useful selectivity (β/β’ = 7:1, entry 14), affording 
product in good yield (53%). These results suggest that the so-called selectivity “rules” may be 
general with regard to substrate preferences in C—H oxidation reactions. 
 
1.2.4 Mechanistic Studies 
  Based on the notable orthogonality in reactivity between iron and rhodium, we sought to 
investigate the origin of these reactivity differences by confirming that [Fe
III
Pc] indeed reacts via 
a different mechanism than Rh2(OAc)4 (Figure 10). We first determined the effect of deuterium 
substitution on the rate of benzylic C—H amination (Figure 10A). The measured kinetic isotope  
Figure 10 Mechanistic studies. (A) Intramolecular KIE experiment. (B) Z-olefin isomerization. 
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effect (KIE) of 2.5±0.2 for the C—H amination of 21 under iron-based catalysis is higher and 
statistically different from that measured for the same substrate under rhodium-based catalysis 
(kH/kD = 1.8±0.2). However, this value is much lower than what has previously been measured 
for C—H amination mechanism (kH/kD = 5-12). More recently, we and others
22c
 have discovered 
flaws in the 
13
C NMR method employed to obtain these values, and revised values using more 
accurate experimental parameters are more consistent with those expected for first row transition 
metal catalysts (see Section 2.2.4). Due to the ambiguity of the KIE value and the observed 
stereoretention in amination of tertiary C—H centers, we performed an additional study on Z-
olefins to determine if scrambling of the double bond geometry occurs during allylic C—H 
amination (Figure 10B). When sulfamate ester 23 (>20:1 Z/E) was subjected to [Fe
III
Pc]-
catalyzed C—H amination, the allylic-functionalized product 24 was obtained as a 9:1 Z/E 
mixture, likely through the intermediacy of a resonance-stabilized carbon-centered radical. 
Importantly, recovered starting material under these conditions showed no erosion of olefin 
stereochemistry (>20:1 Z/E), and no isomerization was observed under Rh2(OAc)4 catalysis, 
suggesting that isomerization occurs on the reaction pathway through the intermediacy of a 
stabilized radical. These results are indicative of different mechanisms for functionalization 
between iron and rhodium catalyzed C—H amination reactions. 
 
1.3 Conclusions 
We have developed the first highly selective and synthetically viable C—H amination 
under iron catalysis.
34
 In addition to using a highly economical and non-toxic metal source, 
[Fe
III
Pc]-catalyzed intramolecular C—H amination is effective for the amination of allylic C—H 
bonds across a range of olefin classes. Allylic C—H amination is strongly preferred over 
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aziridination as well as over amination of stronger C—H bonds (i.e. 3o and 2o aliphatic, ethereal, 
or benzylic), and these reactivity trends are highly complementary to those observed under 
rhodium catalysis. Additionally, allylic C—H amination with this electrophilic, bulky oxidant 
occurs selectively at the most electron rich, least sterically hindered site in polyolefinic 
substrates. Since our initial publication of this chemistry, other groups have further demonstrated 
the ability of iron complexes to catalyze the intramolecular C—H amination of activated C—H 
bonds (Figure 11), and we anticipate the continued synthetic development of this methodology.
35
 
Figure 11 Recent reports of Fe-catalyzed C—H amination reactions. 
 
 
 
1.4 Experimental Information 
General Information: The following commercially obtained reagents for the C—H amination 
were used as received: iron(III) phthalocyanine chloride ([FePc]Cl, Sigma-Aldrich), 5,10,15,20-
Tetraphenyl-21H,23H-porphine iron(III) chloride (Fe(TPP)Cl, Strem), silver 
hexafluoroantimonate (AgSbF6, Strem), (diacetoxyiodo)benzene (PhI(OAc)2, Sigma-Aldrich), 
bis(tert-butylcarbonyloxy)iodobenzene (PhI(OPiv)2, Sigma-Aldrich), and rhodium(II) acetate 
dimer (Rh2(OAc)4, Sigma-Aldrich). All starting materials for the sulfamate ester formation were 
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either commercially available or synthesized according to literature procedures (see end of 
Supporting Information for synthetic sequences and references). All reactions were run in flame- 
or oven-dried glassware under an atmosphere of N2 or Ar gas with dry solvents unless otherwise 
stated. All products were filtered through a glass wool plug prior to obtaining a final weight. 
Solid reagents were stored in a dessicator or glovebox, and anhydrous solvents were purified by 
passage through a bed of activated alumina immediately prior to use (Glass Countour, Laguna 
Beach, California). Deuterochloroform was stored over 3Å molecular sieves in a secondary 
container with drierite. Fe(R,R-PDP)(SbF6)2 and Fe(R,R-salen)Cl were prepared according to 
methods described in the literature
26e,36
 and stored at 4
o
C. Chlorosulfonyl isocyanate 
(ClSO2NCO, Sigma-Aldrich or TCI America) was transferred to a Schlenk-type flask and stored 
at 4
o
C under an inert atmosphere.
37
 Thin-layer chromatography (TLC) was conducted with E. 
Merck silica gel 60 F254 pre-coated plates (0.25 mm) and visualized with UV and ethanolic 
anisaldehyde or potassium permanganate stains. Flash chromatography was performed as 
described by Still
38
 using American International ZEOprep 60 ECO silica gel (230-400 mesh). 
Achiral gas chromatographic (GC) analysis was performed on an Agilent 6890N Series 
instrument equipped with FID detectors using a HP-5 (5%-Phenyl)-methylpolysiloxane column 
(30m, 0.32mm, 0.25mm).  
1
H-NMR spectra were recorded on a Varian Inova-500 (500 MHz) or Varian Unity-500 
(500 MHz) spectrometer and are reported in ppm using solvent as an internal standard (CDCl3 at 
7.26 ppm). Data reported as: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sxt = 
sextet, spt = septet, m = multiplet, br = broad, app = apparent; coupling constant(s) in Hz; 
integration. Proton-decoupled 
13
C-NMR spectra were recorded on a Varian Unity-500 (125 
MHz) spectrometer and are reported in ppm using solvent as an internal standard (CDCl3 at 
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77.16 ppm). Diastereoselectivity and product selectivity ratios for the intramolecular allylic C—
H amination reaction were determined by 
1
H-NMR analysis of the crude product mixture when 
possible. IR spectra were recorded as thin films on NaCl plates on a Mattson Galaxy Series FTIR 
5000 and are reported in frequency of absorption (cm
-1
). Optical rotations were measured using a 
1 mL cell with a 50 mm path length on a Jasco P-1020 polarimeter. Optical rotations were 
obtained with a sodium lamp and are reported as follows: [α]λT
o
C (c = g/100 mL, solvent). High-
resolution mass spectra were obtained at the University of Illinois Mass Spectrometry 
Laboratory. Electrospray ionization (ESI) spectra were performed on a Waters Q-Tof Ultima 
spectrometer, and electron ionization (EI) and field desorption (FD) spectra were performed on a 
Micromass 70-VSE spectrometer.  
 
Preparation of Sulfamate Ester Starting Materials 
General procedure for preparation of sulfamate ester substrates
17a
 
Method A: 
Preparation of ClSO2NH2 solution (2M in MeCN): A 25 mL round-bottom flask equipped with 
stir bar and rubber septum was charged with ClSO2NCO (653 μL, 7.50 mmol, 1.5 equiv). The 
flask was cooled to 0
oC, and then neat formic acid (283 μL, 7.50 mmol, 1.5 equiv) was added 
dropwise. After vigorously stirring for 5 min at 0
o
C, MeCN (3.8 mL, 2M) was added, and the 
reaction stirred vigorously at 0
o
C (1 h) then room temp (~20
o
C) overnight.  
Sulfamate ester formation: A 50 mL round-bottom flask equipped with stir bar and rubber 
septum was charged with 95% NaH (139 mg, 5.50 mmol, 1.1 equiv) and 5 mL DMF and cooled 
to 0
o
C. The alcohol starting material (5.00 mmol, 1.0 equiv) in 4 mL DMF was slowly added. 
The reaction was stirred at room temp. for 1 h, after which it was cooled again to 0
o
C. The 
19 
 
freshly prepared 2M MeCN solution of ClSO2NH2 (vide supra) was then added dropwise via 
syringe, and the reaction stirred at room temp. for 2-4 h. Upon complete consumption of starting 
material as monitored by TLC, the reaction was quenched with H2O until the mixture turned 
clear (~8 mL). The reaction mixture was partitioned between 15 mL H2O and 60 mL Et2O and 
separated. The aqueous layer was then extracted with 2x30 mL Et2O. The organic layers were 
combined, dried over MgSO4 and concentrated under reduced pressure. Following purification of 
the crude product via flash column chromatography, the pure product was dissolved in CH2Cl2 
and filtered through a short silica plug, then twice dissolved in benzene and concentrated under 
reduced pressure to remove trace H2O, then stored in a dessicator until use. 
Method B: 
A 50 mL round-bottom flask equipped with stir bar and rubber septum was charged with 
ClSO2NCO (653 μL, 7.50 mmol, 1.5 equiv). The flask was cooled to 0
o
C, and then neat formic 
acid (283 μL, 7.50 mmol, 1.5 equiv) was added dropwise. After vigorously stirring for 5 min at 
0
o
C, CH2Cl2 (3.8 mL, 2M) was added, and the reaction stirred vigorously at 0
o
C (1 h) then room 
temp. overnight. After cooling the reaction flask back to 0
o
C, the alcohol starting material (5.00 
mmol, 1.0 equiv) with Et3N (1.05 mL, 7.50 mmol, 1.5 equiv) in 7 mL CH2Cl2 was slowly added 
via syringe. After complete addition, the reaction warmed back to room temp. and stirred for 4-6 
h. If conversion is low after 3-4 h, additional Et3N (1-2 equiv) can be added. Upon complete 
consumption of starting material as monitored by TLC, the reaction was quenched with H2O 
until the mixture turned clear (~8 mL). The reaction mixture was partitioned between 15 mL 
H2O and 30 mL CH2Cl2 and separated. The aqueous layer was then extracted with 2x30 mL 
CH2Cl2. The organic layers were combined, dried over MgSO4 and concentrated under reduced 
pressure. Following purification of the crude product via flash column chromatography, the pure 
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product was dissolved in CH2Cl2 and filtered through a short silica plug, then twice dissolved in 
benzene and concentrated under reduced pressure to remove trace H2O, then stored in a 
dessicator until use. 
 
(±)-(E)-1-phenylnon-7-en-4-yl sulfamate (Table 1).  
Prepared according to method A. 1.092 g (5.00 mmol) of (±)-(E)-1-
phenylnon-7-en-4-ol were used. Flash column chromatography on silica 
(35 mm fritted glass column, 150 mm SiO2) using 3:1 hexanes:EtOAc as eluent gave 1.264 g 
(4.25 mmol) of pure product as a colorless oil (>20:1 E:Z, 85% yield). 
1
H-NMR (500 MHz, 
CDCl3) δ 7.30-7.26 (m, 2H), 7.21-7.17 (m, 3H), 5.44 (dq, J = 15.5, 6.0 Hz, 1H), 5.39 (dt, J = 
15.0, 6.0 Hz, 1H), 4.61 (br. s, 3H), 2.65-2.64 (m, 2H), 2.07-2.05 (m, 2H), 1.80-1.70 (m, 6H), 
1.64 (d, J = 6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 141.9, 129.8, 128.6 (2 peaks), 126.2, 
126.1, 84.7, 35.6, 33.9, 33.5, 28.1, 26.5, 18.0; IR (film, cm
-1
) 3381, 3284, 3026, 2933, 2856, 
1554, 1496, 1452, 1358, 1180, 914; HRMS (ESI) m/z calculated for C15H23NO3SNa [M+Na]
+
: 
320.1296, found 320.1299. 
 
(±)-(E)-6-phenylhex-5-en-2-yl sulfamate (Table 2).  
Prepared according to method A. 881 mg (5.00 mmol) of (±)-(E)-6-phenylhex-
5-en-2-ol
39
 were used. Flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using 2:1 hexanes:EtOAc as eluent gave 919 mg (3.60 mmol) of 
pure product as a white solid (>20:1 E:Z, 72% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.35-7.28 
(m, 4H), 7.23-7.20 (m, 1H), 6.43 (d, J = 15.5 Hz, 1H), 6.19 (dt, J = 15.5, 7.0 Hz, 1H), 4.80-1.73 
(m, 1H), 4.64 (br. s, 2H), 2.37-2.33 (m, 2H), 1.97-1.90 (m, 1H), 1.82-1.76 (m, 1H), 1.47 (d, J = 
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6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 137.5, 131.1, 129.1, 128.7, 127.3, 126.2, 81.1, 36.2, 
28.7, 20.8; IR (film, cm
-1
) 3383, 3292, 3026, 2980, 2937, 1554, 1446, 1361, 1182, 922; HRMS 
(ESI) m/z calculated for C12H17NO3SNa [M+Na]
+
: 278.0827, found 278.0837. 
 
(±)-6-methylhept-5-en-2-yl sulfamate (Table 2).  
Prepared according to method A. 641 mg (5.00 mmol) of (±)-6-methylhept-5-en-2-
ol were used. Flash column chromatography on silica (35 mm fritted glass column, 
150 mm SiO2) using 4:1 hexanes:EtOAc as eluent gave 800 mg (3.86 mmol) of pure product as a 
colorless oil (77% yield). 
1
H-NMR (500 MHz, CDCl3) δ 5.10-5.07 (m, 1H), 4.80 (br. s, 2H), 4.70 
(app sxt, J = 6.5 Hz, 1H), 2.15-2.03 (m, 2H), 1.77 (ddt, J = 14.0, 9.0, 6.5 Hz, 1H), 1.69 (s, 3H), 
1.66-1.59 (m, 1H), 1.61 (s, 3H), 1.43 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 132.9, 
123.0, 81.5, 36.6, 25.8, 23.8, 20.7, 17.9; IR (film, cm
-1
) 3379, 3288, 2972, 2929, 2858, 1562, 
1450, 1358, 1182, 1126 924; HRMS (ESI) m/z calculated for C8H17NO3SNa [M+Na]
+
: 230.0827, 
found 230.0828. 
 
(±)-2-methylhept-6-en-3-yl sulfamate (Table 2).  
Prepared according to method A. 641 mg (5.00 mmol) of (±)-2-methylhept-6-en-3-
ol were used. Flash column chromatography on silica (35 mm fritted glass column, 
150 mm SiO2) using 3:1 hexanes:EtOAc as eluent gave 674 mg (3.25 mmol) of pure product as a 
colorless oil (65% yield). 
1
H-NMR (500 MHz, CDCl3) δ 5.81 (ddt, J = 16.5, 10.0, 6.0 Hz, 1H), 
5.07 (dd, J = 17.5, 1.5 Hz, 1H), 5.01 (dd, J = 10.5, 1.5 Hz, 1H), 4.75 (br. s, 2H), 4.47 (dt, J = 7.5, 
4.5 Hz, 1H), 2.24-2.09 (m, 3H), 1.86-1.71 (m, 2H), 0.99 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 6.5 Hz, 
3H); 
13
C-NMR (125 MHz, CDCl3) δ 137.6, 115.6, 89.4, 31.1, 29.6, 29.5, 17.7 (2 peaks); IR 
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(film, cm
-1
) 3381, 3288, 2968, 2879, 1641, 1556, 1468, 1363, 1182, 918; HRMS (ESI) m/z 
calculated for C8H17NO3SNa [M+Na]
+
: 230.0827, found 230.0826. 
 
(-)-3β-cholest-5-enyl sulfamate (Table 2).  
Prepared according to method A. 1.934 g (5.00 mmol) of 3β-
hydroxycholesterol were used. Due to its insolubility in DMF, 
cholesterol was dissolved in CHCl3 (4 mL) instead prior to addition to 
NaH solution; the general procedure was otherwise exactly followed. 
Flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 9:1 
hexanes:EtOAc as eluent followed by recrystallization from ether (in place of the normal silica 
plug filtration) gave 1.514 g (3.25 mmol) of pure product as a white solid (65% yield). 
1
H-NMR 
(500 MHz, CDCl3) δ 5.42 (app. d, J = 5.0 Hz, 1H), 4.64 (br. s, 1H), 4.45 (dddd, J = 11.5, 11.5, 
11.0, 11.0 Hz, 1H), 2.57-2.52 (m, 2H), 2.10-2.07 (m, 1H), 2.04-1.96 (m, 2H) 1.90 (dt, J = 13.5, 
3.8 Hz, 1H), 1.87-1.74 (m, 2H), 1.60-1.43 (m, 7H), 1.38-1.31 (m, 3H), 1.27-1.25 (m, 1H), 1.18-
1.05 (m, 7H), 1.05 (s, 3H), 1.01-0.93 (m, 2H), 0.92 (d, J = 6.5 Hz, 3H), 0.87 (dd, J = 6.5, 2.5 Hz, 
6H), 0.68 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 139.0, 123.8, 83.5, 56.8, 56.3, 50.2, 42.5, 39.9, 
39.7, 38.9, 37.1, 36.6, 36.3, 35.9, 32.1, 32.0, 28.7, 28.4, 28.2, 24.4, 24.0, 23.0, 22.7, 21.2, 19.4, 
18.9, 12.0; IR (film, cm
-1
) 3373, 3273, 2951, 2883, 1545, 1468, 1350, 1196, 1163, 980, 958, 928; 
[α]25D = -36.7
o
 (c = 1.2, CHCl3); HRMS (CI) m/z calculated for C27H47NO3SNa [M+Na]
+
: 
488.3174, found 488.3184. 
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(±)-(E)-3-(sulfamoyloxy)oct-6-en-1-yl acetate (Table 2).  
Prepared according to method B. 931 mg (5.00 mmol) of (±)-(E)-3-
hydroxyoct-6-en-1-yl acetate were used. Flash column chromatography on 
silica (35 mm fritted glass column, 150 mm SiO2) using 3:1 hexanes:EtOAc as eluent gave 703 
mg (2.65 mmol) of pure product as a colorless oil (53% yield). 
1
H-NMR (500 MHz, CDCl3) δ 
5.47 (dq, J = 15.0, 6.0 Hz, 1H), 5.39 (ddt, J = 15.0, 6.5, 1.5 Hz, 1H), 5.03 (br. s, 2H), 4.71-4.66 
(m, 1H), 4.34-4.29 (m, 1H), 4.15-4.10 (m, 1H), 2.12-1.95 (m, 4H), 2.07 (s, 3H), 1.89-1.82 (m, 
1H), 1.79-1.71 (m, 1H), 1.64 (dd, J = 6.5, 1.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 171.6, 
129.5, 126.4, 81.2, 60.3, 34.4, 33.1, 27.9, 21.1, 18.1; IR (film, cm
-1
) 3346, 3269, 3116, 3024, 
2962, 2937, 2856, 1724, 1564, 1450, 1369, 1257, 1182, 1045, 968, 928, 739; HRMS (ESI) m/z 
calculated for C10H19NO5SNa [M+Na]
+
: 288.0882, found 288.0885. 
 
(±)-(E)-ethyl 3-(sulfamoyloxy)oct-6-enoate (Table 2).  
Prepared according to method B. 931 mg (5.00 mmol) of (±)-(E)-ethyl 3-
hydroxyoct-6-enoate were used. Flash column chromatography on silica (35 
mm fritted glass column, 150 mm SiO2) using 2:1 hexanes:EtOAc as eluent gave 796 mg (3.00 
mmol) of pure product as a colorless oil (60% yield). 
1
H-NMR (500 MHz, CDCl3) δ 5.48 (dq, J 
= 15.0, 6.5 Hz, 1H), 5.39 (ddt, J = 15.5, 6.0, 1.0 Hz, 1H), 5.02 (br. s, 2H), 4.98-4.93 (m, 1H), 
4.16 (q, J = 7.0 Hz, 2H), 2.80 (dd, J = 17.0, 8.0 Hz, 1H), 2.63 (dd, J = 17.0, 4.5 Hz, 1H), 2.10 
(app q, J = 7.5 Hz, 2H), 1.86 (app dq, J = 14.8, 7.0 Hz, 1H), 1.80-1.73 (m, 1H), 1.64 (dd, J = 6.0, 
1.5 Hz, 3H), 1.74 (t, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 171.2, 129.3, 126.5, 79.7, 
61.4, 39.2, 34.7, 27.9, 18.0, 14.2; IR (film, cm
-1
) 3367, 3280, 3114, 2981, 2939, 2858, 1724, 
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1562, 1448, 1369, 1321, 1188, 1028, 968, 930, 777; HRMS (ESI) m/z calculated for C10H20NO5S 
[M+H]
+
: 266.1062, found 266.1062. 
 
(±)-1-phenyl-4-methylpentan-3-yl sulfamate (Table 3).  
Prepared according to method A. 891 mg (5.00 mmol) of (±)-1-phenyl-5-
methylpentan-3-ol were used. Flash column chromatography on silica (35 mm 
fritted glass column, 150 mm SiO2) using 3:1 hexanes:EtOAc as eluent gave 901 mg (3.50 
mmol) of pure product as a colorless oil (70% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.30 (t, J = 
7.5 Hz, 2H), 7.22-7.19 (m, 3H), 4.73 (br. s, 2H), 4.50 (dt, J = 7.5, 4.5 Hz, 1H), 2.83-2.77 (m, 
1H), 2.74-2.68 (m, 1H), 2.20-2.13 (m, 1H), 2.07-1.94 (m, 2H), 1.00 (d, J = 6.5 Hz, 3H), 0.97 (d, 
J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 141.4, 128.7, 128.5, 126.2, 89.4, 32.0, 31.7, 
31.2, 17.9, 17.5; IR (film, cm
-1
) 3388, 3284, 3087, 3064, 3028, 2966, 2937, 2877, 1603, 1554, 
1496, 1454, 1360, 1182, 922; HRMS (ESI) m/z calculated for C12H19NO3SNa [M+Na]
+
: 
280.0983, found 280.0985. 
 
(-)-(4R, 6R)-6,10-dimethylundecan-4-yl sulfamate (Table 3).  
Prepared according to method A. 777 mg (3.92 mmol) of a 97:3 anti:syn  
mixture of (-)-(4R, 6R)-6,10-dimethylundecan-4-ol 25 were used, along 
with NaH (109 mg, 4.31 mmol, 1.1 equiv), DMF (4 + 3 mL), ClSO2NCO (511 μL, 5.88 mmol, 
1.5 equiv), formic acid (222 μL, 5.88 mmol, 1.5 equiv) and MeCN (3 mL). Flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 9:1 hexanes:EtOAc 
as eluent gave 771 mg (2.76 mmol) of pure product as a colorless oil (70% yield). 
1
H-NMR (500 
MHz, CDCl3) δ 4.73-4.68 (m, 3H), 1.78-1.67 (m, 3H), 1.62-1.60 (m, 1H), 1.54-1.49 (m, 1H), 
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1.45-1.40 (m, 2H), 1.38-1.30 (m, 2H), 1.29-1.21 (m, 2H), 1.16-1.11 (m, 3H), 0.95 (t, J = 7.3 Hz, 
3H), 0.93 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.5 Hz, 6H); 
13
C-NMR (125 MHz, CDCl3) δ 84.1, 
41.8, 39.4, 37.6, 37.1, 29.2, 28.1, 24.7, 22.8, 22.7, 19.7, 18.3, 14.1; IR (film, cm
-1
) 3369, 3284, 
2956, 2929, 2873, 1556, 1466, 1360, 1184, 920; [α]27D = -11.0
o
 (c = 1.0, CHCl3); HRMS (ESI) 
m/z calculated for C13H29NO3SNa [M+Na]
+
: 302.1766, found 302.1768. 
 
(-)-(4R, 6S)-6,10-dimethylundecan-4-yl sulfamate (Table 3).  
Prepared according to method A. 770 mg (3.88 mmol) of a 5:95 anti:syn  
mixture of (-)-(4R, 6S)-6,10-dimethylundecan-4-ol 25 were used, along 
with NaH (108 mg, 4.27 mmol, 1.1 equiv), DMF (4 + 3 mL), ClSO2NCO (507 μL, 5.82 mmol, 
1.5 equiv), formic acid (220 μL, 5.82 mmol, 1.5 equiv) and MeCN (3 mL). Flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 9:1 hexanes:EtOAc 
as eluent gave 642 mg (2.30 mmol) of pure product as a colorless oil (60% yield). 
1
H-NMR (500 
MHz, CDCl3) δ 4.72-4.67 (m, 3H), 1.74-1.65 (m, 2H), 1.64-1.59 (m, 2H), 1.58-1.39 (m, 4H), 
1.38-1.20 (m, 3H), 1.18-1.07 (m, 3H), 0.95 (t, J = 7.5 Hz, 3H), 0.91 (d, J = 6.5 Hz, 3H), 0.87 (d, 
J = 6.5 Hz, 6H); 
13
C-NMR (125 MHz, CDCl3) δ 84.3, 41.7, 39.3, 37.3, 36.4, 29.5, 28.1, 24.6, 
22.8, 22.8, 22.7, 19.9, 18.1, 14.1; IR (film, cm
-1
) 3371, 3290, 2956, 2929, 2873, 1466, 1363, 
1184, 922; [α]27D = -7.4
o
 (c = 1.0, CHCl3); HRMS (ESI) m/z calculated for C13H29NO3SNa 
[M+Na]
+
: 302.1766, found 302.1772. 
 
(±)-(E)-dec-8-en-5-yl sulfamate (Table 4, entries 1-2).  
Prepared according to method A. 781 mg (5.00 mmol) of (±)-(E)-dec-8-en-5-
ol were used. Flash column chromatography on silica (35 mm fritted glass 
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column, 150 mm SiO2) using 4:1 hexanes:EtOAc as eluent gave 941 mg (4.00 mmol) of pure 
product as a colorless oil (>20:1 E:Z, 80% yield). 
1
H-NMR (500 MHz, CDCl3) δ 5.49 (dq, J = 
15.5, 6.0 Hz, 1H), 5.41 (dt, J = 15.0, 6.5 Hz, 1H), 4.74 (br. s, 2H), 4.62 (p, J = 6.0 Hz, 1H), 2.11-
2.09 (m, 2H), 1.84-1.71 (m, 4H), 1.66 (d, J = 6.0 Hz, 3H), 1.41-1.32 (m, 4H), 0.92 (t, J = 7.0 Hz, 
3H); 
13
C-NMR (125 MHz, CDCl3) δ 130.0, 126.1, 85.2, 34.0, 33.8, 28.1, 27.0, 22.7, 18.0, 14.1; 
IR (film, cm
-1
) 3363, 3292, 2958, 2862, 1556, 1452, 1365, 1182, 916; HRMS (ESI) m/z 
calculated for C10H21NO3SNa [M+Na]
+
: 258.1140, found 258.1138. 
 
(±)-(E)-2-methylnon-7-en-4-yl sulfamate (Table 4, entries 3-4).  
Prepared according to method A. 781 mg (5.00 mmol) of (±)-(E)-2-methylnon-
7-en-4-ol were used. Flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using 4:1 hexanes:EtOAc as eluent gave 1.153 g (4.90 mmol) of 
pure product as a colorless oil (>20:1 E:Z, 98% yield). 
1
H-NMR (500 MHz, CDCl3) δ 5.48 (dq, J 
= 15.5, 6.5 Hz, 1H), 5.41 (dt, J = 15.0, 6.5 Hz, 1H), 4.86 (br. s, 2H), 4.67 (p, J = 6.0 Hz, 1H), 
2.10 (q, J = 7.0 Hz, 2H), 1.81-1.65 (m, 4H), 1.66 (d, J = 6.0 Hz, 3H), 1.49-1.44 (m, 1H), 0.94 (t, 
J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 129.9, 126.1, 83.8, 43.3, 34.4, 27.9, 24.5, 22.9, 
22.5, 18.0; IR (film, cm
-1
) 3391, 3290, 2958, 2871, 1562, 1450, 1360, 1182, 924; HRMS (ESI) 
m/z calculated for C10H21NO3SNa [M+Na]
+
: 258.1140, found 258.1131. 
 
(±)-(E)-1-methoxyoct-6-en-3-yl sulfamate (Table 4, entries 5-6).  
Prepared according to method A. 791 mg (5.00 mmol) of (±)-(E)-1-
methoxyoct-6-en-3-ol were used. Flash column chromatography on silica 
(35 mm fritted glass column, 150 mm SiO2) using 2:1 hexanes:EtOAc as eluent gave 818 mg 
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(3.45 mmol) of pure product as a colorless oil (>20:1 E:Z, 69% yield). 
1
H-NMR (500 MHz, 
CDCl3) δ 5.49 (dq, J = 15.5, 6.0 Hz, 1H), 5.41 (dt, J = 15.5, 6.0 Hz), 4.96 (br. s, 2H), 4.74 (p, J = 
6.0 Hz, 1H), 3.58 (dt, J = 10.0, 6.5 Hz, 1H), 3.49 (dt, J = 10.0, 5.5 H, 1H), 3.35 (s, 3H), 2.12 (q, 
J = 7.0 Hz, 2H), 1.97 (q, J = 6.0 Hz, 2H), 1.88-1.72 (m, 2H), 1.66 (d, J = 5.5 Hz, 3H); 
13
C-NMR 
(125 MHz, CDCl3) δ 129.8, 126.2, 82.1, 68.6, 58.6, 34.9, 34.1, 28.0, 18.0; IR (film, cm
-1
) 3357, 
3280, 2924, 2854, 1452, 1367, 1178, 1107, 910; HRMS (ESI) m/z calculated for C9H19NO4SNa 
[M+Na]
+
: 260.0932, found 260.0928. 
 
(±)-(E)-1-phenyloct-6-en-3-yl sulfamate (Table 4, entries 7-8).  
Prepared according to method A. 1.022 g (5.00 mmol) of (±)-(E)-1-
phenyloct-6-en-3-ol were used. Flash column chromatography on silica (35 
mm fritted glass column, 150 mm SiO2) using 3:1 hexanes:EtOAc as eluent gave 1.261 g (4.45 
mmol) of pure product as a colorless oil (>20:1 E:Z, 89% yield). 
1
H-NMR (500 MHz, CDCl3) δ 
7.31-7.28 (m, 2H), 7.22-7.19 (m, 3H), 5.47 (dq, J = 15.5, 6.0 Hz, 1H), 5.39 (dt, J = 15.5, 6.0 Hz, 
1H), 4.68 (br. s, 2H), 4.65 (p, J = 6.0 Hz, 1H), 2.78-2.69 (m, 2H), 2.10 (q, J = 7.0 Hz, 2H), 2.05 
(q, J = 7.0 Hz, 2H), 1.91-1.76 (m, 2H), 1.65 (d, J = 6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 
141.2, 129.8, 128.7, 128.5, 126.3 (2 peaks), 84.3, 35.7, 34.0, 31.2, 28.0, 18.0; IR (film, cm
-1
) 
3377, 3292, 3028, 2939, 2856, 1554, 1496, 1454, 1358, 1182, 920; HRMS (ESI) m/z calculated 
for C14H21NO3SNa [M+Na]
+
: 306.1140, found 306.1147. 
 
(±)-(E)-methyl 6-(sulfamoyloxy)hept-2-enoate (Table 5, entry 1).  
Prepared according to method B. 790 mg (5.00 mmol) of (±)-(E)-methyl 6-
hydroxyhept-2-enoate were used. Flash column chromatography on silica (35 
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mm fritted glass column, 150 mm SiO2) using 1:1 hexanes:EtOAc as eluent gave 795 mg (3.35 
mmol) of pure product as a colorless oil (67% yield). 
1
H-NMR (500 MHz, CDCl3) δ 6.95 (dt, J = 
15.5, 7.0 Hz, 1H), 5.87 (dt, J = 15.5, 1.5 Hz, 1H), 5.10 (br. s, 2H), 4.73-4.66 (m, 1H), 3.72 (s, 
3H), 2.39-2.31 (m, 2H), 1.91-1.84 (m, 1H), 1.81-1.73 (m, 1H), 1.43 (d, J = 6.5 Hz, 3H); 
13
C-
NMR (125 MHz, CDCl3) δ 167.3, 148.0, 121.8, 80.2, 51.7, 34.8, 27.9, 20.8; IR (film, cm
-1
) 
3356, 3248, 3118, 2985, 2954, 2850, 1711, 1658, 1566, 1441, 1360, 1294, 1221, 1178, 1130, 
1045, 985, 930, 796; HRMS (ESI) m/z calculated for C8H16NO5S [M+H]
+
: 238.0749, found 
238.0738. 
 
(±)-(E)-6-(sulfamoyloxy)hept-2-en-1-yl acetate (Table 5, entry 2).  
Prepared according to method B. 861 mg (5.00 mmol) of (±)-(E)-6-
hydroxyhept-2-en-1-yl acetate were used. Flash column chromatography on 
silica (35 mm fritted glass column, 150 mm SiO2) using 2:1 hexanes:EtOAc as eluent gave 667 
mg (2.65 mmol) of pure product as a colorless oil (53% yield). 
1
H-NMR (500 MHz, CDCl3) δ 
5.75 (dt, J = 15.5, 6.5 Hz, 1H), 5.60 (ddt, J = 15.5, 6.0, 1.5 Hz, 1H), 4.98 (br. s, 2H), 4.67 (app 
sxt, J = 6.5 Hz, 1H), 4.51 (d, J = 6.5 Hz, 2H), 2.19 (app q, J = 7.0 Hz, 2H), 2.06 (s, 3H), 1.84 
(app dq, J = 14.5, 7.0 Hz, 1H) 1.74-1.67 (m, 1H), 1.42 (d, J = 6.0 Hz, 3H); 
13
C-NMR (125 MHz, 
CDCl3) δ 171.3, 134.7, 125.1, 80.5, 65.2, 35.6, 27.9, 21.2, 20.7; IR (film, cm
-1
) 3354, 3271, 
3118, 2981, 2943, 1720, 1566, 1448, 1365, 1259, 1180, 1028, 922; HRMS (ESI) m/z calculated 
for C9H17NO5SNa [M+Na]
+
: 274.0725, found 274.0730. 
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(±)-(2E,9E)-methyl 6-(sulfamoyloxy)undeca-2,9-dienoate (Table 5, entry 3).  
Prepared according to method B. 1.061 g (5.00 mmol) of (±)-(2E,9E)-
methyl 6-hydroxyundeca-2,9-dienoate 26 were used. Flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 3:1 hexanes:EtOAc 
as eluent gave 1.004 g (3.45 mmol) of pure product as a colorless oil (69% yield). 
1
H-NMR (500 
MHz, CDCl3) δ 6.95 (dt, J = 16.0, 6.5 Hz, 1H), 5.87 (d, J = 15.5 Hz, 1H), 5.47 (dq, J = 15.5, 6.5 
Hz, 1H), 5.38 (dt, J = 15.5, 6.5 Hz, 1H), 4.94 (br. s, 2H), 4.61 (app p, J = 6.0 Hz, 1H), 3.73 (s, 
3H), 2.35 (app q, J = 7.5 Hz, 2H), 2.09 (app q, J = 7.0 Hz, 2H), 1.89-1.80 (m, 3H), 1.72 (app dq, 
J = 14.5, 7.5 Hz, 1H), 1.64 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 167.3, 148.0, 
129.6, 126.4, 121.8, 83.5, 51.7, 34.0, 32.4, 28.0, 27.6, 18.0; IR (film, cm
-1
) 3367, 3271, 3113, 
3022, 2953, 2856, 1705, 1657, 1564, 1439, 1362, 1290, 1182, 1041, 970, 918, 752; HRMS (ESI) 
m/z calculated for C12H22NO5S [M+H]
+
: 292.1219, found 292.1218. 
 
(±)-(E)-1-(2,6,6-trimethylcyclohex-1-en-1-yl)oct-6-en-3-yl sulfamate (Table 5, entry 4).  
Prepared according to method A. 1.252 g (5.00 mmol) of (±)-(E)-1-(2,6,6-
trimethylcyclohex-1-en-1-yl)oct-6-en-3-ol 27 were used. Flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 4:1 hexanes:EtOAc 
as eluent gave 1.400 g (4.25 mmol) of pure product as a colorless oil (85% yield). 
1
H-NMR (500 
MHz, CDCl3) δ 5.48 (dq, J = 15.0, 6.5 Hz, 1H), 5.42 (dt, J = 15.0, 6.5 Hz, 1H), 4.70 (br. s, 2H), 
4.60 (app p, J = 6.0 Hz, 1H), 2.15-2.07 (m, 3H), 2.05-1.99 (m, 1H), 1.90 (t, J = 6.5 Hz, 2H), 
1.87-1.72 (m, 4H), 1.65 (d, J = 6.0 Hz, 3H), 1.59 (s, 3H), 1.59-1.54 (m, 2H), 1.42-1.40 (m, 2H), 
0.98 (s, 6H); 
13
C-NMR (125 MHz, CDCl3) δ 136.2, 129.9, 127.9, 126.2, 85.6, 39.9, 35.1, 34.5, 
33.8, 32.9, 28.7 (2 peaks), 28.3, 23.8, 19.9, 19.6, 18.1; IR (film, cm
-1
) 3375, 3286, 2929, 2866, 
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1556, 1473, 1452, 1358, 1184, 966, 922; HRMS (ESI) m/z calculated for C17H31NO3SNa 
[M+Na]
+
: 352.1922, found 352.1926. 
 
(±)-3-deuterio-3-phenylpropan-1-yl sulfamate [21-d1].  
Prepared according to method A. 686 mg (5.00 mmol) of 3-deuterio-3-
phenylpropan-1-ol were used (contained ~20% of an unreactive impurity).
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Flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 2:1 
hexanes:EtOAc as eluent gave 693 mg (3.20 mmol) of pure product as a white solid (64% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.5 Hz, 2H), 7.23-7.19 (m, 3H), 4.81 (br s, 2H), 4.22 
(t, J = 6.5 Hz, 2H), 2.74 (t, J = 7.5 Hz, 1H), 2.07 (dt, J = 7.0, 6.5 Hz, 2H); 
13
C-NMR (125 MHz, 
CDCl3) δ 140.5, 128.7, 128.6, 126.4, 70.7, 31.3 (1:1:1 triplet), 30.3; IR (film, cm
-1
) 3379, 3292, 
3028, 2960, 2927, 1554, 1496, 1452, 1365, 1180, 931; HRMS (ESI) m/z calculated for 
C9H12DNO3SNa [M+Na]
+
: 239.0577, found 239.0577. 
(±)-3-phenylpropan-1-yl sulfamate [21].  
Prepared according to method A. 686 mg (5.00 mmol) of 3-phenylpropan-1-ol 
were used. Flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 2:1 hexanes:EtOAc as eluent gave 907 mg (4.20 mmol) of pure 
product as a white solid (84% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.5 Hz, 2H), 
7.23-7.19 (m, 3H), 4.75 (br s, 2H), 4.22 (t, J = 6.5 Hz, 2H), 2.76 (dd, J = 7.5 Hz, 2H), 2.08 (dt, J 
= 7.5, 7.0 Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 140.6, 128.7, 128.6, 126.4, 70.7, 31.7, 30.4; 
IR (film, cm
-1
) 3381, 3276, 3028, 2960, 2939, 2864, 1554, 1496, 1454, 1365, 1180, 939; HRMS 
(ESI) m/z calculated for C9H13NO3SNa [M+Na]
+
: 238.0514, found 238.0516. 
 
31 
 
(±)-(Z)-hept-5-en-2-yl sulfamate [Z-23].  
Prepared according to method A. 571 mg (5.0 mmol) of (±)-(Z)-hept-6-en-3-ol were 
used. Flash column chromatography on silica (35 mm fritted glass column, 150 mm 
SiO2) using 3:1 hexanes:EtOAc as eluent gave 715 mg (3.70 mmol) of pure product as a 
colorless oil (74% yield). 
1
H-NMR (500 MHz, CDCl3) δ 5.49 (dq, J = 11.0, 7.0 Hz, 1H), 5.36 
(dt, J = 11.0, 7.0 Hz, 1H), 4.79 (br. s, 2H), 4.71 (app. sxt, J = 6.5 Hz, 1H), 2.19-2.11 (m, 2H), 
1.85-1.78 (m, 1H), 1.69-1.65 (m, 1H), 1.62 (dd, J = 6.5, 1.5 Hz, 3H), 1.44 (d, J = 6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) 130.0, 125.3, 81.4, 36.3, 22.7, 20.7, 13.0; IR (film, cm
-1
) 3381, 
3278, 3014, 2981, 2939, 2866, 1562, 1448, 1358, 1176, 1124, 1039, 930; HRMS (ESI) m/z 
calculated for C7H15NO3SNa [M+Na]
+
: 216.0670, found 216.0675. 
(±)-(E)-hept-5-en-2-yl sulfamate [E-23].  
Prepared according to method A. 571 mg (5.0 mmol) of (±)-(E)-hept-6-en-3-ol 
were used. Flash column chromatography on silica (35 mm fritted glass column, 
150 mm SiO2) using 3:1 hexanes:EtOAc as eluent gave 733 mg (4.00 mmol) of pure product as a 
colorless oil (80% yield). 
1
H-NMR (500 MHz, CDCl3) δ 5.47 (dq, J = 15.5, 6.0 Hz, 1H), 5.40 
(dt, J = 15.0, 6.5 Hz, 1H), 4.75 (br. s, 2H), 4.70 (app. sxt, J = 6.5 Hz, 1H), 2.12-2.05 (m, 2H), 
1.85-1.77 (m, 1H), 1.68-1.60 (m, 1H), 1.65 (dd, J = 6.0, 1.0 Hz, 3H), 1.42 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) 129.7, 126.3, 81.3, 36.4, 28.3, 20.7, 18.1; IR (film, cm
-1
) 3377, 
3286, 2981, 2939, 2920, 2856, 1562, 1450, 1358, 1182, 1124, 926; HRMS (ESI) m/z calculated 
for C7H15NO3SNa [M+Na]
+
: 216.0670, found 216.0674. 
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Optimization of Fe-catalyzed Intramolecular C—H Amination 
(±)-4-((1E)-1-propenyl)-6-(3-phenylpropyl)tetrahydro-1,2,3-oxathiazine-2,2-dioxide [1]. 
In general, the syn and anti oxathiazinanes can be isolated pure via flash column chromatography 
directly from the crude reaction mixture. The minor (anti) diastereomer co-elutes with starting 
material under hexanes/EtOAc eluent conditions, but can be easily separated in cases of 
incomplete conversion when CH2Cl2/hexanes is instead used as the eluent system. See general 
procedure for single catalyst addition for specific experimental details (vide infra). All products 
were obtained with an olefin geometry of >20:1 E/Z. 
The relative stereochemistry of the oxathiazinanes was confirmed via nOe NMR 
experiments (500 MHz, CDCl3) in which the C4 and C6 protons for each diastereomer were 
irradiated (irradiated protons are highlighted in red). Syn oxathiazinanes have a characteristic 
weak nOe between the C4 and C6 pseudo-axial hydrogens. Conversely, the C4 and C6 
hydrogens in the anti oxathiazinane fall on opposite sides of the ring and therefore experience no 
observable nOe. Instead, for anti allylic C—H amination products a weak nOe can be observed 
between the C3 vinylic hydrogen of the pseudo-axial propenyl group and the pseudo-axial C6 
hydrogen. All products described in this paper are assumed to have the same relative 
stereochemistry as 1 by analogy. The experimental data are consistent with previously reported 
studies in the literature.
41
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 Syn (major) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 
MHz, CDCl3) δ 7.30-7.27 (m, 2H), 7.21-7.16 (m, 3H), 5.76 (dq, J = 15.5, 
6.5 Hz, 1H), 5.39 (dd, J = 15.5, 5.5 Hz, 1H), 4.77-4.73 (m, 1H), 4.21-4.18 (m, 1H), 3.78 (br. d, J 
= 10.0 Hz, 1H), 2.65 (t, J = 7.0 Hz, 2H), 1.88-1.63 (m, 8H), 1.51 (app. q, J = 12.0 Hz, 1H); 
13
C-
NMR (125 MHz, CDCl3) δ 141.5, 129.5, 128.6, 128.5, 128.2, 126.2, 83.9, 56.1, 35.8, 35.4, 34.8, 
26.3, 17.9; IR (film, cm
-1
) 3265, 3028, 2924, 2856, 1416, 1360, 1188, 872; HRMS (ESI) m/z 
calculated for C15H22NO3S [M+H]
+
: 296.1320, found 296.1325. 
 Anti (minor) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 
MHz, CDCl3) δ 7.29 (t, J = 7.3 Hz, 2H), 7.21-7.17 (m, 3H), 5.80 (ddd, J 
= 15.5, 6.5, 1.5 Hz, 1H), 5.70 (dq, J = 15.5, 6.0 Hz, 1H), 4.88-4.83 (m, 1H), 4.38 (br. d, J = 7.0 
Hz, 1H), 4.17 (app. p, J = 6.0 Hz, 1H), 2.66 (dt, J = 7.5, 2.0 Hz, 2H), 1.99-1.85 (m, 3H), 1.83-
1.79 (m, 1H), 1.73 (d, J = 6.5 Hz, 3H), 1.74-1.60 (m, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 141.6, 
129.2, 128.6, 128.5, 128.4, 126.1, 82.7, 55.0, 35.4, 34.1, 33.9, 26.7, 17.9; IR (film, cm
-1
) 3280, 
3028, 2937, 2860, 1496, 1452, 1419, 1367, 1184, 966, 874; HRMS (ESI) m/z calculated for 
C15H21NO3SNa [M+Na]
+
: 318.1140, found 318.1142. 
(±)-trans-4-(3-phenylpropyl)-8-methyl-3-oxa-2-thia-1-azabicyclo[5.1.0]octane-2,2-dioxide. 
In general, the aziridine is formed in only trace quantities under the 
standard Fe-catalyzed C—H amination conditions. The trace aziridine is 
more polar than the insertion products and is easily separated from the desired oxathiazinane 
products via flash column chromatography on silica. Most of the aziridine side products from 
substrates described in this paper share a characteristic peak near δ = 3.0 ppm (1H), which was 
used to determine ins./azir. ratios in the crude 
1
H-NMR.  
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Prepared as a standard using Rh-catalyzed C—H amination conditions (vide infra). Purified via 
flash column chromatography on silica using 4:1  2:1 hexanes/EtOAc as the eluent system. 
Isolated as a colorless oil. 
1
H-NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.5 Hz, 2H), 7.20-7.15 (m, 
3H), 4.33-4.28 (m, 1H), 2.99 (app. p, J = 5.5 Hz, 1H), 2.66-2.59 (m, 3H), 2.49-2.38 (m, 2H), 
1.83-1.78 (m, 2H), 1.75-1.64 (m, 4H), 1.60-1.55 (m, 1H), 1.34 (d, J = 5.5 Hz, 3H); 
13
C-NMR 
(125 MHz, CDCl3) δ 141.6, 128.5 (2 peaks), 126.1, 83.7, 47.2, 38.6, 35.3, 34.0, 32.3, 27.2, 24.7, 
17.1; IR (film, cm
-1
) 3060, 3026, 2929, 2862, 1496, 1454, 1373, 1261, 1180, 999, 901; HRMS 
(ESI) m/z calculated for C15H22NO3S [M+H]
+
: 296.1320, found 296.1314. 
 
General procedure for single catalyst addition (Table 1, entries 1-8) 
Into a 10 mL round-bottom flask was added AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv, entries 
5-7), catalyst (0.040 mmol, 0.10 equiv), and a stir bar in a glovebox. The flask was then sealed 
with a rubber septum, covered in aluminum foil (when AgSbF6 was used), and taken out of the 
box. (±)-(E)-1-phenylnon-7-en-4-yl sulfamate (119 mg, 0.400 mmol, 1.0 equiv) dissolved in 
solvent was added via syringe, followed by PhI(O2CR)2 (0.800 mmol, 2.0 equiv) in a single 
portion. After addition of oxidant, the dark turquoise solution gradually turned dark brown. The 
reaction stirred for 6h at room temp (~20
o
C), and then concentrated under reduced pressure. The 
remaining dark brown residue was suspended in Et2O and filtered through a pad of Celite. Upon 
removal of solvent under reduced pressure, flash column chromatography on silica allowed 
separate isolation of each component as colorless oils. When reaction gave <5% recovered 
starting material (rsm), the column conditions were as follows: (35 mm fritted glass column, 150 
mm SiO2), 5:1 hexanes/EtOAc. For incomplete conversion of starting material, column 
35 
 
conditions were as follows: 35 mm fritted glass column, 110 mm SiO2, 4:1 CH2Cl2/hex (600 mL) 
 9:1 CH2Cl2/hexanes (350 mL)  100% CH2Cl2. 
 
Entry 1. Single addition protocol was followed, except product was isolated as a diastereomeric 
mixture with starting material under the hexanes/EtOAc column conditions. (±)-(E)-9-
phenylnon-2-en-6-yl sulfamate (119 mg, 0.400 mmol, 1.0 equiv), Fe(R,R-PDP)(SbF6)2 (33.6 mg, 
0.040 mmol, 0.10 equiv), PhI(OAc)2 (257 mg, 0.800 mmol, 2.0 equiv) and MeCN (4.0 mL, 
0.1M) were used. By 
1
H-NMR analysis of the crude product, ins./azir. was >20:1 and d.r. was 
~1:1 (syn:anti).  
Run 1: (13 mg of 1.1:1 syn:anti mixture, 0.044 mmol, 11%), (68 mg rsm, 0.228 mmol, 57%). 
Run 2: (9 mg of 1.2:1 syn:anti mixture, 0.032 mmol, 8%), (70 mg rsm, 0.236 mmol, 59%). 
Average: 10% yield, 58% rsm. 
 
Entry 2. Single addition protocol was followed, except product was isolated as a diastereomeric 
mixture with starting material under the hexanes/EtOAc column conditions. (±)-(E)-9-
phenylnon-2-en-6-yl sulfamate (119 mg, 0.400 mmol, 1.0 equiv), Fe(TPP)Cl (28.2 mg, 0.040 
mmol, 0.10 equiv), PhI(OAc)2 (257 mg, 0.800 mmol, 2.0 equiv) and MeCN (4.0 mL, 0.1M) were 
used. By 
1
H-NMR analysis of the crude product, ins./azir. was >20:1 and d.r. was ~1:1 
(syn:anti).  
Run 1: (24 mg of 1:1 syn:anti mixture, 0.081 mmol, 20%), (53 mg rsm, 0.178 mmol, 45%). Run 
2: (26 mg of 1.1:1 syn:anti mixture, 0.088 mmol, 22%), (44 mg rsm, 0.148 mmol, 37%). 
Average: 21% yield, 41% rsm. 
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Entry 3. Single addition protocol was followed; starting material was reisolated via flash column 
(35 mm fritted glass column, 110 mm SiO2) using 4:1 hexanes/EtOAc. (±)-(E)-9-phenylnon-2-
en-6-yl sulfamate (119 mg, 0.400 mmol, 1.0 equiv), Fe(R,R-salen)Cl (22.8 mg, 0.040 mmol, 
0.10 equiv), PhI(OAc)2 (257 mg, 0.800 mmol, 2.0 equiv) and MeCN (4.0 mL, 0.1M) were used. 
1
H-NMR analysis of the crude product indicated formation of neither the desired insertion 
product nor aziridine. Due to the presence of an unidentified impurity after column 
chromatography, recovery of starting material was determined via 
1
H-NMR analysis using 
PhNO2 as an internal standard (delay = 60 s).  
Run 1: (0 mg, 0 mmol, 0% yield), (107 mg rsm, 0.360 mmol, 90%). Run 2: (0 mg, 0 mmol, 0% 
yield), (99 mg rsm, 0.333 mmol, 83%). Average: 0% yield, 87% rsm. 
 
Entry 4. Single addition protocol was followed. (±)-(E)-9-phenylnon-2-en-6-yl sulfamate (119 
mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24 mg, 0.040 mmol, 0.10 equiv), PhI(OAc)2 (257 mg, 
0.800 mmol, 2.0 equiv) and MeCN (800 μL, 0.5M) were used. By 1H-NMR analysis of the crude 
product, ins./azir. was 18:1 and d.r. was 2.3:1 (syn:anti).  
Run 1: (31.8 mg syn + 10.9 mg anti (2.9:1 d.r.), 0.145 mmol, 36%), (26.3 mg rsm, 0.088 mmol, 
22%). Run 2: (29.8 mg syn + 11.1 mg anti (2.7:1 d.r.), 0.138 mmol, 35%), (24.4 mg rsm, 0.082 
mmol, 21%). Run 3: (26.8 mg syn + 10.0 mg anti (2.7:1 d.r.), 0.125 mmol, 31%), (26.1 mg rsm, 
0.088 mmol, 22%). Average: 34% yield, 22% rsm. 
 
Entry 5. Single addition protocol was followed. (±)-(E)-9-phenylnon-2-en-6-yl sulfamate (119 
mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 
0.040 mmol, 0.10 equiv), PhI(OAc)2 (257 mg, 0.800 mmol, 2.0 equiv) and MeCN (800 μL, 
37 
 
0.5M) were used. By 
1
H-NMR analysis of the crude product, ins./azir. was 16:1 and d.r. was 
2.3:1 (syn:anti).  
Run 1: (36.6 mg syn + 10.0 mg anti (3.7:1 d.r.), 0.158 mmol, 39%), (18.6 mg rsm, 0.063 mmol, 
16%). Run 2: (38.8 mg syn + 9.6 mg anti (4:1 d.r.), 0.164 mmol, 41%), (12.7 mg rsm, 0.043 
mmol, 11%). Run 3: (35.0 mg syn + 9.3 mg anti (3.7:1 d.r.), 0.150 mmol, 38%), (19.6 mg rsm, 
0.066 mmol, 16%). Average: 39% yield, 14% rsm. 
 
Entry 6. Single addition protocol was followed. (±)-(E)-9-phenylnon-2-en-6-yl sulfamate (119 
mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 
0.040 mmol, 0.10 equiv), PhI(OAc)2 (257 mg, 0.800 mmol, 2.0 equiv) and 4:1 PhMe:MeCN 
(800 μL, 0.5M) were used. By 1H-NMR analysis of the crude product, ins./azir. was >20:1 and 
d.r. was 3.1:1 (syn:anti).  
Run 1: (48 mg syn + 10.4 mg anti (4.6:1 d.r.), 0.198 mmol, 49%), (12 mg rsm, 0.040 mmol, 
10%). Run 2: (53.4 mg syn + 9.6 mg anti (5.5:1 d.r.), 0.213 mmol, 53%), (8 mg rsm, 0.027 
mmol, 7%). Run 3: (53.6 mg syn + 9.8 mg anti (5.4:1 d.r.), 0.215 mmol, 54%), (4.1 mg rsm, 
0.014 mmol, 3%). Average: 52% yield, 7% rsm. 
 
Entry 7. Single addition protocol was followed. (±)-(E)-9-phenylnon-2-en-6-yl sulfamate (119 
mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 
0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 4:1 PhMe:MeCN 
(800 μL, 0.5M) were used. By 1H-NMR analysis of the crude product, ins./azir. was >20:1 and 
d.r. was 4.0:1 (syn:anti). The crude material was purified via flash column chromatography on 
silica (35 mm fritted glass column, 150 mm SiO2) using 6:1 hexanes/EtOAc + 1% AcOH as 
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eluent (the AcOH additive prevents streaking of PivOH and allows it to be more easily separated 
from the desired products).  
Run 1: (62.4 mg syn + 14.8 mg anti (4.2:1 d.r.), 0.262 mmol, 65%), <5% rsm. Run 2: (67.4 mg 
syn + 13.2 mg anti (5:1 d.r.), 0.273 mmol, 68%), <5% rsm. Run 3: (69.4 mg syn + 13.7 mg anti 
(5:1 d.r.), 0.282 mmol, 70%), <5% rsm. Average: 68% yield, <5% rsm. 
 
Entry 8. Single addition protocol was followed. (±)-(E)-9-phenylnon-2-en-6-yl sulfamate (119 
mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL, 0.5M) were used. By 1H-NMR analysis 
of the crude product, ins./azir. was >20:1 and d.r. was 3:1 (syn:anti). The crude material was 
purified via flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) 
using 6:1 hexanes/EtOAc + 1% AcOH as eluent. 
Run 1: (47.7 mg syn + 19.7 mg anti (2.4:1 d.r.), 0.228 mmol, 57%), (8.7 mg rsm, 0.028 mmol, 
7%). Run 2: (50.0 mg syn + 16.1 mg anti (3.1:1 d.r.), 0.224 mmol, 56%), (7.5 mg rsm, 0.025 
mmol, 6%). Average: 57% yield, 7% rsm. 
 
Entry 9. AgSbF6 (3x4.5 mg, 0.040 mmol, 0.10 equiv) and [FePc]Cl (3x8 mg, 0.040 mmol, 0.10 
equiv) were weighed out into three separate ½-dram borosilicate vials in a glovebox, sealed, 
covered in aluminum foil, taken out of the box and temporarily stored in a dessicator. A 10 mL 
round-bottom flask covered in aluminum foil and equipped with a stir bar and rubber septum was 
charged with (±)-(E)-9-phenylnon-2-en-6-yl sulfamate (119 mg, 0.400 mmol, 1.0 equiv) 
dissolved in 4:1 PhMe:MeCN (800 μL, 0.5M), and then PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 
equiv). The contents of one vial were quickly added to the reaction flask under a stream of N2, 
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and then the rubber septum was replaced. After stirring for 2h at rt, a second portion was added 
in the same manner; this was then repeated once more in 2h intervals for a total of three catalyst 
additions. The reaction stirred for 2h more at room temp after addition of the final portion for a 
total reaction time of 6h, then the reaction was concentrated under reduced pressure. Work-up 
and purification were performed in a manner identical to that described in the single catalyst 
addition protocol (vide supra). By 
1
H-NMR analysis of the crude product, ins./azir. was >20:1 
and d.r. was 3.5:1 (syn:anti). The crude material was purified via flash column chromatography 
on silica (35 mm fritted glass column, 150 mm SiO2) using 6:1 hexanes/EtOAc + 1% AcOH as 
eluent.  
Run 1: (66.2 mg syn + 14.9 mg anti (4.4:1 d.r.), 0.275 mmol, 69%), <5% rsm. Run 2: (62.8 mg 
syn + 15.0 mg anti (4.2:1 d.r.), 0.263 mmol, 66%), <5% rsm. Run 3: (66.5 mg syn + 15.0 mg anti 
(4.4:1 d.r.), 0.276 mmol, 69%), <5% rsm. Average: 68% yield, <5% rsm. 
 
Olefin and Substrate Scope for Fe-catalyzed Intramolecular C—H Amination 
Single catalyst addition protocol for [FePc]Cl-mediated intramolecular amination 
Into a 10 mL round-bottom flask was added AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
[FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), and a stir bar in a glovebox. The flask was then 
sealed with a rubber septum, covered in aluminum foil, and taken out of the box. 4:1 
PhMe:MeCN (800 μL, 0.5M), sulfamate ester (0.400 mmol, 1.0 equiv), and PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv) were then added sequentially; if sulfamate ester was an oil, it was taken 
up in the solvent mixture and added to the flask via syringe. After addition of oxidant, the deep 
violet solution gradually turned dark brown. The reaction stirred for 6h at room temp (~20
o
C), 
then the reaction was concentrated under reduced pressure. The remaining dark brown residue 
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was suspended in Et2O and filtered through a pad of Celite. Upon removal of solvent under 
reduced pressure, flash column chromatography on silica allowed separate isolation of each 
component.  
 
Iterative catalyst addition protocol for [FePc]Cl-mediated intramolecular amination 
AgSbF6 (4x4.5 mg, 0.053 mmol, 0.13 equiv) and [FePc]Cl (4x8 mg, 0.053 mmol, 0.13 equiv) 
were weighed out into four separate ½-dram borosilicate vials in a glovebox, sealed, covered in 
aluminum foil, taken out of the box and temporarily stored in a dessicator. A 10 mL round-
bottom flask covered in aluminum foil and equipped with a stir bar and rubber septum was 
charged with 4:1 PhMe:MeCN (800 μL, 0.5M), sulfamate ester (0.400 mmol, 1.0 equiv), and 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv); if sulfamate ester is an oil, it was taken up in the 
solvent mixture and added to the flask via syringe. The contents of one vial were quickly added 
to the reaction flask under a stream of N2, and then the rubber septum was replaced. After 
stirring for 2h at room temp, a second portion was added in the same manner; this was then 
repeated twice more in 2h intervals for a total of four catalyst additions. The reaction stirred for 
2h more at room temp after addition of the final portion for a total reaction time of 8h, then the 
solvent was removed under reduced pressure. Work-up and purification were performed in a 
manner identical to that described in the single catalyst addition protocol (vide supra). The 
iterative addition protocol was used for substrates that did not react to completion under the 
standard single catalyst addition reaction conditions. While simply increasing catalyst loading 
under standard reaction conditions with less reactive substrates did not result in improved 
reactivity, iterative addition of the precatalyst mixture had a beneficial effect on overall reactivity 
and yield of the desired product. 
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(±)-4-(E-styrenyl)-6-methyl-tetrahydro-1,2,3-oxathiazine-2,2-dioxide [2]. 
Single catalyst addition protocol for Fe conditions was followed. (±)-(E)-6-phenylhex-5-en-2-yl 
sulfamate (102 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), 
AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 
4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, E:Z was 
>20:1, d.r. was 3.5:1 syn:anti, and ins./azir. was >20:1. Flash column chromatography on silica 
(35 mm fritted glass column, 150 mm SiO2) using 3:1 hexanes:EtOAc + 1% AcOH as eluent 
gave pure syn and anti allylic oxathiazinanes separately.  
Run 1: (60.3 mg syn + 11.9 mg anti (5:1 d.r.), 0.286 mmol, 71%), 0% rsm. Run 2: (59.6 mg syn 
+ 10.4 mg anti (5.7:1 d.r.), 0.278 mmol, 69%), 0% rsm. Run 3: (58.4 mg syn + 11.2 mg anti 
(5.2:1 d.r.), 0.276 mmol, 69%), 0% rsm. Average: 70% yield, 0% rsm. 
Syn (major) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 7.38-7.28 (m, 5H), 6.65 (d, J = 16.0 Hz, 1H), 6.10 (dd, J = 16.0, 6.0 Hz, 
1H), 4.99-4.93 (m, 1H), 4.49-4.44 (m, 1H), 3.90 (br. d, J = 10.0 Hz, 1H), 2.02 (dt, J = 14.0, 2.0 
Hz, 1H), 1.66 (dt, J = 14.0 12.0 Hz, 1H), 1.48 (d, J = 6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) 
δ 136.0, 133.1, 129.2, 128.9, 127.0, 126.2, 80.8, 56.6, 37.6, 21.5; IR (film, cm-1) 3259, 3028, 
2985, 2935, 1728, 1495, 1415, 1360, 1188, 1066, 866; HRMS (ESI) m/z calculated for 
C12H16NO3S [M+H]
+
: 254.0851, found 254.0857. 
Anti (minor) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 7.40 (d, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 7.27 (t, J = 7.0 Hz, 
1H), 6.60 (d, J = 16.5 Hz, 1H), 6.53 (dd, J = 16.5, 6.5 Hz, 1H), 5.13-5.07 (m, 1H), 4.54 (br. d, J 
= 6.5 Hz, 1H), 4.43 (app. p, J = 5.5 Hz, 1H), 2.06-1.96 (m, 2H), 1.53 (d, J = 6.5 Hz, 3H); 
13
C-
NMR (125 MHz, CDCl3) δ 136.0, 132.7, 128.8, 128.5, 128.4, 126.8, 126.7, 79.2, 55.2, 35.4, 
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21.0; IR (film, cm
-1
) 3269, 3027, 2983, 2931, 1416, 1365, 1184, 1074, 968, 885; HRMS (ESI) 
m/z calculated for C12H15NO3SNa [M+Na]
+
: 276.0670, found 276.0674. 
 
(±)-5-isopropyl-4-((E)-styryl)-1,2,3-oxathiazinane 2,2-dioxide [3]. 
Single catalyst addition protocol for Fe conditions was followed. (±)-(E)-2-
isopropyl-5-phenylpent-4-en-1-yl sulfamate (113 mg, 0.400 mmol, 1.0 equiv), 
[FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL) were used. By 
1
H-
NMR analysis of the crude product, E:Z was >20:1, d.r. was 1:1.2 syn:anti, and ins./azir. was 
>20:1. Flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 
4:1 hexanes:EtOAc + 1% AcOH as eluent gave pure syn and anti allylic oxathiazinanes and 
recovered starting material separately.  
(27.0 mg syn + 32.4 mg anti (1:1.2 d.r.), 0.212 mmol, 53%), (9.0 mg rsm, 0.032 mmol, 8%). 
 
(±)-4-(2-methylprop-1-en-1-yl)-6-methyltetrahydro-1,2,3-oxathiazine-2,2-dioxide [4]. 
Iterative catalyst addition protocol for Fe conditions was followed. (±)-2-methylhept-6-en-3-yl 
sulfamate (82.8 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (4x8 mg, 0.053 mmol, 0.13 equiv), 
AgSbF6 (4x4.5 mg, 0.053 mmol, 0.13 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 
4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, d.r. was 2.7:1 
syn:anti and ins./azir. was >20:1. Flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 9:1 CH2Cl2/hexanes (300 mL)  19:1 CH2Cl2/hexanes as eluent 
gave syn and anti allylic oxathiazinanes separately.  
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Run 1: (35.1 mg syn + 11.3 mg anti (3.1:1 d.r.), 0.228 mmol, 57%), <10% rsm. Run 2: (32.3 mg 
syn + 9.8 mg anti (3.3:1 d.r.), 0.205 mmol, 51%), <10% rsm. Run 3: (31.1 mg syn + 9.6 mg anti 
(3.2:1 d.r.), 0.198 mmol, 50%), <10% rsm. Average: 53% yield, <10% rsm. 
Syn (major) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, CDCl3) 
δ 4.96 (dt, J = 8.0, 1.5 Hz, 1H), 4.91-4.85 (m, 1H), 4.43-4.37 (m, 1H), 3.86 (br. d, 
J = 9.5 Hz, 1H), 1.76 (dt, J = 14.5, 2.5 Hz, 1H), 1.74 (s, 3H), 1.73 (d, J = 1.0 Hz, 3H), 1.49 (dt, J 
= 14.0, 12.0 Hz, 1H), 1.41 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 139.8, 121.7, 
80.5, 53.2, 37.8, 25.7, 21.3, 18.7; IR (film, cm
-1
) 3269, 2983, 2935, 2920, 1419, 1354, 1186, 
1066, 931, 916, 866, 820, 791; HRMS (ESI) m/z calculated for C8H15NO3SNa [M+Na]
+
: 
228.0670, found 228.0673. 
Anti (minor) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.57 (dt, J = 8.5, 1.0 Hz, 1H), 5.06-4.99 (m, 1H), 4.47-4.40 (m, 2H), 1.87 
(ddd, J = 14.0, 9.0, 5.0 Hz, 1H), 1.77-1.73 (m, 1H), 1.75 (app s, 3H), 1.68 (d, J = 1.0 Hz, 3H), 
1.50 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 137.4, 121.7, 79.4, 51.3, 35.8, 25.8, 
20.9, 18.2; IR (film, cm
-1
) 3271, 2981, 2937, 2920, 2885, 1421, 1371, 1354, 1290, 1238, 1182, 
1136, 1065, 964, 908, 883, 833, 791; HRMS (ESI) m/z calculated for C8H15NO3SNa [M+Na]
+
: 
228.0670, found 228.0670. 
 
(±)-4-vinyl-6-(1-methylethyl)tetrahydro-1,2,3-oxathiazine-2,2-dioxide [5]. 
Iterative catalyst addition protocol for Fe conditions was followed. (±)-2-methylhept-6-en-3-yl 
sulfamate (82.8 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (4x8 mg, 0.053 mmol, 0.13 equiv), 
AgSbF6 (4x4.5 mg, 0.053 mmol, 0.13 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 
4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, d.r. was 3:1 
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syn:anti and ins./azir. was 12:1. Flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 6:1 hexanes/EtOAc + 1% AcOH (300 mL)  4:1 hexanes/EtOAc 
+ 1% AcOH as eluent gave syn and anti allylic oxathiazinanes separately.  
Run 1: (35.5 mg syn + 7.8 mg anti (4.5:1 d.r.), 0.211 mmol, 53%), <10% rsm. Run 2: (33.2 mg 
syn + 7.8 mg anti (4.3:1 d.r.), 0.200 mmol, 50%), <10% rsm. Run 3: (35.1 mg syn + 7.8 mg anti 
(4.5:1 d.r.), 0.209 mmol, 52%), <10% rsm. Average: 52% yield, <10% rsm. 
Syn (major) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, CDCl3) 
δ 5.82 (ddd, J = 15.5, 10.5, 5.0 Hz, 1H), 5.32 (dd, J = 17.5, 1.5 Hz, 1H), 5.28 (dd, 
J = 10.5, 1.5 Hz, 1H), 4.54 (ddd, J = 12.0, 6.0, 2.0 Hz, 1H), 4.30-4.23 (m, 1H), 3.84 (br. d, J = 
10.0 Hz, 1H), 1.93 (app. sxt, J = 6.5 Hz, 1H), 1.89 (dt, J = 14.0, 2.0 Hz, 1H), 1.54 (dt, J = 14.5, 
12.0 Hz, 1H), 1.03 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 
135.3, 117.4, 88.7, 56.3, 32.7, 32.3, 18.0, 17.7; IR (film, cm
-1
) 3261, 2968, 2927, 2881, 1470, 
1419, 1360, 1190, 918, 879, 818; HRMS (ESI) m/z calculated for C8H15NO3SNa [M+Na]
+
: 
228.0670, found 228.0671. 
Anti (minor) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 6.19 (ddd, J = 16.5, 10.5, 5.5 Hz, 1H), 5.29 (dd, J = 10.5, 1.5 Hz, 1H), 
5.26 (dd, J = 17.0, 1.5 Hz, 1H), 4.61-4.56 (m, 2H), 4.24-4.19 (m, 1H), 2.06-1.98 (m, 2H), 1.88 
(dt, J = 14.5, 3.5 Hz, 1H), 1.03 (d, J = 6.5 Hz, 3H), 0.98 (d, J = 7.0 Hz, 3H); 
13
C-NMR (125 
MHz, CDCl3) δ 136.1, 117.3, 86.8, 55.3, 32.4, 30.6, 18.1, 17.8; IR (film, cm
-1
) 3282, 2970, 2933, 
2879, 1470, 1410, 1363, 1182 1032, 993, 883, 831; HRMS (ESI) m/z calculated for 
C8H15NO3SNa [M+Na]
+
: 228.0670, found 228.0669. 
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(±)-4-(1-methylethyl)-3-oxa-2-thia-1-azabicyclo[5.1.0]octane-2,2-dioxide. 
Prepared as a standard using general protocol for Rh conditions. Purified via flash 
column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 
4:1 hexanes/EtOAc as eluent system. Isolated as a white solid. 
1
H-NMR (500 MHz, CDCl3) δ 
4.32 (dt, J = 8.0, 5.0 Hz, 1H), 2.72 (d, J = 4.5 Hz, 1H), 2.64 (d, J = 5.0 Hz, 1H), 2.63-2.58 (m, 
1H), 2.49-2.34 (m, 1H), 2.05-1.90 (m, 4H), 1.02 (d, J = 7.0 Hz, 6H); 
13
C-NMR (125 MHz, 
CDCl3) δ 91.5, 40.1, 39.2, 32.5, 29.3, 27.1, 18.9, 17.9; IR (film, cm
-1
) 2968, 2931, 2881, 1470, 
1360, 1269, 1173, 1014, 985, 960, 899, 860; HRMS (ESI) m/z calculated for C8H15NO3SNa 
[M+Na]
+
: 228.0670, found 228.0670. 
 
(-)-4,5β-(cholest-5-enyl)-1,2,3-oxathiazole-2,2-dioxide [6].  
Iterative catalyst addition protocol for Fe conditions was followed, 
with the exception that a small amount of toluene (2-3 mL) was added 
to the Et2O suspension prior to Celite filtration in order to improve 
solubility of starting material and product. (-)-3β-cholest-5-enyl 
sulfamate (186 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (4x8 mg, 0.053 mmol, 0.10 equiv), 
AgSbF6 (4x4.5 mg, 0.053 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 
4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product ins./azir. was 
>20:1, and d.r. was >20:1 syn:anti. Flash column chromatography on silica (35 mm fritted glass 
column, 110 mm SiO2) using 9:1 hexanes:EtOAc + 1% AcOH as eluent gave pure syn product as 
a white solid (% rsm was determined based on crude ratios). 
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Run 1: (105 mg, 0.227 mmol, 57%), (20.3 mg rsm, 0.044 mmol, 11%). Run 2: (102.9 mg, 0.222 
mmol, 56%), (20.8 mg rsm, 0.045 mmol, 11%). Run 3: (112.3 mg, 0.243 mmol, 61%), (17.0 mg 
rsm, 0.037 mmol, 9%). Average: 58% yield, 10% rsm. 
1
H-NMR (500 MHz, CDCl3) δ 5.82 (app t, J = 2.5 Hz, 1H), 4.74 (dt, J = 10.5, 6.0 Hz, 1H), 4.53 
(t, J = 5.0 Hz, 1H), 4.34 (d, J = 5.0 Hz, 1H), 2.27 (dq, J = 3.0, 14.0 Hz, 1H), 2.14 (dt, J = 18.0, 
4.5 Hz, 1H), 2.08-2.02 (m, 2H), 1.91 (dt, J = 14.0, 4.0 Hz, 1H), 1.87-1.81 (m, 1H), 1.65-1.43 (m, 
7H), 1.41-1.24 (m, 5H), 1.20 (s, 3H), 1.18-1.05 (m, 6H), 1.02-0.89 (m, 2H), 0.91 (d, J = 7.0 Hz, 
3H), 0.86 (dd, J = 7.0, 2.5 Hz, 6H), 0.69 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 135.8, 133.9, 
84.3, 62.4, 56.9, 56.2, 49.4, 42.5, 39.6 (2 peaks), 36.3, 36.2, 35.9, 33.6, 32.3, 31.6, 28.3, 28.2, 
24.3, 23.9, 23.8, 23.0, 22.7, 21.3, 20.7, 18.8, 12.0; IR (film, cm
-1
) 3292, 2953, 2937, 2866, 1466, 
1379, 1338, 1281, 1192, 989, 970; [α]25D = -67.7
o
 (c = 1.0, CHCl3); HRMS (EI) m/z calculated 
for C27H45NO3S [M]
+
: 463.3120, found 463.3139. 
 
(±)-2-(2,2-dioxido-4-((E)-prop-1-en-1-yl)-1,2,3-oxathiazinan-6-yl)ethyl acetate [7]. 
Iterative catalyst addition protocol for Fe conditions was followed. (±)-(E)-3-(sulfamoyloxy)oct-
6-en-1-yl acetate (106 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (4x8 mg, 0.053 mmol, 0.13 equiv), 
AgSbF6 (4x4.5 mg, 0.053 mmol, 0.13 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 
4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, d.r. was 3:1 
syn:anti and ins./azir. was >20:1. Flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 2:1 hexanes/EtOAc as eluent gave syn and anti allylic 
oxathiazinanes separately.  
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Run 1: (52.1 mg syn + 11.9 mg anti (4.4:1 d.r.), 0.244 mmol, 61%), 0% rsm. Run 2: (53.1 mg 
syn + 12.3 mg anti (4.3:1 d.r.), 0.249 mmol, 62%), 0% rsm. Run 3: (50.3 mg syn + 12.2 mg anti 
(4.1:1 d.r.), 0.238 mmol, 60%), 0% rsm. Average: 61% yield, 0% rsm. 
Syn (major) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 
MHz, CDCl3) δ 5.75 (dq, J = 15.5, 6.5 Hz, 1H), 5.39 (ddd, J = 15.5, 6.0, 
1.5 Hz, 1H), 4.88-4.82 (m, 1H), 4.26 (br. d, J = 10.0 Hz, 1H), 4.23-4.12 (m, 3H), 2.05-1.94 (m, 
2H), 2.04 (s, 3H), 1.84 (dt, J = 14.0, 2.5 Hz, 1H), 1.70 (d, J = 7.0 Hz, 3H), 1.57 (dt, J = 14.0, 
12.0 Hz, 1H); 
13
C-NMR (125 MHz, CDCl3) δ 171.1, 129.6, 127.9, 80.7, 59.5, 56.2, 35.4, 34.3, 
21.0, 17.9; IR (film, cm
-1
) 3255, 2966, 2939, 2922, 2858, 1728, 1425, 1367, 1248, 1188, 1136, 
1095, 1051, 970, 866, 823, 769; HRMS (ESI) m/z calculated for C10H17NO5SNa [M+Na]
+
: 
286.0725, found 286.0722. 
Anti (minor) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 
MHz, CDCl3) δ 5.80-5.69 (m, 2H), 4.99 (app spt, J = 4.5 Hz, 1H), 4.49 (br. 
d, J = 7.0 Hz, 1H), 4.28-4.17 (m, 3H), 2.30 (ddt, J = 15.0, 9.0, 5.0 Hz, 1H), 2.06 (s, 3H), 2.00-
1.87 (m, 3H), 1.74 (d, J = 5.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 171.1, 129.5, 128.2, 79.6, 
60.0, 54.7, 33.6 (2 peaks), 21.0, 17.9; IR (film, cm
-1
) 3255, 2962, 2920, 1738, 1425, 1367, 1246, 
1186, 1099, 1047, 968, 870, 766; HRMS (ESI) m/z calculated for C10H17NO5SNa [M+Na]
+
: 
286.0725, found 286.0725. 
 (±)-2-(8-methyl-2,2-dioxido-3-oxa-2-thia-1-azabicyclo[5.1.0]octan-4-
yl)ethyl acetate. 
Prepared as a standard using general protocol for Rh conditions. Purified via flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 2:1 hexanes/EtOAc 
(600 mL)  1:1 hexanes/EtOAc as eluent system. Isolated as a white solid. 1H-NMR (500 MHz, 
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CDCl3) δ 4.45-4.40 (m, 1H), 4.19 (dt, J = 11.5, 5.5 Hz, 1H), 4.22-4.11 (m, 2H), 3.01 (app p, J = 
5.3 Hz, 1H), 2.66-2.64 (m, 1H), 2.53-2.42 (m, 2H), 2.05 (s, 3H), 1.99-1.91 (m, 2H), 1.90-1.84 
(m, 1H), 1.81-1.72 (m, 1H), 1.35 (d, J = 6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 171.0, 
80.4, 60.3, 47.1, 38.8, 33.7, 32.3, 24.7, 21.0, 17.1; IR (film, cm
-1
) 2970, 2931, 1739, 1439, 1373, 
1248, 1180, 1047, 1005, 903, 754, 687; HRMS (ESI) m/z calculated for C10H17NO5SNa 
[M+Na]
+
: 286.0725, found 286.0722. 
 
(±)-ethyl 2-(2,2-dioxido-4-((E)-prop-1-en-1-yl)-1,2,3-oxathiazinan-6-yl)acetate [8]. 
Single catalyst addition protocol for Fe conditions was followed. (±)-(E)-ethyl 3-
(sulfamoyloxy)oct-6-enoate (106 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24.0 mg, 0.040 mmol, 
0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 
equiv) and 4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, d.r. 
was 3:1 syn:anti and ins./azir. was >20:1. Flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using 3:1 hexanes/EtOAc as eluent gave syn and anti allylic 
oxathiazinanes separately.  
Run 1: (58.4 mg syn + 18.2 mg anti (3.2:1 d.r.), 0.292 mmol, 73%), 0% rsm. Run 2: (57.3 mg 
syn + 15.1 mg anti (3.8:1 d.r.), 0.276 mmol, 69%), 0% rsm. Run 3: (53.1 mg syn + 14.8 mg anti 
(3.6:1 d.r.), 0.259 mmol, 65%), 0% rsm. Average: 69% yield, 0% rsm. 
Syn (major) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ; 5.77 (dq, J = 15.5, 6.5 Hz, 1H), 5.41-5.38 (m, 1H), 5.13 (ddt, J = 
15.0, 6.5, 2.0 Hz, 1H), 4.23-4.22 (m, 2H), 4.16 (q, J = 7.0 Hz, 2H), 2.78 (dd, J = 16.3, 6.8 Hz, 
1H), 2.63 (dd, J = 16.3, 6.3 Hz, 1H), 1.97 (app d, J = 14.5 Hz, 1H), 1.70 (d, J = 6.5 Hz, 3H), 
1.63-1.54 (m, 1H), 1.26 (t, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 169.0, 129.6, 127.8, 
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79.7, 61.3, 56.1, 40.1, 35.0, 17.9, 14.2; IR (film, cm
-1
) 3257, 2983, 2941, 2920, 1736, 1423, 
1365, 1311, 1219, 1188, 1047, 10128, 941, 870, 791; HRMS (ESI) m/z calculated for 
C10H18NO5S [M+H]
+
: 264.0906, found 264.0914. 
Anti (minor) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.78-5.71 (m, 2H), 5.30-5.25 (m, 1H), 4.53 (br. d, J = 7.5 Hz, 1H), 
4.23-4.21 (m, 1H), 4.17 (q, J = 7.0 Hz, 2H), 2.99 (dd, J = 16.5, 6.5 Hz, 1H), 2.78 (dd, J = 16.5, 
7.5 Hz, 1H), 2.04-1.93 (m, 2H), 1.73 (d, J = 4.0 Hz, 3H), 1.27 (t, J = 7.0 Hz, 3H); 
13
C-NMR (125 
MHz, CDCl3) δ 169.4, 129.4, 128.0, 78.5, 61.4, 54.5, 39.1, 32.8, 18.0, 14.2; IR (film, cm
-1
) 3267, 
2983, 2939, 2922, 1732, 1425, 1371, 1309, 1186, 1034, 968, 881, 787; HRMS (ESI) m/z 
calculated for C10H18NO3S [M+H]
+
: 264.0906, found 264.0900. 
 
 
Procedure for iron-catalyzed intermolecular allylic C—H amination [9] 
Into a 10 mL round-bottom flask was added AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
[FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), and a stir bar in a glovebox. The flask was then 
sealed with a rubber septum, covered in aluminum foil, and taken out of the box. 4:1 
C6H6:MeCN (800 μL, 0.5M), sulfamate ester (92.9 mg, 0.400 mmol, 1.0 equiv), and, lastly, 
TcesNIPh (206 mg, 0.480 mmol, 1.2 equiv) were then added sequentially. After addition of 
oxidant, the deep violet solution gradually turned dark brown. The reaction stirred for 4h at room 
temp (~20
o
C), then the reaction was concentrated under reduced pressure. The remaining dark 
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brown residue was suspended in Et2O and filtered through a pad of Celite. Upon removal of 
solvent under reduced pressure, flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 9:1 hexanes/EtOAc  4:1 hexanes/EtOAc as eluent afforded 9 
(63.3 mg, 0.138 mmol, 1.3:1 mixture of constitutional isomers) as a pale yellow oil (35% yield). 
50.1 mg (0.217 mmol) of starting material was also recovered (54%). 
 
Procedure for rhodium-catalyzed intermolecular C—H amination42 
Into a 10 mL round-bottom flask was added Rh2(esp)2 (6.1 mg, 0.008 mmol, 0.02 equiv), 
TcesNH2 (91.4 mg, 0.440 mmol, 1.1 equiv), substrate (92.0 mg, 0.400 mmol, 1.0 equiv), and 
C6H6 (800 µL). A solution of PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) in C6H6 (800 µL) was 
added over 3h via syring pump. After oxidant addition, reaction stirred at rt for an additional 2h. 
Upon completion, reaction was diluted with 5 mL CH2Cl2 and 2 mL sat. aq. Thiourea, then 
stirred for 30 min. The mixture was transferred to a separatory funnel, and the aqueous layer was 
extracted with CH2Cl2 (2x10 mL). The combined organic layers were washed with a 0.1M pH 7 
Na2HPO4/NaH2PO4 buffer and dried over MgSO4. Purification via flash column chromatography 
on silica (35 mm fritted glass column, 150 mm SiO2) using 9:1 hexanes/EtOAc afforded 
aziridine (131 mg, 0.284 mmol) as a colorless oil (71% yield). 
 
(±)-4-phenyl-6-(1-methylethyl)-tetrahydro-1,2,3-oxathiazine-2,2-dioxide [10]. 
Single catalyst addition protocol for Fe conditions was followed. (±)-1-phenyl-5-methylpentan-
3-yl sulfamate (103 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), 
AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 
4:1 PhMe:MeCN (800 μL) were used. Flash column chromatography on silica (35 mm fritted 
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glass column, 110 mm SiO2) using 4:1 hexanes:EtOAc + 1% AcOH as eluent gave pure syn and 
anti oxathiazinanes separately.  
Run 1: (65.8 mg syn + 4.0 mg anti (16:1 d.r.), 0.274 mmol, 68%), <5% rsm. Run 2: (63.8 mg syn 
+ 3.8 mg anti (17:1 d.r.), 0.262 mmol, 65%), <5% rsm. Run 3: (63.9 mg syn + 3.8 mg anti (17:1 
d.r.), 0.265 mmol, 66%), <5% rsm. Average: 66% yield, <5% rsm. 
 Syn (major) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 7.43-7.34 (m, 5H), 4.78 (ddd, J = 12.0, 9.0, 3.0 Hz, 1H), 4.65 (ddd, J = 
11.5, 6.5, 2.0 Hz, 1H), 4.15 (br. d, J = 8.5 Hz, 1H), 2.06 (dt, J = 14.0, 2.5 Hz, 1H), 1.99 (app. sxt, 
J = 7.0 Hz, 1H), 1.91 (dt, J = 14.0, 12.0 Hz, 1H), 1.06 (d, J = 6.5 Hz, 3H), 1.03 (d, J = 6.5 Hz, 
3H); 
13
C-NMR (125 MHz, CDCl3) δ 138.4, 129.3, 129.1, 126.5, 89.0, 58.4, 33.6, 32.8, 18.1, 
17.8; IR (film, cm
-1
) 3267, 2968, 2935, 2879, 1456, 1416, 1363, 1190, 874; HRMS (ESI) m/z 
calculated for C12H18NO3S [M+H]
+
: 256.1007, found 256.1010. 
Anti (minor) diastereomer: Isolated as a white waxy solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 7.41-7.39 (m, 4H), 7.37-7.33 (m, 1H), 4.83 (dt, J = 8.0, 5.5 Hz, 1H), 
4.58 (br. d, J = 8.0 Hz, 1H), 4.50 (dt, J = 7.5, 4.5 Hz, 1H), 2.36-2.22 (m, 3H), 1.11 (d, J = 6.5 Hz, 
3H), 1.00 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 138.2, 129.1, 128.5, 126.5, 88.1, 
55.5, 31.6, 31.4, 18.6, 18.5; IR (film, cm
-1
) 3284, 2968, 2935, 2902, 2875, 1450, 1423, 1360, 
1176, 891; HRMS (ESI) m/z calculated for C12H17NO3SNa [M+Na]
+
: 278.0827, found 278.0829. 
 
Benzyl (4S,5R)-4-phenyl-1,2,3-oxathiazolidine-5-carboxylate 2,2-dioxide [11]. 
Single catalyst addition protocol for Fe conditions was followed. Benzyl (R)-3-
phenyl-2-(sulfamoyloxy)propanoate (134 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl 
(24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
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PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL) were used. Flash 
column chromatography on silica (35 mm fritted glass column, 110 mm SiO2) using 4:1 
hexanes:EtOAc + 1% AcOH as eluent gave syn and anti oxathiazinanes as a mixture (71.8 mg 
total, 0.216 mmol, 54% yield, 1:3 syn:anti) and recovered starting material separately (14.7 mg, 
0.044 mmol, 11% rsm).  
 
(+)-(4R, 6R)-4-methyl 4-(4-methylpentyl)-6-propyl-tetrahydro-1,2,3-oxathiazine-2,2-dioxide 
[syn-12]. 
Iterative catalyst addition protocol for Fe conditions was followed. (-)-(4R, 
6R)-6,10-dimethylundecan-4-yl sulfamate (112 mg, 0.400 mmol, 1.0 equiv, 
97:3 anti:syn), [FePc]Cl (4x8 mg, 0.053 mmol, 0.13 equiv), AgSbF6 (4x4.5 mg, 0.053 mmol, 
0.13 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL) were 
used. By achiral GC analysis of the crude reaction mixture, d.r. was 97:3 syn:anti (the 
diastereomers in this case are based on the oxathiazinane ring rather than the 1,3 relationship 
between the oxygen and chiral methyl substituent). Flash column chromatography on silica (35 
mm fritted glass column, 150 mm SiO2) using 9:1 hexanes:EtOAc + 1% AcOH as eluent gave 
oxathiazinane product as a ~40:1 syn:anti mixture of diastereomers. If desired, the diastereomers 
could be readily separated under the stated purification conditions; the pure syn oxathiazinane 
was isolated as a white solid in this case.  
Run 1: (49.6 mg (39:1 syn:anti), 0.179 mmol, 45%), (32.0 mg rsm, 0.114 mmol, 29%). Run 2: 
(51.1 mg (40:1 syn:anti), 0.184 mmol, 46%), (30.6 mg rsm, 0.109 mmol, 27%). Run 3: (47.8 mg 
(40:1 syn:anti), 0.172 mmol, 43%), (28.4 mg rsm, 0.101 mmol, 25%).  Average: 45% yield, 
27% rsm. 
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1
H-NMR (500 MHz, CDCl3) δ 4.85 (ddt, J = 11.0, 7.0, 4.0 Hz, 1H), 4.01 (br. s, 1H), 1.76-1.71 
(m, 1H), 1.61-1.49 (m, 5H), 1.49-1.27 (m, 5H), 1.46 (s, 3H), 1.16 (q, J = 7.5 Hz, 2H), 0.95 (t, J = 
7.5 Hz, 3H), 0.88 (d, J = 6.5 Hz, 6H); 
13
C-NMR (125 MHz, CDCl3) δ 80.8, 58.5, 45.2, 40.6, 
39.1, 37.5, 28.0, 22.7 (2 peaks), 22.6, 20.5, 18.0, 13.8; IR (film, cm
-1
) 3257, 2956, 2872, 1466, 
1419, 1383, 1356, 1190, 877; [α]26D = +11.1
o
 (c = 1.0, CHCl3); HRMS (ESI) m/z calculated for 
C13H27NO3SNa [M+Na]
+
: 300.1609, found 300.1610. 
(-)-(4R, 6S)-4-methyl 4-(4-methylpentyl)-6-propyl-tetrahydro-1,2,3-oxathiazine-2,2-dioxide 
[anti-12]. 
Iterative catalyst addition protocol for Fe conditions was followed. (+)-
(4R, 6R)-6,10-dimethylundecan-4-yl sulfamate (112 mg, 0.400 mmol, 1.0 
equiv, 97:3 anti:syn), [FePc]Cl (4x8 mg, 0.053 mmol, 0.13 equiv), AgSbF6 (4x4.5 mg, 0.053 
mmol, 0.13 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL) 
were used. By achiral GC analysis of the crude reaction mixture, d.r. was 5:95 syn:anti (the 
diastereomers in this case are based on the oxathiazinane ring rather than the 1,3 relationship 
between the oxygen and chiral methyl substituent). Flash column chromatography on silica (35 
mm fritted glass column, 150 mm SiO2) using 9:1 hexanes:EtOAc + 1% AcOH as eluent gave 
oxathiazinane product as a ~1:30 syn:anti mixture of diastereomers. If desired, the diastereomers 
could be readily separated under the stated purification conditions; the pure anti oxathiazinane 
was isolated as a white solid in this case.  
Run 1: (47.4 mg (1:19 syn:anti), 0.172 mmol, 43%), (27.5 mg rsm, 0.098 mmol, 25%). Run 2: 
(48.1 mg (1:19 syn:anti), 0.172 mmol, 43%), (23.6 mg rsm, 0.084 mmol, 21%). Run 3: (44.3 mg 
(1:19 syn:anti), 0.160 mmol, 40%), (22.3 mg rsm, 0.080 mmol, 20%).  Average: 42% yield, 
22% rsm. 
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1
H-NMR (500 MHz, CDCl3) δ 4.86-4.81 (m, 1H), 3.91 (br. s, 1H), 2.14-2.09 (m, 1H), 1.76-1.67 
(m, 2H), 1.59-1.37 (m, 7H), 1.28-1.14 (m, 3H), 1.23 (s, 3H), 0.95 (t, J = 7.5 Hz, 3H), 0.88 (d, J = 
2.0 Hz, 3H), 0.87 (d, J = 2.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 80.6, 58.5, 41.4, 39.2, 
37.4, 36.8, 28.9, 27.9, 22.7, 21.6, 18.0, 13.8; IR (film, cm
-1
) 3269, 2956, 2872, 1466, 1421, 1383, 
1354, 1190, 1157, 876; [α]26D = -35.5
o
 (c = 0.5, CHCl3); HRMS (ESI) m/z calculated for 
C13H27NO3SNa [M+Na]
+
: 300.1609, found 300.1607. 
 
Confirmation of Stereoretention in a Stereochemically Defined 3
o
 C—H Bond 
In order to confirm the configuration of the tertiary center in 12 following C—H amination under 
[FePc]
.
SbF6 catalysis, standards representing each diasteromeric configuration were prepared. A 
diastereomeric mixture, resulting from the non-selective addition of allylmagnesium bromide to 
chirally pure (+)-citronellal, was carried forward for use as a standard for quantitative analysis 
(vide infra). Authentic standards of each oxathiazinane product, (+)-syn-12 and (-)-anti-12, were 
prepared under Rh-catalyzed C—H amination conditions. These products are readily separated 
via flash column chromatography, allowing for full characterization of pure samples of each 
possible diastereomer that could be formed under the [FePc]
.
SbF6-catalyzed C—H amination 
conditions. NOTE: the standard that was prepared for the minor diastereomer in each case has 
the opposite enantiomeric configuration to that which would be formed in the case of 
epimerization at the reacting tertiary C—H center of 12 (if the correct enantiomer is desired, (-)-
citronellal can instead be used as the starting material). 
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The relative configurations of (+)-syn-12 and (-)-anti-12 were confirmed based on nOe 
1
H-NMR 
experiments (500 MHz, CDCl3). The ethereal proton peaks at δ = 4.85 ppm and δ = 4.85-4.81 
ppm, respectively, were irradiated in each case, and the resulting observed relationships are 
illustrated below (irradiated protons are highlighted in red). (+)-syn-12 gave a characteristic nOe 
between the pseudo-axial ethereal proton and the axial methyl group. Conversely, (-)-anti-12 
gave no measurable nOe for these two groups, as the ethereal proton in this case is in a pseudo-
equatorial position, placing it on the opposite side of the ring from the axial methyl group. 
 
Quantitative determination of stereoretention was accomplished via achiral GC analysis. 
Hydrogenation of the Grignard addition product gave compound 25 as a mixture of 
diastereomers, which was used as a standard to establish a baseline separation of the 
diastereomers by GC. The corresponding diastereomerically enriched (-)-anti-25 or (+)-anti-25 
were subjected to GC analysis to establish the initial diastereomeric ratio of the starting material 
that would be subjected to the [FePc]
.
SbF6-catalyzed C—H amination reaction. The 
diastereomeric mixture of (+)-syn-12 and (-)-anti-12, prepared by the synthetic pathway 
illustrated above, was used as a standard to establish a baseline separation of the oxathiazinane 
diastereomers by GC. Following standard work-up protocol for the [FePc]
.
SbF6-catalyzed C—H 
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amination reaction, the crude reaction mixture was subjected to GC analysis in triplicate runs 
using the optimized method established by the standard mixture. The stereoretention under the 
reaction was then determined by comparing the diastereomeric ratio of the starting material with 
that of oxathiazinane product 12. No loss of d.r. suggests that the purported carbon-centered 
radical intermediate has a lifetime shorter than 1x10
-9
s, whereas a change in d.r. would indicate 
that the radical is sufficiently long-lived to at least partially racemize a stereodefined tertiary 
center. 
 
Competition studies for Allylic C—H amination 
General procedure for Rh2(OAc)4-mediated intramolecular amination
18
 
A 10 mL round bottom flask equipped with a stir bar and rubber septum was charged with 
sulfamate ester (0.400 mmol, 1.0 equiv), CH2Cl2 (2.6 mL, 0.15M), magnesium oxide (37.1 mg, 
0.920 mmol, 2.3 equiv), PhI(OAc)2 (142 mg, 0.440 mmol, 1.1 equiv), and Rh2(OAc)4 (3.5 mg, 
0.008 mmol, 0.02 equiv) sequentially (if sulfamate ester is an oil, it was taken up in solvent and 
added to the flask via syringe). The reaction stirred at room temp for 4h. Upon completion, the 
mint green reaction mixture was filtered through a small pad of MgSO4 over Celite and rinsed 
with CH2Cl2. Upon removal of solvent under reduced pressure, flash column chromatography on 
silica allowed separate isolation of each component. 
 
(±)-4-((1E)-1-propenyl)-6-butyltetrahydro-1,2,3-oxathiazine-2,2-dioxide [13].  
Entry 1: Single catalyst addition protocol for Fe conditions was followed. (±)-(E)-dec-8-en-5-yl 
sulfamate (94.0 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), 
AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 
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4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, β:β’ was 
>20:1, ins./azir. was >20:1, and d.r. was 3.8:1 syn:anti. Flash column chromatography on silica 
(35 mm fritted glass column, 150 mm SiO2) using 6:1 hexanes/EtOAc + 1% AcOH as eluent 
gave pure syn and anti oxathiazinanes separately; the olefin maintained a >20:1 E/Z geometry in 
each case.  
Run 1: (42.5 mg syn + 13.8 mg anti (3.1:1 d.r. – this was 2.9:1 in crude), 0.242 mmol, 61%), 
<5% rsm. Run 2: (51.0 mg syn + 10.8 mg anti (4.7:1 d.r.), 0.264 mmol, 66%), <5% rsm. Run 3: 
(50.2 mg syn + 11.3 mg anti (4.4:1 d.r.), 0.264 mmol, 66%), <5% rsm. Average: 64% yield 
allylic, <5% rsm. 
Entry 2: General protocol for Rh conditions was followed. (±)-(E)-dec-8-en-5-yl sulfamate 
(94.0 mg, 0.400 mmol, 1.0 equiv), Rh2(OAc)4 (3.5 mg, 0.008 mmol, 0.02 equiv), MgO (37.1 mg, 
0.920 mmol, 2.3 equiv), PhI(OAc)2 (142 mg, 0.440 mmol, 1.1 equiv), CH2Cl2 (2.6 mL, 0.15M) 
were used. By 
1
H-NMR analysis of the crude product, β:β’ was >20:1, ins./azir. was 4:1, and d.r. 
was 4:1. Flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) 
using 5:1 hexanes/EtOAc (400 mL)  3:1 hexanes/EtOAc as eluent gave pure syn and anti 
oxathiazinanes and aziridine separately; the olefin maintained a >20:1 E/Z geometry in each 
case.  
Run 1: (48.0 mg syn + 8.9 mg anti (5:1 d.r.), 0.245 mmol, 61%), (15.6 mg aziridine (3.6:1 
ins/azir), 0.067 mmol, 17%), <5% rsm. Run 2: (51.8 mg syn + 10.1 mg anti (5:1 d.r.), 0.267 
mmol, 66%), (16.5 mg aziridine (3.8:1 ins/azir), 0.067 mmol, 17%), <5% rsm. Run 3: (49.3 mg 
syn + 8.7 mg anti (5.7:1 d.r.), 0.247 mmol, 62%), (17.4 mg mg aziridine (3.3:1 ins/azir), 0.074 
mmol, 19%), <5% rsm. Average: 63% yield allylic, <5% rsm. 
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Syn (major) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.77 (dq, J = 15.0, 7.0 Hz, 1H), 5.41 (dd, J = 15.5, 6.0 Hz, 1H), 
4.76-4.71 (m, 1H), 4.23-4.18 (m, 1H), 3.83 (br. d, J = 9.0 Hz, 1H), 1.84 (dt, J = 14.5, 2.5 Hz, 
1H), 1.78-1.71 (m, 1H), 1.72 (d, J = 6.5 Hz, 3H), 1.66-1.59 (m, 1H), 1.57-1.31 (m, 5H), 0.91 (t, J 
= 7.3 Hz, 3H) ; 
13
C-NMR (125 MHz, CDCl3) δ 129.6, 128.6, 84.5, 56.5, 36.1, 35.3, 27.0, 22.6, 
18.1, 14.2; IR (film, cm
-1
) 3261, 2937, 2872, 1417, 1362, 1188, 870; HRMS (ESI) m/z calculated 
for C10H20NO3S [M+H]
+
: 234.1164, found 234.1161. 
Anti (minor) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.81 (ddd, J = 15.0, 6.5, 1.5 Hz, 1H), 5.71 (dq, J = 15.5, 6.0 Hz, 
1H), 4.87-4.82 (m, 1H), 4.40 (br. d, J = 7.0 Hz, 1H), 4.19 (app. p, J = 5.5 Hz, 1H), 1.95-1.88 (m, 
2H), 1.84 (ddd, J = 14.5, 5.0, 3.5 Hz, 1H), 1.73 (d, J = 6.5 Hz, 3H), 1.65-1.59 (m, 1H), 1.50-1.46 
(m, 1H), 1.40-1.31 (m, 3H), 0.91 (t, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 129.1, 
128.5, 83.0, 55.0, 34.4, 33.9, 27.1, 22.4, 17.9, 14.0; IR (film, cm
-1
) 3375, 2958, 2935, 2872, 
1421, 1367, 1184, 874; HRMS (ESI) m/z calculated for C10H19NO3SNa [M+Na]
+
: 256.0983, 
found 256.0984. 
(±)-trans-4-butyl-8-methyl-3-oxa-2-thia-1-azabicyclo[5.1.0]octane-2,2-dioxide. 
Isolated under Rh conditions (entry 2). Purified via flash column 
chromatography on silica using 4:1 hexanes/EtOAc  2:1 hexanes/EtOAc 
as the eluent system. Isolated as a colorless oil. 
1
H-NMR (500 MHz, CDCl3) δ 4.31-4.26 (m, 
1H), 3.00 (app. p, J = 5.5 Hz, 1H), 2.65-2.62 (m, 1H), 2.51-2.39 (m, 2H), 1.87-1.82 (m, 1H), 
1.76-1.63 (m, 2H), 1.58-1.52 (m, 1H), 1.46-1.25 (m, 4H), 1.35 (d, J = 5.5 Hz, 3H), 0.89 (t, J = 
7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 84.0, 47.2, 38.6, 34.4, 32.4, 27.7, 24.8, 22.4, 17.1, 
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14.0; IR (film, cm
-1
) 2956, 2932, 2870, 1437, 1373, 1180, 1003, 901, 837; HRMS (ESI) m/z 
calculated for C10H20NO3S [M+H]
+
: 234.1164, found 234.1168. 
 
(±)-4-((1E)-1-propenyl)-6-(2-methylpropyl)tetrahydro-1,2,3-oxathiazine-2,2-dioxide [14].  
Entry 3: Single catalyst addition protocol for Fe conditions was followed. (±)-(E)-2-methylnon-
7-en-4-yl sulfamate (94.0 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24.0 mg, 0.040 mmol, 0.10 
equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) 
and 4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, β:β’ was 
>20:1, ins./azir. was >20:1, and d.r. was 3.7:1 syn:anti. Flash column chromatography on silica 
(35 mm fritted glass column, 150 mm SiO2) using 6:1 hexanes:EtOAc + 1% AcOH as eluent 
gave pure syn and anti oxathiazinanes separately; the olefin maintained a >20:1 E/Z geometry in 
each case.  
Run 1: (54.6 mg syn + 12.1 mg anti (4.5:1 d.r.), 0.286 mmol, 72%), <5% rsm. Run 2: (56.0 mg 
syn + 11.1 mg anti (5:1 d.r.), 0.288 mmol, 72%), <5% rsm. Run 3: (56.3 mg syn + 11.2 mg anti 
(5:1 d.r.), 0.290 mmol, 73%), <5% rsm. Average: 72% yield allylic, <5% rsm. 
Entry 4: General protocol for Rh conditions was followed. (±)-(E)-2-methylnon-7-en-4-yl 
sulfamate (94.0 mg, 0.400 mmol, 1.0 equiv), Rh2(OAc)4 (3.5 mg, 0.008 mmol, 0.02 equiv), MgO 
(37.1 mg, 0.920 mmol, 2.3 equiv), PhI(OAc)2 (142 mg, 0.440 mmol, 1.1 equiv), CH2Cl2 (2.6 mL, 
0.15M) were used. By 
1
H-NMR analysis of the crude product, β:β’ was 1.3:1, ins./azir. was 6:1, 
and d.r. was 4:1. Flash column chromatography on silica (35 mm fritted glass column, 110 mm 
SiO2) using 4:1 hexanes:EtOAc as eluent gave syn and anti oxathiazinanes separately, along with 
product of 3
o
 insertion (the allylic minor diasteromer and 3
o
 products co-eluted) and aziridine; 
the olefin maintained a >20:1 E/Z geometry in each case.  
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Run 1: (32.3 mg syn + 5.1 mg anti (6:1 d.r.), 0.161 mmol, 40%), (28.1 mg tertiary (β:β’ = 1.3:1), 
0.121 mmol, 30%), (10.1 mg aziridine (6:1 ins/azir), 0.043 mmol, 11%), 0% rsm. Run 2: (35.2 
mg syn + 6.4 mg anti (5.5:1 d.r.), 0.179 mmol, 45%), (31.7 mg tertiary (β:β’ = 1.3:1), 0.136 
mmol, 34%), (9.3 mg aziridine (8:1 ins/azir), 0.040 mmol, 10%), 0% rsm. Run 3: (33.0 mg syn + 
7.5 mg anti (4.4:1 d.r.), 0.174 mmol, 44%), (37.5 mg tertiary (β:β’ = 1.1:1), 0.136 mmol, 34%), 
(15.0 mg aziridine (5:1 ins/azir), 0.065 mmol, 16%), 0% rsm. Average: 43% yield allylic, 0% 
rsm. 
Syn (major) diastereomer: Isolated as a waxy solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.78 (dq, J = 15.5, 6.5 Hz, 1H), 5.41 (dd, J = 15.5, 6.0 Hz, 1H), 4.85-
4.80 (m, 1H), 4.25-4.20 (m, 1H), 3.79 (br. d, J = 9.5 Hz, 1H), 1.90-1.83 (m, 1H), 1.82 (dt, J = 
14.0, 2.0 Hz, 1H), 1.75-1.69 (m, 1H), 1.73 (d, J = 5.5 Hz, 3H), 1.55-1.47 (m, 1H), 1.38 (ddd, J = 
12.5, 8.5, 4.0 Hz, 1H), 0.94 (t, J = 6.8 Hz, 6H); 
13
C-NMR (125 MHz, CDCl3) δ 129.4, 128.4, 
82.7, 56.2, 44.4, 36.3, 24.0, 23.0, 22.0, 17.84; IR (film, cm
-1
) 3261, 2958, 2873, 1416, 1365, 
1188, 876; HRMS (ESI) m/z calculated for C10H19NO3SNa [M+Na]
+
: 256.0983, found 256.0984. 
Anti (minor) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.83 (ddd, J = 15.5, 6.5, 1.5 Hz, 1H), 5.72 (dq, J = 15.5, 6.5 Hz, 1H), 
4.95 (app. spt, J = 4.5 Hz, 1H), 4.25 (br. d, J = 7.0 Hz, 1H), 4.19 (app. p, J = 5.5 Hz, 1H), 1.95-
1.81 (m, 4H), 1.75 (d, J = 6.5 Hz, 3H), 1.38-1.33 (m, 1H), 0.95 (t, J = 6.0 Hz, 6H); 
13
C-NMR 
(125 MHz, CDCl3) δ 129.2, 128.5, 81.2, 55.1, 43.5, 34.3, 24.1, 23.0, 21.9, 17.9; IR (film, cm
-1
) 
3275, 2960, 2873, 1421, 1369, 1184, 1012, 996, 874; HRMS (ESI) m/z calculated for 
C10H19NO3SNa [M+Na]
+
: 256.0983, found 256.0983. 
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(±)-4-((3E)-3-pentenyl)-6,6-dimethyltetrahydro-1,2,3-oxathiazine-2,2-dioxide.  
Isolated under Rh conditions (entry 4). Purified via flash column 
chromatography on silica (35 mm fritted glass column, 110 mm SiO2) using 
6:1 hexanes/EtOAc as eluent system. Isolated as a colorless oil; the olefin maintained a >20:1 
E/Z geometry. 
1
H-NMR (500 MHz, CDCl3) δ 5.48 (dq, J = 15.0, 6.5 Hz, 1H), 5.38 (ddt, J = 15.5, 
6.5, 1.5 Hz, 1H), 4.82 (ddt, J = 11.0, 5.0, 4.5 Hz, 1H), 4.18 (br. s, 1H), 2.17-2.09 (m, 2H), 1.84-
1.77 (m, 1H), 1.65 (dd, J = 6.0, 1.5 Hz, 3H), 1.66-1.58 (m, 3H), 1.48 (s, 3H), 1.29 (s, 3H); 
13
C-
NMR (125 MHz, CDCl3) δ 129.2, 126.8, 80.7, 56.0, 41.5, 35.1, 32.0, 27.7, 25.2, 18.0; IR (film, 
cm
-1
) 3267, 2972, 2939, 2922, 2856, 1421, 1389, 1352, 1192, 1157, 968, 941, 872; HRMS (ESI) 
m/z calculated for C10H19NO3SNa [M+Na]
+
: 256.0983, found 256.0983. 
 (±)-trans-4-butyl-8-methyl-3-oxa-2-thia-1-azabicyclo[5.1.0]octane-2,2-dioxide. 
Isolated under Rh conditions (entry 4). Purified via flash column 
chromatography on silica (35 mm fritted glass column, 110 mm SiO2) using 
6:1 hexanes/EtOAc  2:1 hexanes/EtOAc as the eluent system. Isolated as a white solid. 1H-
NMR (500 MHz, CDCl3) δ 4.36 (ddt, J = 11.5, 4.0, 2.0 Hz, 1H), 3.00 (app. p, J = 5.5 Hz, 1H), 
2.65-2.63 (m, 1H), 2.53-2.40 (m, 2H), 1.84-1.70 (m, 2H), 1.68-1.61 (ddd, J = 14.5, 9.5, 5.0 Hz, 
1H), 1.35 (d, J = 5.5 Hz, 3H), 1.29-1.24 (m, 2H), 0.92 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 7.0 Hz, 
3H); 
13
C-NMR (125 MHz, CDCl3) δ 82.3, 47.2, 43.5, 38.6, 32.9, 24.8, 24.7, 23.1, 21.6, 17.1; IR 
(film, cm
-1
) 2960, 2931, 2873, 1439, 1375, 1180, 1003, 903, 764; HRMS (ESI) m/z calculated for 
C10H19NO3SNa [M+Na]
+
: 256.0983, found 256.0981. 
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(±)-4-((1E)-1-propenyl)-6-(2-methoxyethyl)tetrahydro-1,2,3-oxathiazine-2,2-dioxide [15].  
Entry 5: Single catalyst addition protocol for Fe conditions was followed. (±)-(E)-1-
methoxyoct-6-en-3-yl sulfamate (94.8 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24 mg, 0.040 
mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 
mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude 
product, β:β’ was 7:1, ins./azir. was >20:1, and d.r. was 3.8:1 syn:anti. Flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 3:1 hexanes/EtOAc 
as eluent gave pure syn and anti oxathiazinanes separately; the olefin maintained a >20:1 E/Z 
geometry in each case. Due to the instability of the ethereal product on silica, product ratios in 
this case were based solely on the crude 
1
H-NMR integrations.  
Run 1: (53.6 mg syn + 13.7 mg anti (4:1 d.r.), 0.286 mmol, 72%), 0% rsm. Run 2: (54.5 mg syn 
+ 11.9 mg anti (4.5:1 d.r.), 0.283 mmol, 71%), 0% rsm. Run 3: (54.4 mg syn + 11.8 mg anti 
(4.6:1 d.r.), 0.282 mmol, 70%), 0% rsm. Average: 71% yield allylic, 0% rsm. 
Entry 6: General protocol for Rh conditions was followed. (±)-(E)-1-methoxyoct-6-en-3-yl 
sulfamate (94.8 mg, 0.400 mmol, 1.0 equiv), Rh2(OAc)4 (3.5 mg, 0.008 mmol, 0.02 equiv), MgO 
(37.1 mg, 0.920 mmol, 2.3 equiv), PhI(OAc)2 (142 mg, 0.440 mmol, 1.1 equiv), CH2Cl2 (2.6 mL, 
0.15M) were used. By 
1
H-NMR analysis of the crude product, β:β’ was 4:1 and ins./azir. was 4:1 
(only the ethereal and aziridine products gave clear peaks in the crude 
1
H-NMR, so product 
ratios were based on these peaks and isolated yields). Flash column chromatography on silica (35 
mm fritted glass column, 150 mm SiO2) using 2:1 hexanes:EtOAc + 2% Et3N (500 mL)  1:1 
hexanes/EtOAc as eluent gave syn and anti allylic oxathiazinanes and aziridine separately; the 
olefin maintained a >20:1 E/Z geometry in each case. In one case (Run 3), the crude material was 
purified using Davisil grade 643 silica gel in order to confirm the crude ratios for the ethereal 
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product (the ethereal product is acid-sensitive and decomposes on normal silica, precluding 
quantitative isolation); 3:1 hexanes/EtOAc (300 mL)  2:1 hexanes/EtOAc (300 mL)  1:1 
hexanes/EtOAc was used as the eluent.  
Run 1: (35.4 mg syn + 8.5 mg anti (4:1 d.r.), 0.188 mmol, 47%), (14.3 mg aziridine (3.5:1 
ins./azir.), 0.060 mmol, 15%), <5% rsm. Run 2: (35.3 mg syn + 8.9 mg anti (4:1 d.r.), 0.188 
mmol, 47%), (14.9 mg aziridine (3.7:1 ins/azir), 0.064 mmol, 16%), <5% rsm. Run 3: (30.0 mg 
syn + 7.6 mg anti (3.9:1 d.r.), 0.160 mmol, 40%), (11.0 mg ethereal (β:β’ = 3.4:1), 0.047 mmol, 
12% yield), (13.4 mg aziridine (3.6:1 ins/azir), 0.057 mmol, 14%), 0% rsm.  Average: 45% 
yield allylic, <5% rsm. 
Syn (major) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.79 (dq, J = 15.5, 6.5 Hz, 1H), 5.42 (dd, J = 15.5, 6.0 Hz, 1H), 
4.96-4.91 (m, 1H), 4.23-4.19 (m, 1H), 3.90-3.83 (m, 1H), 3.55-3.48 (m, 2H), 3.35 (s, 3H), 2.01-
1.89 (m, 3H), 1.74 (d, J = 6.5 Hz, 3H), 1.57 (dt, J = 14.0, 12.0 Hz, 1H); 
13
C-NMR (125 MHz, 
CDCl3) δ 129.5, 128.2, 81.6, 67.6, 59.0, 56.2, 35.9, 35.7, 17.9; IR (film, cm
-1
) 3259, 3174, 2934, 
2881, 1421, 1360, 1188, 1117, 864; HRMS (ESI) m/z calculated for C9H17NO4SNa [M+Na]
+
: 
258.0776, found 258.0778. 
Anti (minor) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.78 (dd, J = 15.5, 6.0 Hz, 1H), 5.72 (dq, J = 16.0, 6.0 Hz, 1H), 
5.05 (app. spt, J = 4.5 Hz, 1H), 4.35 (br. d, J = 7.5 Hz, 1H), 4.21 (app. p, J = 6.0 Hz, 1H), 3.57-
3.48 (m, 2H), 3.35 (s, 3H), 2.24-2.18 (m, 1H), 1.97-1.87 (m, 3H), 1.73 (d, J = 6.0 Hz, 3H); 
13
C-
NMR (125 MHz, CDCl3) δ 129.3, 128.4, 80.4, 67.9, 59.0, 54.8, 34.7, 33.9, 17.9; IR (film, cm
-1
) 
3273, 2924, 2885, 1423, 1369, 1186, 1119, 968 870; HRMS (ESI) m/z calculated for 
C9H17NO4SNa [M+Na]
+
: 258.0776, found 258.0775. 
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 (±)-4-((3E)-3-pentenyl)-6-methoxytetrahydro-1,2,3-oxathiazine-2,2-dioxide.  
Due to its instability under silica-based flash column chromatography 
conditions, the minor ethereal product could not be isolated in a quantitative 
manner. However, a sufficient amount was isolated pure for the purposes of characterization, to 
ensure use of appropriate 
1
H-NMR peaks for product ratio determination in the crude reaction 
mixture. Isolated as a colorless oil; the olefin maintained a >20:1 E/Z geometry. 
1
H-NMR (500 
MHz, CDCl3) δ 5.49 (dq, J = 15.0, 6.5 Hz, 1H), 5.37 (ddt, J = 15.0, 7.0, 1.5 Hz, 1H), 4.73 (dt, J 
= 10.0, 3.0 Hz, 1H), 4.61-4.56 (m, 1H), 3.76 (br. d, J = 10.0 Hz, 1H), 3.52 (s, 3H), 2.19-2.10 (m, 
2H), 2.09 (dt, J = 14.0, 2.5 Hz, 1H), 1.87-1.80 (m, 1H), 1.71-1.65 (m, 1H), 1.65 (d, J = 6.0 Hz, 
3H), 1.60-1.53 (m, 1H); 
13
C-NMR (125 MHz, CDCl3) δ 128.9, 127.1, 87.9, 80.0, 56.9, 37.0, 
34.8, 27.6, 18.1; IR (film, cm
-1
) 3246, 2922, 2852, 1450, 1416, 1365, 1192, 968, 866; HRMS 
(ESI) m/z calculated for C9H17NO4SNa [M+Na]
+
: 258.0776, found 258.0774. 
(±)-trans-4-(2-methoxyethyl)-8-methyl-3-oxa-2-thia-1-azabicyclo[5.1.0]octane-2,2-dioxide. 
Isolated under Rh conditions (entry 6). Purified via flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) 
using 3:1 hexanes/EtOAc (300 mL)  2:1 hexanes/EtOAc (500 mL)  1:1 hexanes/EtOAc as 
the eluent system.  Isolated as a colorless oil. 
1
H-NMR (500 MHz, CDCl3) δ 4.49-4.44 (m, 1H), 
3.49-3.42 (m, 2H), 3.33 (s, 3H), 3.01 (app. p, J = 5.5 Hz, 1H), 2.64 (dt, J = 4.5, 2.0 Hz, 1H), 
2.53-2.40 (m, 2H), 1.91-1.71 (m, 4H), 1.35 (d, J = 5.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 
81.2, 68.4, 59.0, 47.2, 38.7, 34.9, 32.5, 24.8, 17.1; IR (film, cm
-1
) 2974, 2924, 2879, 1439, 1373, 
1180, 1003, 903; HRMS (ESI) m/z calculated for C9H18NO4S [M+H]
+
: 236.0957, found 
236.0957. 
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(±)-4-((1E)-1-propenyl)-6-(2-phenylethyl)tetrahydro-1,2,3-oxathiazine-2,2-dioxide [16]. 
Entry 7: Single catalyst addition protocol for Fe conditions was followed. (±)-(E)-1-phenyloct-
6-en-3-yl sulfamate (113 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24 mg, 0.040 mmol, 0.10 
equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) 
and 4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, ins./azir. 
was >20:1 and d.r. was 3.5:1 syn:anti (for benzylic product, d.r. was >20:1 syn:anti). Flash 
column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 9:1 
hexanes/EtOAc + 1% AcOH (180 mL)  6:1 hexanes/EtOAc + 1% AcOH (180 mL)  4:1 
hexanes/EtOAc + 1% AcOH as eluent gave pure benzylic and syn and anti allylic oxathiazinanes 
separately; the olefin maintained a >20:1 E/Z geometry in each case. Due to overlapping peaks in 
crude reaction mixture, β:β’ was calculated based on isolated yields of the allylic and benzylic 
products after column purification; β:β’ = 5:1.  
Run 1: (56.2 mg syn + 10.8 mg anti (5.2:1 d.r.), 0.238 mmol, 60%), (13.0 mg benzylic (5:1 
allylic/benzylic), 0.046 mmol, 12%), 0% rsm. Run 2: (53.2 mg syn + 13.8 mg anti (3.9:1 d.r.), 
0.238 mmol, 60%), (14.5 mg benzylic (4.6:1 allylic/benzylic), 0.052 mmol, 13%), 0% rsm. Run 
3: (61.6 mg syn + 12.8 mg anti (4.8:1 d.r.), 0.264 mmol, 66%), (9.6 mg benzylic (7:1 
allylic/benzylic), 0.036 mmol, 9%). Average: 62% yield allylic, 0% rsm. 
Entry 8: General protocol for Rh conditions was followed. (±)-(E)-1-phenyloct-6-en-3-yl 
sulfamate (113 mg, 0.400 mmol, 1.0 equiv), Rh2(OAc)4 (3.5 mg, 0.008 mmol, 0.02 equiv), MgO 
(37.1 mg, 0.920 mmol, 2.3 equiv), PhI(OAc)2 (142 mg, 0.440 mmol, 1.1 equiv), CH2Cl2 (2.6 mL, 
0.15M) were used. Due to significant overlap of relevant peaks, 
1
H-NMR analysis of the crude 
product was not possible. Flash column chromatography on silica (35 mm fritted glass column, 
110 mm SiO2) using 6:1 hexanes/EtOAc (500 mL)  3:1 hexanes/EtOAc (250 mL)  2:1 
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hexanes/EtOAc as eluent gave benzylic, syn and anti allylic oxathiazinanes and aziridine 
separately; the olefin maintained a >20:1 E/Z geometry in each case. β:β’, ins./azir. and d.r. were 
calculated based on isolated yields of the allylic and benzylic products after column purification; 
β:β’ = 2:1, ins./azir. = 4:1, d.r. = 5:1.  
Run 1: (46.2 mg syn + 9.4 mg anti (5:1 d.r.), 0.199 mmol, 50%), (26.0 mg benzylic (β:β’ = 2:1), 
0.093 mmol, 23%), (18.9 mg aziridine (4:1 ins./azir.), 0.068 mmol, 17%), 0% rsm. Run 2: (43.3 
mg syn + 10.2 mg anti (4:1 d.r.), 0.191 mmol, 48%), (24.1 mg benzylic (β:β’ = 2:1), 0.086 
mmol, 22%), (17.6 mg aziridine (4:1 ins/azir), 0.063 mmol, 16%), 0% rsm. Run 3: (50.2 mg syn 
+ 9.3 mg anti (5.4:1 d.r.), 0.213 mmol, 53%), (22.3 mg benzylic (β:β’ = 2.6:1), 0.080 mmol, 
20%), (13.9 mg aziridine (6:1 ins/azir), 0.050 mmol, 12%), 0% rsm. Average: 50% yield allylic, 
0% rsm. 
Syn (major) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 
MHz, CDCl3) δ 7.32-7.29 (m, 2H), 7.23-7.18 (m, 3H), 5.76 (dq, J = 15.5, 
6.5 Hz, 1H), 5.40 (dd, J = 15.5, 6.5 Hz, 1H), 4.77-4.72 (m, 1H), 4.22-4.16 (m, 1H), 3.81 (d, J = 
10.0 Hz, 1H), 2.87-2.81 (m, 1H), 2.77-2.71 (m, 1H), 2.11-2.03 (m, 1H), 1.94-1.87 (m, 1H), 1.82 
(dt, J = 14.0, 2.5 Hz, 1H), 1.72 (d, J = 7.0 Hz, 3H), 1.57 (dt, J = 14.0, 12.0 Hz, 1H); 
13
C-NMR 
(125 MHz, CDCl3) δ 140.5, 129.5, 128.8, 128.7, 128.2, 126.5, 83.0, 56.1, 37.2, 35.8, 30.8, 17.9; 
IR (film, cm
-1
) 3263, 3028, 2922, 2856, 1417, 1360, 1186, 870; HRMS (ESI) m/z calculated for 
C14H19NO3SNa [M+Na]
+
: 304.0983, found 304.0978. 
Anti (minor) diastereomer: Isolated as a colorless waxy oil. 
1
H-NMR 
(500 MHz, CDCl3) δ 7.30 (t, J = 7.5 Hz, 2H), 7.23-7.20 (m, 3H), 5.76 (dd, 
J = 15.5, 6.0 Hz, 1H), 5.70 (dq, J = 15.5, 6.0 Hz, 1H), 4.85 (app. spt, J = 4.5 Hz, 1H), 4.28 (br. d, 
J = 7.5 Hz, 1H), 4.22 (app. p, J = 6.0 Hz, 1H), 2.88 (ddd, J = 14.0, 9.0, 5.0 Hz, 1H), 2.74 (ddd, J 
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= 13.5, 9.0, 7.0 Hz, 1H), 2.33 (ddt, J = 9.0, 5.5, 14.5 Hz, 1H), 1.95-1.82 (m, 3H), 1.72 (d, J = 6.0 
Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 140.6, 129.3, 128.7 (2 peaks), 128.3, 126.4, 82.0, 54.9, 
36.4, 34.0, 31.2, 17.9; IR (film, cm
-1
) 3286, 3271, 3028, 2922, 2856, 1419, 1367, 1186, 1038, 
996, 876; HRMS (ESI) m/z calculated for C14H19NO3SNa [M+Na]
+
: 304.0983, found 304.0984. 
(±)-4-((3E)-3-pentenyl)-4-phenyltetrahydro-1,2,3-oxathiazine-2,2-dioxide.  
Isolated as a colorless oil. 
1
H-NMR (500 MHz, CDCl3) δ 7.43-7.33 (m, 5H), 
5.51 (dq, J = 15.5, 6.0 Hz, 1H), 5.39 (dt, J = 15.0, 6.5 Hz, 1H), 4.91-4.86 (m, 
1H), 4.80 (ddd, J = 12.0, 9.5, 2.5 Hz, 1H), 4.14-4.12 (br. m, 1H), 2.22-2.13 (m, 2H), 2.07 (dt, J = 
14.5, 2.5 Hz, 1H), 1.94-1.85 (m, 2H), 1.75-1.69 (m, 1H), 1.67 (d, J = 6.0 Hz, 3H); 
13
C-NMR 
(125 MHz, CDCl3) δ 138.2, 129.3, 129.1, 129.0, 127.1, 126.4, 83.7, 58.3, 36.3, 35.2, 27.6, 18.1; 
IR (film, cm
-1
) 3261, 3024, 2960, 2937, 2920, 2856, 1456, 1416, 1360, 1186, 1053, 864; HRMS 
(ESI) m/z calculated for C14H20NO3S [M+H]
+
: 282.1164, found 282.1162. 
 (±)-trans-4-(2-phenylethyl)-8-methyl-3-oxa-2-thia-1-azabicyclo[5.1.0]octane-2,2-dioxide. 
Isolated under Rh conditions (entry 8). Purified via flash column 
chromatography on silica (35 mm fritted glass column, 110 mm SiO2) using 
9:1 hexanes/EtOAc  4:1 hexanes/EtOAc  2:1 hexanes/EtOAc as eluent system. Isolated as a 
colorless oil. 
1
H-NMR (500 MHz, CDCl3) δ 7.29 (t, J = 7.0 Hz, 2H), 7.22-7.17 (m, 3H), 4.32-
4.27 (m, 1H), 3.03 (app. p, J = 5.5 Hz, 1H), 2.82 (ddd, J = 14.0, 9.5, 5.5 Hz, 1H), 2.72-2.67 (m, 
1H), 2.65-2.63 (m, 1H), 2.50-2.39 (m, 2H), 2.02-1.95 (m, 1H), 1.87-1.74 (m, 3H), 1.37 (d, J = 
5.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 128.7 (2 peaks), 126.4, 121.8, 82.8, 47.1, 38.7, 36.6, 
32.5, 31.8, 24.6, 17.1; IR (film, cm
-1
) 3026, 2929, 2864, 1496, 1454, 1373, 1180, 1036, 997, 901; 
HRMS (ESI) m/z calculated for C14H20NO3S [M+H]
+
: 282.1164, found 282.1164. 
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(±)-(E)-methyl 3-(6-methyl-2,2-dioxido-1,2,3-oxathiazinan-4-yl)acrylate [17]. 
Iterative catalyst addition protocol for Fe conditions was followed. (±)-(E)-methyl 6-
(sulfamoyloxy)hept-2-enoate (94.9 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (4x8 mg, 0.053 mmol, 
0.13 equiv), AgSbF6 (4x4.5 mg, 0.053 mmol, 0.13 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 
equiv) and 4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude product, d.r. 
was 3:1 syn:anti and ins./azir. was >20:1. Flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using 2:1 hexanes/EtOAc as eluent gave syn allylic oxathiazinane, 
recovered starting material and anti allylic oxathiazinane separately.  
Run 1: (30.6 mg syn + 8.2 mg anti (3.7:1 d.r.), 0.165 mmol, 41%), (21.7 mg rsm, 0.091 mmol, 
23%). Run 2: (31.2 mg syn + 5.9 mg anti (5.2:1 d.r.), 0.158 mmol, 39%), (14.8 mg rsm, 0.062 
mmol, 16%). Run 3: (26.4 mg syn + 7.5 mg anti (3.5:1 d.r.), 0.144 mmol, 36%), (14.8 mg rsm, 
0.062 mmol, 16%). Average: 39% yield, 18% rsm. 
Syn (major) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 6.84 (dd, J = 16.0, 5.0 Hz, 1H), 6.04 (dd, J = 16.0, 2.0 Hz, 1H), 4.92 
(dddd, J = 12.0, 10.5, 6.5, 2.0 Hz, 1H), 4.49-4.42 (m, 1H), 4.31 (br. d, J = 10.5 Hz, 1H), 3.76 (s, 
3H), 1.96 (dt, J = 14.5, 2.5 Hz, 1H), 1.57 (dt, J = 14.0, 12.0 Hz, 1H), 1.45 (d, J = 6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 166.1, 143.4, 122.5, 80.5, 55.2, 52.2, 36.4, 21.2; IR (film, cm
-1
) 
3244, 2985, 2956, 1712, 1664, 1439, 1363, 1323, 1286, 1254, 1188, 1124, 1076, 1028, 980, 941, 
866, 796; HRMS (ESI) m/z calculated for C8H13NO5SNa [M+Na]
+
: 258.0412, found 258.0413. 
Anti (minor) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 7.12 (dd, J = 16.0, 5.0 Hz, 1H), 6.08 (dd, J = 16.0, 2.0 Hz, 1H), 5.00 
(dddd, J = 16.0, 9.5, 6.5, 3.5 Hz, 1H), 4.56 (br. d, J = 6.5 Hz, 1H), 4.42-4.37 (m, 1H), 3.77 (s, 
3H), 2.02 (ddd, J = 15.0, 9.5, 5.5 Hz, 1H), 1.95 (dt, J = 14.5, 3.5 Hz, 1H), 1.50 (d, J = 6.5 Hz, 
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3H); 
13
C-NMR (125 MHz, CDCl3) δ 166.2, 144.3, 123.5, 78.7, 53.9, 52.1, 34.3, 21.1; IR (film, 
cm
-1
) 3251, 2993, 2953, 1712, 1662, 1437, 1369, 1321, 1282, 1182, 1072, 885, 862, 808; HRMS 
(ESI) m/z calculated for C8H13NO3SNa [M+Na]
+
: 258.0412, found 258.0410. 
 
(±)-(E)-3-(6-methyl-2,2-dioxido-1,2,3-oxathiazinan-4-yl)allyl acetate [18]. 
Iterative catalyst addition protocol for Fe conditions was followed. (±)-(E)-6-
(sulfamoyloxy)hept-2-en-1-yl acetate (101 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (4x8 mg, 0.053 
mmol, 0.13 equiv), AgSbF6 (4x4.5 mg, 0.053 mmol, 0.13 equiv), PhI(OPiv)2 (325 mg, 0.800 
mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude 
product, d.r. was 3:1 syn:anti and ins./azir. was >20:1. Flash column chromatography on silica 
(35 mm fritted glass column, 150 mm SiO2) using 19:1 CH2Cl2/EtOAc (800 mL)  9:1 
CH2Cl2/EtOAc (150 mL)  6:1 CH2Cl2/EtOAc as eluent gave syn and anti allylic 
oxathiazinanes plus recovered starting material separately.  
Run 1: (39.4 mg syn + 10.5 mg anti (3.8:1 d.r.), 0.200 mmol, 50%), (12.5 mg rsm, 0.050 mmol, 
12%). Run 2: (36.2 mg syn + 8.0 mg anti (4.5:1 d.r.), 0.177 mmol, 44%), (12.3 mg rsm, 0.049 
mmol, 12%). Run 3: (37.2 mg syn + 10.6 mg anti (3.5:1 d.r.), 0.191 mmol, 48%), (16.4 mg rsm, 
0.065 mmol, 16%). Average: 47% yield, 13% rsm. 
Syn (major) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.83 (ddt, J = 16.0, 5.5, 1.5 Hz, 1H), 5.70 (dd, J = 16.0, 5.5 Hz, 
1H), 4.86 (dddd, J = 12.5, 10.5, 6.5, 2.0 Hz, 1H), 4.55 (d, J = 5.5 Hz, 2H), 4.33-4.24 (m, 1H), 
4.31 (br. d, J = 10.5 Hz, 1H), 2.05 (s, 3H), 1.87 (dt, J = 14.5, 2.5 Hz, 1H), 1.54 (dt, J = 14.0, 12.0 
Hz, 1H), 1.41 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 170.8, 130.6, 127.3, 80.5, 
63.7, 55.6, 36.7, 21.2, 20.9; IR (film, cm
-1
) 3244, 2985, 2939, 1736, 1425, 1363, 1238, 1188, 
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1111, 1066, 1030, 970, 933, 864, 796; HRMS (ESI) m/z calculated for C9H15NO5SNa [M+Na]
+
: 
272.0569, found 272.0569. 
Anti (minor) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 MHz, 
CDCl3) δ 6.10 (ddt, J = 15.5, 5.5, 1.5 Hz, 1H), 5.82 (ddt, J = 16.0, 6.0, 2.0 
Hz, 1H), 5.02 (dddd, J = 16.0, 10.0, 6.5, 3.5 Hz, 1H), 4.60 (d, J = 6.0 Hz, 2H), 4.52 (br. d, J = 
6.5 Hz, 1H), 4.28 (app p, J = 5.3 Hz, 1H), 2.08 (s, 3H), 1.95 (ddd, J = 14.5, 9.0, 5.0 Hz, 1H), 
1.89 (dt, J = 14.5, 4.0 Hz, 1H), 1.50 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 170.9, 
131.5, 127.3, 78.9, 64.0, 54.3, 34.8, 21.0 (2 peaks); IR (film, cm
-1
) 3261, 2985, 2939, 1738, 
1425, 1367, 1240, 1184, 1095, 1061, 1030, 970, 883, 837, 796; HRMS (ESI) m/z calculated for 
C9H15NO5SNa [M+Na]
+
: 272.0569, found 272.0570. 
 
(±)-(E)-methyl 5-(2,2-dioxido-4-((E)-prop-1-en-1-yl)-1,2,3-oxathiazinan-6-yl)pent-2-enoate 
[19]. 
Iterative catalyst addition protocol for Fe conditions was followed. (±)-(2E,9E)-methyl 6-
(sulfamoyloxy)undeca-2,9-dienoate (117 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (4x8 mg, 0.053 
mmol, 0.13 equiv), AgSbF6 (4x4.5 mg, 0.053 mmol, 0.13 equiv), PhI(OPiv)2 (325 mg, 0.800 
mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR analysis of the crude 
product, ins./azir. was >20:1. By GC analysis of the crude product, β:β’ = 14:1 and d.r. = 4:1 
syn:anti. Flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) 
using 3:1 hexanes/EtOAc as eluent gave syn ester allylic oxathiazinane plus syn and anti methyl 
allylic oxathiazinanes separately.  
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Run 1: (50.3 mg syn + 12.4 mg anti (4.0:1 d.r.), 0.216 mmol, 54%), 0% rsm. Run 2: (50.1 mg 
syn + 11.9 mg anti (4.2:1 d.r.), 0.214 mmol, 53%), 0% rsm. Run 3: (52.6 mg syn + 13.7 mg anti 
(3.8:1 d.r.), 0.229 mmol, 57%), 0% rsm. Average: 55% yield, 0% rsm. 
Syn (major) diastereomer:  Isolated as a white solid. 
1
H-NMR (500 
MHz, CDCl3) δ 6.90 (dt, J = 15.5, 7.0 Hz, 1H), 5.85 (dt, J = 15.5, 1.5 
Hz, 1H), 5.75 (dq, J = 15.5, 6.5 Hz, 1H), 5.41-5.37 (m, 1H), 4.74-4.69 (m, 1H), 4.19-4.18 (m, 
2H), 3.71 (s, 3H), 2.45-2.38 (m, 1H), 2.36-2.28 (m, 1H), 1.91-1.73 (m, 3H), 1.70 (d, J = 6.5 Hz, 
3H), 1.59-1.51 (m, 1H); 
13
C-NMR (125 MHz, CDCl3) δ 166.9, 147.0, 129.5, 127.9, 122.2, 82.8, 
56.1, 51.6, 35.5, 33.5, 27.2, 17.9; IR (film, cm
-1
) 3236, 2953, 2922, 2856, 1722, 1657, 1437, 
1362, 1323, 1286, 1188, 1049, 968, 868; HRMS (ESI) m/z calculated for C12H19NO5SNa 
[M+Na]
+
: 312.0882, found 312.0883. 
Anti (minor) diastereomer: Isolated as a colorless oil. 
1
H-NMR (500 
MHz, CDCl3) δ 6.93 (dt, J = 16.0, 6.5 Hz, 1H), 5.88 (d, J = 16.0 Hz, 
1H), 5.80-5.68 (m, 2H), 4.84 (app spt, J = 4.5 Hz, 1H), 4.51 (br. d, J = 7.0 Hz, 1H), 4.21 (app p, 
J = 5.8 Hz, 1H), 3.73 (s, 3H), 2.50-2.43 (m, 1H), 2.38-2.31 (m, 1H), 2.12 (ddd, J = 14.5, 9.5, 5.0 
Hz, 1H), 1.92 (ddd, J = 14.5, 8.5, 5.5 Hz, 1H), 1.84 (ddd, J = 14.5, 5.5, 4.0 Hz, 1H), 1.77-1.67 
(m, 1H), 1.73 (d, J = 5.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 167.0, 147.1, 129.4, 128.2, 
122.3, 81.7, 54.8, 51.7, 33.8, 32.9, 27.6, 17.9; IR (film, cm
-1
) 3257, 2951, 2931, 2854, 1722, 
1658, 1437, 1367, 1286, 1184, 1043, 968, 872; HRMS (ESI) m/z calculated for C12H19NO5SNa 
[M+Na]
+
: 312.0882, found 312.0884. 
 (±)-(E)-methyl 3-(2,2-dioxido-6-((E)-pent-3-en-1-yl)-1,2,3-oxathiazinan-4-yl)acrylate. 
Isolated as a colorless oil. 
1
H-NMR (500 MHz, CDCl3) δ 6.83 (dd, J = 
16.0, 5.0 Hz, 1H), 6.03 (dd, J = 16.0, 2.0 Hz, 1H), 5.48 (dq, J = 15.0, 
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6.5 Hz, 1H), 5.36 (ddt, J = 15.0, 6.5, 1.5 Hz, 1H), 4.82-4.77 (m, 1H), 4.48-4.42 (m, 1H), 4.27 (br. 
d, J = 10.5 Hz, 1H), 3.76 (s, 3H), 2.19-2.08 (m, 2H), 1.92 (dt, J = 14.5, 2.0 Hz, 1H), 1.88-1.79 
(m, 1H), 1.73-1.65 (m, 1H), 1.65 (d, J = 5.5 Hz, 3H), 1.57 (dt, J = 14.0, 12.0 Hz, 1H); 
13
C-NMR 
(125 MHz, CDCl3) δ 166.1, 143.4, 128.9, 127.1, 122.5, 83.4, 55.2, 52.2, 35.1, 34.9, 27.5, 18.0; 
IR (film, cm
-1
) 3236, 3024, 2995, 2953, 2920, 2856, 1712, 1664, 1439, 1365, 1323, 1284, 1259, 
1188, 1126, 970, 868, 821; HRMS (ESI) m/z calculated for C12H19NO5SNa [M+Na]
+
: 312.0882, 
found 312.0883. 
(±)-(E)-methyl 5-(8-methyl-2,2-dioxido-3-oxa-2-thia-1-azabicyclo 
[5.1.0]octan-4-yl)pent-2-enoate. 
Prepared as a standard using general protocol for Rh conditions. Purified via flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 3:1 hexanes/EtOAc 
(400 mL)  2:1 hexanes/EtOAc (200 mL)  1:1 hexanes/EtOAc as eluent system. Isolated as a 
white solid. 
1
H-NMR (500 MHz, CDCl3) δ 6.89 (dt, J = 15.5, 7.0 Hz, 1H), 5.85 (dd, J = 16.0, 1.5 
Hz, 1H), 4.30-4.25 (m, 1H), 3.72 (s, 3H), 3.00 (app p, J = 5.3 Hz, 1H), 2.65-2.63 (m, 1H), 2.51-
2.36 (m, 3H), 2.33-2.26 (m, 1H), 1.86-1.67 (m, 4H), 1.35 (d, J = 5.5 Hz, 3H); 
13
C-NMR (125 
MHz, CDCl3) δ 166.9, 147.0, 122.3, 82.6, 51.6, 47.2, 38.7, 33.0, 32.4, 28.2, 24.7, 17.1; IR (film, 
cm
-1
) 2953, 2931, 2852, 1722, 1658, 1439, 1373, 1273, 1180, 1041, 1001, 901, 837, 687, 631; 
HRMS (ESI) m/z calculated for C12H19NO5SNa [M+Na]
+
: 312.0882, found 312.0884. 
(±)-ethyl trans-2-(8-methyl-2,2-dioxido-3-oxa-2-thia-1-azabicyclo[5.1.0]octan-4-yl)acetate. 
Prepared as a standard using general protocol for Rh conditions. Purified 
via flash column chromatography on silica (35 mm fritted glass column, 
150 mm SiO2) using 2:1 hexanes/EtOAc as eluent system. Isolated as a white solid. 
1
H-NMR 
(500 MHz, CDCl3) δ 4.73-4.68 (m, 1H), 4.21-4.11 (m, 2H), 3.03 (app p, J = 5.5 Hz, 1H), 2.73 
73 
 
(dd, J = 16.0, 6.5 Hz, 1H), 2.67-2.65 (m, 1H), 2.58 (dd, J = 16.0, 6.0 Hz, 1H), 2.52 (d, J = 12.5 
Hz, 1H), 2.48-2.42 (m, 1H), 1.98-1.93 (m, 1H), 1.86-1.78 (m, 1H), 1.35 (d, J = 6.0 Hz, 3H), 1.26 
(t, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 169.1, 79.2, 61.3, 47.1, 39.6, 38.9, 31.9, 24.6, 
17.1, 14.2; IR (film, cm
-1
) 2981, 2931, 1738, 1443, 1375, 1298, 1265, 1221, 1180, 1034, 1016, 
908, 771; HRMS (ESI) m/z calculated for C10H18NO3S [M+H]
+
: 264.0906, found 264.0905. 
 
(±)-4-((E)-prop-1-en-1-yl)-6-(2-(2,6,6-trimethylcyclohex-1-en-1-yl)ethyl)-1,2,3-
oxathiazinane 2,2-dioxide [20]. 
Iterative catalyst addition protocol for Fe conditions was followed. (±)-(E)-1-(2,6,6-
trimethylcyclohex-1-en-1-yl)oct-6-en-3-yl sulfamate (132 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl 
(4x8 mg, 0.053 mmol, 0.13 equiv), AgSbF6 (4x4.5 mg, 0.053 mmol, 0.13 equiv), PhI(OPiv)2 
(325 mg, 0.800 mmol, 2.0 equiv) and 4:1 PhMe:MeCN (800 μL) were used. By 1H-NMR 
analysis of the crude product, d.r. was 3.5:1 syn:anti, ins./azir. was >20:1 and β:β’ was 7:1. Flash 
column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 19:1 
hexanes/EtOAc + 1% AcOH as eluent gave syn methyl allylic oxathazinane separately; the anti 
methyl and syn tetrasubstituted allylic oxathiazinanes were isolated as a mixture.  
Run 1: (51.6 mg syn + 13.3 mg anti (3.9:1 d.r.), 0.198 mmol, 50%), (6.6 mg syn-tetrasubstituted 
(β:β’ = 9.8:1), 0.020 mmol, 5%), 0% rsm. Run 2: (59.7 mg syn + 13.1 mg anti (4.6:1 d.r.), 0.220 
mmol, 55%), (8.9 mg syn-tetrasubstituted (β:β’ = 8.2:1), 0.027 mmol, 7%), 0% rsm. Run 3: (59.1 
mg syn + 13.3 mg anti (4.4:1 d.r.), 0.221 mmol, 55%), (8.3 mg syn-tetrasubstituted (β:β’ = 
8.7:1), 0.025 mmol, 6%), 0% rsm. Average: 53% yield, 0% rsm. 
Syn (major) diastereomer:  Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.77 (ddq, J = 15.5, 6.5, 1.5 Hz, 1H), 5.41 (ddd, J = 15.5, 5.5, 1.5 
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Hz, 1H), 4.76-4.71 (m, 1H), 4.23-4.18 (m, 1H), 3.97 (br. d, J = 10.0 Hz, 1H), 2.23 (dt, J = 13.5, 
5.0 Hz, 1H), 2.01 (dt, J = 13.0, 5.0 Hz, 1H), 1.89 (t, J = 6.5 Hz, 2H), 1.84 (dt, J = 14.5, 2.5 Hz, 
1H), 1.80-1.75 (m, 1H), 1.73-1.66 (m, 1H), 1.72 (dt, J = 7.0, 1.5 Hz, 3H), 1.57-1.52 (m, 3H), 
1.57 (s, 3H), 1.41-1.39 (m, 2H), 0.97 (s, 6H); 
13
C-NMR (125 MHz, CDCl3) δ 135.8, 129.4, 
128.2, 128.1, 84.7, 56.2, 39.8, 35.9, 35.5, 35.1, 32.8, 28.6, 23.6, 19.9, 19.5, 17.9; IR (film, cm
-1
) 
3261, 2956, 2927, 2866, 2831, 1473, 1419, 1360, 1188, 1057, 966, 912, 870, 818, 735; HRMS 
(ESI) m/z calculated for C17H29NO3SNa [M+Na]
+
: 350.1766, found 350.1765. 
Anti (minor) diastereomer: Isolated as a colorless oil by resubjecting the 
product mixture from above to flash column chromatography (25 mm 
fritted glass column, 140 mm SiO2) in 3:1 CH2Cl2/hex (the β’ product could not be isolated, even 
after flushing column). 
1
H-NMR (500 MHz, CDCl3) δ 5.83 (ddd, J = 15.5, 6.5, 1.5 Hz, 1H), 5.72 
(dq, J = 15.5, 6.0 Hz, 1H), 4.87-4.83 (m, 1H), 4.34 (br. d, J = 6.5 Hz, 1H), 4.19 (app p, J = 5.8 
Hz, 1H), 2.29-2.23 (m, 1H), 2.04-1.93 (m, 3H), 1.90 (t, J = 6.3 Hz, 2H), 1.85 (app dt, J = 14.0, 
4.0 Hz, 1H), 1.75 (d, J = 6.0 Hz, 3H), 1.72-1.63 (m, 1H) 1.59-1.54 (m, 2H), 1.59 (s, 3H), 1.42-
1.40 (m, 2H), 0.99 (s, 3H), 0.98 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 135.9, 129.3, 128.5, 
128.2, 83.4, 55.1, 39.9, 35.4, 35.1, 33.9, 32.9, 28.7 (2 peaks), 24.2, 20.0, 19.6, 18.0; IR (film, cm
-
1
) 3273, 2947, 2927, 2864, 1423, 1367, 1186, 1051, 966, 874; HRMS (ESI) m/z calculated for 
C17H30NO3S [M+H]
+
: 328.1946, found 328.1946. 
 
Intramolecular Kinetic Isotope Effect Study 
(±)-4-deuterio-4-phenyl-tetrahydro-1,2,3-oxathiazine-2,2-dioxide [22]. 
Rh conditions: General protocol for Rh conditions was followed, at a scale of 0.250 mmol for 
the sulfamate ester. (±)-3-deuterio-3-phenylprop-1-yl sulfamate 21 (53.8 mg, 0.250 mmol, 1.0 
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equiv), Rh2(OAc)4 (2.2 mg, 0.005 mmol, 0.02 equiv), MgO (23.0 mg, 0.570 mmol, 2.3 equiv), 
PhI(OAc)2 (90.2 mg, 0.280 mmol, 1.1 equiv), CH2Cl2 (1.6 mL, 0.15M) were used, and reaction 
stirred at room temp for 6h. Flash column chromatography on silica (35 mm fritted glass column, 
110 mm SiO2) using 3:1 hexanes/EtOAc as eluent gave 46.2 mg of the deuterated and protonated 
oxathiazinanes as a mixture (0.218 mmol, 87% yield, <5% rsm). This sample was used as a 
control to confirm the KIE determination method. KIE = 1.8±0.2 (1.9, 1.9, 1.6); this is in good 
agreement with that reported by Du Bois and co-workers for the same substrate (1.9±0.2).
9
 
Fe conditons: Iterative catalyst addition protocol for Fe conditions was followed, at a scale of 
0.600 mmol for the sulfamate ester. (±)-3-deuterio-3-phenylprop-1-yl sulfamate 21 (130 mg, 
0.600 mmol, 1.0 equiv), [FePc]Cl (4x12.1 mg, 0.080 mmol, 0.13 equiv), AgSbF6 (4x6.8 mg, 
0.080 mmol, 0.13 equiv), PhI(OPiv)2 (487 mg, 1.20 mmol, 2.0 equiv) and 4:1 PhMe:MeCN (1.2 
mL) were used. Flash column chromatography on silica (35 mm fritted glass column, 150 mm 
SiO2) using 4:1 hexanes/EtOAc + 1% AcOH as eluent gave the deuterated and protonated 
oxathiazinanes as a mixture, and the recovered starting material separately.  
Run 1: (33.0 mg, 0.153 mmol, 26%), (47.0 mg rsm, 0.217 mmol, 36%), KIE = 2.5±0.1 (2.4, 2.4, 
2.6). Run 2: (35.8 mg, 0.167 mmol, 28%), (39.5 mg rsm, 0.182 mmol, 30%), KIE = 2.7±0.2 (2.7, 
2.5, 2.8). Run 3: (32.8 mg, 0.153 mmol, 25%), (42.0 mg rsm, 0.194 mmol, 32%), KIE = 2.4±0.1 
(2.5, 2.3, 2.4). Average: 26% yield, 33% rsm, KIE = 2.5±0.2. 
1
H-NMR (500 MHz, CDCl3) δ 7.43-7.35 (m, 5H), 4.90-4.85 (m, 2H – protonated), 
4.87 (ddd, J = 13.0, 11.5, 2.0 Hz, 1H – deuterated), 4.66 (ddd, J = 11.5, 5.0, 1.5 Hz, 
1H), 4.35 (br. s, 1H – deuterated), 4.35 (br. d, J = 9.0 Hz, 1H – protonated), 2.30-2.21 (m, 1H), 
2.05-2.00 (m, 1H); 
13
C-NMR (125 MHz, CDCl3) δ 137.7 (protonated), 137.7 (deuterated), 129.0, 
128.7, 126.1, 71.8, 58.7 (protonated), 58.4 (deuterated – 1:1:1 triplet), 30.0 (protonated) 29.9 
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(deuterated); IR (film, cm
-1
) 3261, 3062, 3033, 2964, 2926, 2852, 1728, 1498, 1450, 1410, 1354, 
1190, 1024, 995, 930, 874, 779; HRMS (ESI) m/z calculated for C9H10DNO3SNa [M+Na]
+
: 
237.0420, found 237.0419; HRMS (ESI) m/z calculated for C9H11NO3SNa [M+Na]
+
: 236.0357, 
found 237.0355. 
 
Method for KIE Determination: The column-purified product mixture 22 (35-40 mg in 700 μL 
CDCl3, in a straight-walled NMR tube) was analyzed by 
13
C-NMR.
8,43
 In order to obtain an 
accurately integratable 
13
C-NMR, the experiment was run under inverse-gated decoupling 
conditions (decoupling switched off during the relaxation delay; for Varian, the command is 
dm=’nny’). A delay of 5 s was used, with sufficient scans to obtain a signal-to-noise (S/N) ratio 
of >30:1 on the deuterated peak. The KIE was reported as the area of the deuterated peak over 
that of the protonated peak. Three identical experiments were run and an average value was 
calculated with measurement error.  
Alternative Method: 15 mg Cr(acac)3 was added to the NMR sample; this additive significantly 
reduces relaxation time for 
13
C-NMR and allows for more accurate integration than inverse-gated 
decoupling alone.
44
 Experimental conditions were otherwise identical to the standard method. It 
was found that for both the Rh- and Fe-catalyzed C—H amination reactions, the calculated KIEs 
were noticeably higher, although the trend remains the same. The following KIEs were 
determined: Rh conditions – 3.5±0.4 (3.7, 3.7, 3.1); Fe conditions – 4.8±0.3 (4.7, 5.1, 4.7).  
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Evidence of Olefin Isomerization in Fe-catalyzed C—H Amination 
(±)-4-((1Z)-1-propenyl)-6-methyl-tetrahydro-1,2,3-oxathiazine-2,2-dioxide [Z-24]. 
Rh conditions: General protocol for Rh conditions was followed. (±)-(Z)-hept-5-en-2-yl 
sulfamate 23 (77.3 mg, 0.400 mmol, 1.0 equiv), Rh2(OAc)4 (3.5 mg, 0.008 mmol, 0.02 equiv), 
MgO (37.0 mg, 0.920 mmol, 2.3 equiv), PhI(OAc)2 (142 mg, 0.440 mmol, 1.1 equiv), CH2Cl2 
(2.6 mL, 0.15M) were used, and reaction stirred at room temp for 4h. By GC analysis of the 
crude product, Z:E was >30:1. By 
1
H-NMR analysis, d.r. was 4:1 syn:anti, and ins./azir. was 
2.7:1.  Flash column chromatography on silica (35 mm fritted glass column, 110 mm SiO2) using 
4:1 hexanes/EtOAc as eluent gave pure syn and anti oxathiazinanes and aziridine separately: 
(42.1 mg syn + 10.4 mg anti (4:1 d.r.), 0.275 mmol, 69% yield), (17.4 mg aziridine (3:1 
ins./azir.), 0.091 mmol, 23%). 
Fe Conditions: Single catalyst addition protocol for Fe conditions was followed. (±)-(Z)-hept-5-
en-2-yl sulfamate 23 (77.3 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24.0 mg, 0.040 mmol, 0.10 
equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) 
and 4:1 PhMe:MeCN (800 μL) were used. By GC analysis of the crude product, Z:E was 9:1 
(this ratio was confirmed by subjecting column-purified Z/E mixtures of products to GC 
analysis). By 
1
H-NMR analysis, d.r. was 3:1 syn:anti, and ins./azir. was >10:1. Flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 9:1 CH2Cl2/hexanes 
(500 mL)  19:1 CH2Cl2/hexanes as eluent gave syn and anti oxathiazinanes as a mixture. This 
mixture was further purified by flash column chromatography using 4:1 hexanes:EtOAc + 1% 
AcOH as eluent; this gave pure syn and anti allylic oxathiazinanes separately (as E/Z mixtures). 
Although the reaction did not go to complete conversion, the remaining starting material was not 
isolated under the given purification conditions.  
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Run 1: (21.3 mg syn + 7.2 mg anti (3:1 d.r.), 0.149 mmol, 37%). Run 2: (18.1 mg syn + 5.8 mg 
anti (3.1:1 d.r.), 0.125 mmol, 31%), 0% rsm. Run 3: (17.9 mg syn + 5.7 mg anti (3.1:1 d.r.), 
0.123 mmol, 31%). Average: 33% yield. 
 Syn (major) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, CDCl3) 
δ 5.72 (ddq, J = 10.5, 6.5, 1.0 Hz, 1H), 5.21 (ddd, J = 10.5, 6.5, 1.5 Hz, 1H), 4.91 
(ddt, J = 12.0, 6.5, 2.0 Hz, 1H), 4.56-4.49 (m, 1H), 3.99 (br. d, J = 9.5 Hz, 1H), 1.76 (dt, J = 
14.5, 2.5 Hz, 1H), 1.73 (dd, J = 7.0, 2.0 Hz, 3H), 1.53 (dt, J = 14.5, 12.0 Hz, 1H), 1.42 (d, J = 6.5 
Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 130.6, 127.1, 80.6, 52.0, 37.5, 21.2, 13.7; IR (film, cm
-
1
) 3234, 3033, 2983, 2943, 2852, 1429, 1385, 1346, 1296, 1171, 1078, 947, 910, 864; HRMS 
(ESI) m/z calculated for C7H13NO3SNa [M+Na]
+
: 214.0514, found 214.0515. 
 Anti (minor) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, CDCl3) 
δ 5.88 (ddd, J = 10.5, 7.0, 1.5 Hz, 1H), 5.69 (ddq, J = 11.0, 7.0, 1.0 Hz, 1H), 5.04 
(dddd, J = 15.5, 9.0, 6.5, 3.0 Hz, 1H), 4.56-4.51 (m, 1H), 4.48 (br. d, J = 6.0 Hz, 1H), 1.91 (ddd, 
J = 14.5, 9.5, 5.5 Hz, 1H), 1.77 (ddd, J = 14.5, 4.0, 3.5 Hz, 1H), 1.69 (dd, J = 7.0, 1.5 Hz, 3H), 
1.50 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 128.6, 127.4, 79.2, 50.3, 35.7, 21.0, 
13.3; IR (film, cm
-1
) 3280, 3026, 2983, 2935, 2860, 1425, 1402, 1379, 1358, 1184, 1080, 957, 
904, 883, 835, 796 750; HRMS (ESI) m/z calculated for C7H13NO3SNa [M+Na]
+
: 214.0514, 
found 214.0517. 
 (±)-cis-4,8-dimethyl-3-oxa-2-thia-1-azabicyclo[5.1.0]octane-2,2-dioxide. 
Purified via flash column chromatography on silica (35 mm fritted glass column, 
150 mm SiO2) using 4:1 hexanes/EtOAc  3:1 hexanes/EtOAc as eluent system. 
Isolated as a white solid. 
1
H-NMR (500 MHz, CDCl3) δ 4.84-4.82 (m, 1H), 3.00 (app q, J = 6.0 
Hz, 1H), 2.88 (app. p, J = 6.0 Hz, 1H), 2.50-2.44 (m, 1H), 2.27-2.20 (m, 1H), 2.08-2.01 (m, 1H), 
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1.83 (dd, J = 14.5, 9.0 Hz, 1H), 1.60 (d, J = 6.5 Hz, 3H), 1.33 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 
MHz, CDCl3) δ 78.7, 45.2, 41.9, 29.7, 20.9, 18.2, 9.3; IR (film, cm
-1
) 3284, 2983, 2943, 2877, 
1448, 1371, 1298, 1176, 1146, 1117, 1076, 1005, 962, 893, 839, 785, 768; HRMS (ESI) m/z 
calculated for C7H13NO3SNa [M+Na]
+
: 214.0514, found 214.0513. 
 
(±)-4-((1E)-1-propenyl)-6-methyl-tetrahydro-1,2,3-oxathiazine-2,2-dioxide [E-24]. 
Prepared as a standard under the Rh conditions described above: (±)-(E)-hept-5-en-2-yl 
sulfamate 23 (77.3 mg, 0.400 mmol, 1.0 equiv), Rh2(OAc)4 (3.5 mg, 0.008 mmol, 0.02 equiv), 
MgO (37.0 mg, 0.920 mmol, 2.3 equiv), PhI(OAc)2 (142 mg, 0.440 mmol, 1.1 equiv), CH2Cl2 
(2.6 mL, 0.15M) were used, and reaction stirred at room temp for 4h. Flash column 
chromatography on silica (35 mm fritted glass column, 110 mm SiO2) using 4:1 hexanes/EtOAc 
as eluent gave pure syn and anti oxathiazinanes separately. These compounds were used in order 
to confirm Z/E ratios by GC analysis. 
 Syn (major) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.76 (ddq, J = 15.0, 6.5, 1.5 Hz, 1H), 5.39 (ddd, J = 15.5, 6.0, 1.5 Hz, 
1H), 4.86 (ddt, J = 12.0, 6.0, 2.0 Hz, 1H), 4.22-4.16 (m, 1H), 4.03 (br. d, J = 10.0 Hz, 1H), 1.84 
(dt, J = 14.5, 2.5 Hz, 1H), 1.71 (d, J = 6.5 Hz, 3H), 1.52 (dt, J = 14.5, 12.0 Hz, 1H), 1.41 (d, J = 
6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 129.4, 128.1, 80.6, 56.2, 37.1, 21.2, 17.9; IR (film, 
cm
-1
) 3263, 2983, 2939, 2922, 2858, 1421, 1360, 1186, 1136, 1093, 1061, 966, 945, 914, 866, 
796; HRMS (ESI) m/z calculated for C7H13NO3SNa [M+Na]
+
: 214.0514, found 214.0513. 
Anti (minor) diastereomer: Isolated as a white solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 5.82 (ddd, J = 15.5, 6.5, 1.5 Hz, 1H), 5.72 (ddq, J = 15.0, 6.5, 1.0 Hz, 
1H), 5.03 (ddd, J = 6.5, 6.5, 1.5 Hz, 1H), 4.34 (br. d, J = 7.0 Hz, 1H), 4.21 (app. p, J = 6.0 Hz, 
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1H), 1.93-1.83 (m, 2H), 1.74 (dd, J = 6.5, 1.5 Hz, 3H), 1.51 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 
MHz, CDCl3) δ 129.3, 128.6, 79.3, 55.0, 35.4, 21.0, 18.0; IR (film, cm
-1
) 3267, 2985, 2964, 
2922, 2856, 1429, 1360, 1327, 1236, 1182, 1136, 1092, 1051, 964, 879, 862; HRMS (ESI) m/z 
calculated for C7H13NO3SNa [M+Na]
+
: 214.0514, found 214.0518. 
 
Synthesis of Starting Materials 
Synthesis of alcohol 25 for 3
o
 C—H stereoretention substrate 
 
6,10-dimethylundeca-1,9-dien-4-ol.  
This compound was prepared according to the methods described in the literature.
45
 The initial 
product was isolated as a 1:1 anti:syn mixture of diastereomers following flash column 
chromatography on silica using 9:1 hexanes/EtOAc as eluent. It was diastereomerically enriched 
via MPLC purification with a 240 g basic alumina column (Activity II-III) using neat CH2Cl2 as 
eluent (the order of elution was the anti diastereomer first, then syn). After 4-6 iterations in 
which fractions containing only one diastereomer were removed each time, the pure products 
were isolated as a >20:1 mixture (as determined by 
1
H-NMR analysis). This compound has been 
previously reported in the literature as a diastereomeric mixture. 
1
H-NMR (500 MHz, CDCl3) δ 5.83 (ddt, J = 16.5, 9.5, 7.0 Hz, 1H), 5.15-5.08 (m, 3H), 3.77-3.72 
(m, 1H), 2.27 (dt, J = 14.0, 4.5 Hz, 1H), 2.15 (dt, J = 14.0, 8.0 Hz, 1H), 2.04-1.93 (m, 2H), 1.68-
1.64 (m, 1H), 1.68 (s, 3H), 1.60 (s, 3H), 1.52-1.46 (m, 2H), 1.35-1.27 (m, 1H), 1.23-1.16 (m, 
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2H), 0.95 (d, J = 6.5 Hz, 3H – syn), 0.91 (d, J = 6.5 Hz, 3H - anti). These data are in agreement 
with the literature.
45
 
6,10-dimethylundecan-4-ol [25].  
6,10-dimethylundeca-1,9-dien-4-ol (1.0 equiv) was dissolved in MeOH (0.1M) in a flask 
equipped with a stir bar. Activated 30% Pd/C (10 mg per mmol of substrate) was added, and then 
the flask was sealed with a rubber septum. A balloon of H2 was placed over the flask, and H2 was 
bubbled through the reaction mixture with stirring until complete disappearance of olefins was 
observed, as monitored by 
1
H-NMR analysis. Upon completion, the reaction mixture was filtered 
through a short silica plug, which was washed with additional MeOH. The filtrate was dried over 
Na2SO4 and concentrated in vacuo. No further purification was necessary. 
 (-)-(4R,6R)-6,10-dimethylundecan-4-ol: The diastereomeric ratio was 
quantitatively established by achiral GC analysis in triplicate, and was found to be 97:3 anti:syn. 
1
H-NMR (500 MHz, CDCl3) δ 3.72-3.67 (m, 1H), 1.66-1.59 (m, 1H), 1.56-1.48 (m, 1H), 1.47-
1.38 (m, 3H), 1.38-1.20 (m, 6H), 1.19-1.10 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H), 0.89 (d, J = 6.5 Hz, 
3H), 0.86 (d, J = 6.5 Hz, 6H); 
13
C-NMR (125 MHz, CDCl3) 69.5, 45.2, 40.7, 39.4, 38.3, 29.4, 
28.1, 24.9, 22.8 (2 peaks), 19.4, 10.0, 14.3; IR (film, cm
-1
) 3350, 2956, 2927, 2872, 1466, 1379, 
1367, 1146, 1122, 1066, 1024; [α]25D = -10.1
o
 (c = 1.0, CHCl3); HRMS (EI) m/z calculated for 
C13H26 [M-H2O]
+
: 182.20345, found 182.20253 (ESI failed for this compound, and the the peak 
resulting from alcohol elimination was the dominant peak in the EI spectrum, the minor peak 
being extrusion of H
+
 – no M+ peak was observed under ESI, EI, or FD methods). 
 (+)-(4R,6S)-6,10-dimethylundecan-4-ol: The diastereomeric ratio was 
quantitatively established by achiral GC analysis in triplicate, and was found to be 5:95 anti:syn. 
1
H-NMR (500 MHz, CDCl3) δ 3.70 (m, 1H), 1.62-1.18 (m, 12H), 1.17-1.10 (m, 2H), 1.09-1.02 
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(m, 1H), 0.93 (t, J = 6.8 Hz, 3H), 0.90 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 7.0 Hz, 6H); 
13
C-NMR 
(125 MHz, CDCl3) 69.9, 45.5, 40.1, 39.5, 37.0, 29.8, 28.1, 24.7, 22.9, 22.7, 20.5, 18.9, 14.3; IR 
(film, cm
-1
) 3338, 2956, 2927, 2872, 1466, 1379, 1367, 1124, 1005; [α]25D = +6.7
o
 (c = 1.0, 
CHCl3). 
 
Synthesis of alcohol 26 for olefin electronic competition substrate
46,47,48,49
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CHAPTER 2: A GENERAL CATALYST FOR C(sp
3
)—H AMINATION 
2.1 Introduction 
The complex architecture of enzyme active sites allows them to catalyze chemical 
transformations of small molecule substrates with both high reactivity and often exquisite site- 
and chemoselectivity.
50
 In particular, iron P450 enzymes are able to harness highly reactive iron-
oxo species to directly oxidize strong aliphatic C—H bonds (BDE >95 kcal/mol) with excellent 
tolerance of more readily oxidized functionalities (e.g. olefins, aromatics).
51
 For example, taxa-
4,11-diene has 20 oxidizable aliphatic C—H bonds, but a single allylic C—H bond is 
hydroxylated by the P450 TYH5a.
52
 The rest of the hydrocarbon scaffold is then selectively 
functionalized in a sequential fashion via other P450 mutants, with complete catalyst control 
over site- and chemoselectivity (Figure 12A). This type of approach rapidly introduces oxygen 
functionality into a molecular scaffold, while also allowing access to a broad diversity of 
compounds, as any intermediate can be selectively diverted along different synthetic pathways. 
Interestingly, despite the isoelectronic relationship between iron-oxos and iron-nitrenes, no 
known natural enzymatic analogs exist that directly install nitrogen into C—H bonds. Instead,  
Figure 12 Enzyme-catalyzed C—H functionalization. (A) P450 oxidations in the biosynthesis of 
taxol. (B) Benzylic C—H amination with modified P450 enzymes. 
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nature employs a functional group approach with enzymes such as transaminases and ammonia 
lysases, which transfer nitrogen functionality from one amino acid to another.
53
 However, 
pioneering work by the Breslow and Arnold groups has demonstrated that modified cytochrome 
P450 enzymes can catalyze benzylic C—H amination reactions (Figure 12B).54 Nonetheless, the 
practical simplicity and facile modularity of small molecule transition metal catalysts makes 
them a more desirable strategy for C—H amination synthetic methods. To this end, the discovery 
of a small molecule catalyst for C—H amination that achieves an enzyme-like balance of high 
reactivity with high site- and chemoselectivity would represent an important methodological and 
synthetic advance. 
Significant progress has been made in the last decade with regard to the synthetic 
development of synthetic methods for nitrene-based C—H amination reactions.3,55 However, 
existing C—H amination catalysts achieve high reactivity by sacrificing selectivity, or vice versa 
(Figure 13). Dirhodium carboxylate catalysts have demonstrated the ability to efficiently 
functionalize strong 3° and 2° aliphatic C—H bonds,17 but generally directly oxidize olefins and  
Figure 13 Reactivity versus selectivity in small molecule C—H amination catalysts. 
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alkynes.
18
 Attempts to develop dirhodium catalysts with improved chemoselectivity for the 
amination of allylic C—H bonds have led to significant reductions in reactivity (see Section 1.1, 
Figures 3 and 5).
19
 Other metals are able to aminate with high chemoselectivity in the presence 
of π-bonds, with orthogonal reactivity to rhodium. For example, the previous chapter of this 
dissertation described the development of a small molecule iron catalyst that functionalizes 
allylic C—H bonds in synthetically useful yields with high chemoselectivity in the presence of 
olefins (generally >20:1 ins./azir.), a characteristic that has since been shown to be general 
among iron catalysts.
34,35
 In addition, ruthenium catalysts display good chemoselectivity in many 
cases for allylic C—H amination.22 These catalysts, however, are poorly reactive toward stronger 
aliphatic C—H bonds. As a result, a truly general catalyst for the amination of sp3 C—H bonds 
does not yet exist. Due to the ubiquity of nitrogen functionality in natural products and synthetic 
drugs, the development of a single small molecule catalyst that is able to achieve both high 
reactivity and high selectivity for the amination of sp
3
 C—H bonds would find immediate 
application in the synthesis and diversification of bioactive compounds.
8
 We sought to exploit 
the characteristically high chemoselectivity of first-row transition metal complexes in order to 
improve upon our previous method and develop such a general C—H amination catalyst.56 
 
2.2 Results and Discussion 
2.2.1 Initial Studies and Reaction Optimization 
Although nature rarely uses manganese metal centers to mediate oxidations, early studies 
using synthetic metalloporphryins as models for cytochrome P450 explored manganese variants 
alongside iron.
57
 In these reports, it was established that iron and manganese porphyrins react via 
mechanistically analogous stepwise mechanisms, with KIE studies on cyclohexane suggesting 
that more bond breakage occurs in the C—H cleavage transition state for iron (kH/kD = 12.9 
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kcal/mol) compared to manganese (kH/kD = 3.5 kcal/mol).
58
 In addition, the manganese variants 
exhibited significantly higher C—H hydroxylation yields for aliphatic substrates.59 Based on this 
precedent, we hypothesized that an earlier transition state for C—H abstraction with manganese 
would lead to attenuated radical character and lower sensitivity to C—H bond strength, resulting 
in significantly improved amination reactivity for challenging C(sp
3
)—H bonds while 
maintaining the exquisite chemoselectivity characteristic of first row transition metal amination 
catalysts.
60
 Consistent with this hypothesis, preliminary results with substrates containing 3° (29) 
and 2° (27) aliphatic C—H bonds showed markedly enhanced reactivity with [MnIIIPc] relative 
to [Fe
III
Pc], affording promising yields of C—H amination products 28 amd 30 (Figure 14). This 
improvement was also apparent in substrates lacking turning elements to bias reactivity, such as 
31 (Table 6, entries 1-2). We questioned whether this observation was anomalous or represented 
a general trend, and so we examined several different ligand classes and compared the iron and 
manganese variants of each. Higher product yields of 32 were obtained with the manganese 
complexes across all ligand classes relative to their iron counterparts (entries 3-8). 
Figure 14 Preliminary aliphatic C—H amination results. 
 
The phthalocyanine ligand remained the most effective for catalyzing C—H amination, 
and so [Mn
III
Pc] was employed for further optimization. Addition of manually crushed 4Å 
molecular sieve beads significantly improved reactivity, affording 60% of the C—H amination 
product (entry 9). The identity of the molecular sieves was crucial – whole activated beads had  
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Table 6 Catalyst studies and reaction optimization. 
 
 
no impact on reactivity, and activated powdered molecular sieves had a strong inhibitory effect – 
but it is unclear at this point whether this additive is playing a role in the reaction beyond acting 
as a dessicant. Introducing tert-butyl groups to the periphery of the Pc ligand structure further 
improved the yield to 75% (entry 11). Interestingly, this ligand modification was not similarly 
beneficial for the corresponding Fe complex, resulting in low yields and poor mass balance (29% 
yield, entry 12). The enhanced productivity of [Mn(
t
BuPc)] enables the catalyst loading to be 
halved to 5 mol% with a negligible reduction in reactivity, representing the optimal reaction 
conditions (72%, entry 13). Further reduction in catalyst loading to 2.5 mol% again affords a 
roughly equivalent product yield for this substrate (71%, entry 14), although at 0.4 mmol scale, 
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measurement error for weighing the catalysts is large enough to lead to reproducibility issues. In 
addition, the amount of oxidant can be reduced from 2 equiv. to 1.2 equiv while still maintaining 
high reactivity with [Mn(
t
BuPc)] (68%, entry 15). Importantly, the metal source used for the 
preparation of the catalyst, Mn(OAc)2, does not itself catalyze the reaction, nor does AgSbF6; 
complete recovery of starting material is observed in both cases (entries 16 and 17). However, 
AgSbF6 is still crucial for reactivity, as product yield drops to 22% when it is omitted from the 
reaction conditions (entry 18). The effect of the silver salt, which likely generates a cationic 
complex via in situ metathesis of the chloride counterion, is much more pronounced with these 
challenging substrates than previously observed with activated substrates (see Table 1, entry 5). 
 
2.2.2 Aliphatic C—H Bond Scope 
[Mn(
t
BuPc)] efficiently functionalizes a broad range of 3°, 2°, and 1° aliphatic C—H bonds with 
high functional group tolerance and site-selectivity (Table 7). Adjacent functionality on linear 
substrates such as protected nitrogen (33, 79%) and silyl ethers (34, 71%) are well tolerated, with 
no epimerization observed for the proximal stereocenter in the latter example. Cyclic substrates 
are also efficiently functionalized, leading to the formation of a 6,6- azaspirocycle (35, 52%) and 
a menthol-derived fused bicycle (36, 86%). [Mn(
t
BuPc)] demonstrates the ability to discriminate 
among different C—H bonds in a molecule, functionalizing at the 3° C—H bond in an 
isopinocampheol derivative to form five-membered heterocycle 37 in 63% yield; although it is 
sterically accessible, amination of the alternative 2° C—H site is not observed. 
Typically, 2° and 1° aliphatic C—H bonds are the least reactive sites for C—H amination 
reactions due to their high BDEs (98-101 kcal/mol) and low electron density, but these types of 
C—H bonds are readily functionalized with [Mn(tBuPc)], affording synthetically useful yields of 
94 
 
Table 7 Aliphatic substrate scope. 
 
aminated products. This catalyst exhibits sensitivity to substrate electronics for strong 2° 
aliphatic C—H bonds, exemplified by a low-yielding linear γ-ester (38, 29%), but reactivity is 
restored as the ester group is made more remote (39, 57% yield). Other functional handles, such 
as a tosylate leaving group, are tolerated under the reaction conditions, affording 42 in 54% 
yield. This group can then be displaced in an intramolecular fashion to generate heterobicycle 43 
in 80% yield (Figure 15). 
Figure 15 Formation of heterobicycles via C—H amination. 
 
Functionalization is also facile adjacent to quaternary centers in cyclohexane derivatives, 
affording oxathiazinane 40 in 82% yield, albeit with lower diastereoselectivity than has been 
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previously observed for this substrate.
17a,22a
 In this case, a small amount of product resulting 
from C—H amination of the 1° methyl group was also observed (Table 7). For cyclohexanol-
based substrates, the site-selectivity for C—H amination appears to be dependent on the 
conformational preference of the sulfamate ester group within the cyclohexane (Figure 16). 
When the sulfamate ester is equatorial, formation of five-membered rings is preferred, but when 
it is in the axial position, six-membered rings are preferred. Consistent with this, C—H 
amination of simple cyclohexanol derivatives affords a roughly 1:1 mixture of six- and five-
membered sulfamidates (44 and 45). When sterically encumbering 4-substitution biases the 
sulfamate ester into an axial position, C—H amination occurs exclusively in a 1,3-fashion, 
producing excellent yields of functionalization adjacent to a bulky tert-butyl group in a cis 
relationship (46, 90%). This 1,3,4-cis motif would be challenging to generate using traditional 
synthetic methods, particularly in such a highly stereoselective fashion.
61
 
Figure 16 C—H amination of cyclohexanol derivatives. 
 
The preference for formation of six-membered versus five-membered sulfamidates is 
well-established, with α-functionalization typically occurring only when β C—H bonds are either 
unavailable or configurationally inaccessible.
55a
 However, 1° aliphatic C—H functionalization 
even at the β-position is rare for C—H amination reactions. The few known reports involve long-
lived radical catalysts, such as cobalt
62
 and silver,
63
 that are not hypothesized to react via 
metallonitrenes. The only known examples of 1° aliphatic C—H amination reactions that 
proceed via a metallonitrene intermediate suffer from poor reactivity under catalytic conditions 
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(Figure 17A).
64
 In stark contrast to this precedent, we observed that a borneol derivative was 
functionalized under [Mn(
t
BuPc)] catalysis selectively at the 1° C—H bond of the adjacent 
methyl group in preference to the α-2° C—H bond to afford amination product 41 in 
synthetically useful yield (53%) (Table 7). Consistent with the general preference for formation 
of six-membered sulfamidates, a similar selectivity for this substrate was also observed with 
Rh2(esp)2; however, the reactivity was notably diminished under rhodium-catalyzed reaction 
conditions (1.5:1 1°/2°; 33% of 1° C—H amination product isolated). In complex molecule 
settings, this site-selectivity is further magnified; the 1° aliphatic C—H amination products 47 
and 48 are formed exclusively in the presence of 2° and even 3° α-C—H sites in excellent yields, 
as demonstrated by Jinpeng Zhao in our group (Figure 17B). 
Figure 17 1° aliphatic C—H amination reactions. (A) Previous examples with metallonitrene 
catalysts. (B) Selective amination of 1° C—H bonds in complex molecules (with Jinpeng Zhao). 
 
 
 
2.2.3 Differential Reactivity of Fe and Mn 
The enhanced catalytic activity of manganese is clearly evident across all substrates 
classes (Table 8). Unsubstituted linear sulfamate esters lack turning elements to bias reactivity 
and are poor substrates under iron catalysis even when containing activated C—H bonds (49,  
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Table 8 Differential C—H amination reactivity among Fe and Mn catalysts. 
 
12% and 50, 22%). A significant improvement in yield is observed in switching from the iron to 
the manganese phthalocyanine catalyst. While [Mn(
t
BuPc)] and [MnPc] afford similar product 
yields for activated C—H bonds, [Mn(tBuPc)] maintains synthetically useful reactivity across all 
bond types. Strong aliphatic 2° C—H  bonds (51, BDE ~ 98 kcal/mol) and even 1° C—H bonds 
(52, BDE ~ 101 kcal/mol) are highly reactive with [Mn(
t
BuPc)]. In contrast, [FePc] is essentially 
unreactive for these bond types (<5% yield), and even [MnPc] is poorly reactive for the most 
challenging aliphatic substrates (37% and 39%, respectively). Importantly, despite the high 
reactivity of [Mn(
t
BuPc)], excellent chemoselectivity (>20:1) is maintained for allylic C—H 
amination. We have fully explored the scope of this catalyst and have found that in addition to 
aliphatic substrates, [Mn(
t
BuPc)] efficiently functionalizes all types of sp
3
 C—H bonds, 
including allylic, benzylic, ethereal, and propargylic C—H bonds (24 examples). In all cases, this 
catalytic system tolerates a variety of functionality, including pharmacophoric nitrogen-based 
heterocycles, and achieves excellent chemoselectivity for C—H amination in the presence of 
olefins and alkynes. The scope of activated C—H bonds was established primarily by Jennifer 
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Griffin (allylic, propargylic, ethereal), Jinpeng Zhao (benzylic), and Aaron Petronico 
(heteroaromatic), and will not be discussed in this dissertation. 
 
2.2.4 Mechanistic Studies 
Figure 18 Proposed general stepwise mechanism for C—H amination. 
 
 
 
To gain insight into the basis for the often dramatic reactivity differences observed 
between manganese and iron, we conducted a series of mechanistic studies to probe different 
steps of the proposed catalytic cycle. In contrast to the concerted asynchronous mechanism 
posited for rhodium catalysis, we hypothesized that [Mn
III
(
t
BuPc)], like [Fe
III
Pc], operates via a 
stepwise mechanism involving H–atom abstraction by a manganese nitrenoid to generate an 
alkyl radical and an amidomanganese species, followed by rapid radical rebound to form the 
aminated product (Figure 18, also see Section 1.1, Figure 3). We first sought to evaluate the 
nature of the C—H cleavage step for both the [FeIIIPc] and [MnIIIPc] catalysts. To accomplish 
this, we systematically compared the C—H bond reactivity trends for both catalysts through a 
series of intramolecular competition experiments comparing 3° aliphatic C—H bonds to other 
bond types (53-56, Table 9). The reactivity trends correlate with the homolytic C—H bond 
dissociation energies (BDE) for both manganese and iron, with the weakest C—H bond (allylic, 
BDE ~ 85 kcal/mol) being the most reactive, in agreement with our previous results (see Section 
1.2.3). However, manganese shows less discrimination between the different bond types, 
generally forming more of the aliphatic C—H amination product relative to iron (13,57-59).  
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Table 9 C—H bond reactivity trends. 
 
While the identity of the metal has a noticeable effect on site-selectivity, the ligand does not, as 
no measurable selectivity differences were observed between [Mn
III
Pc] and [Mn(
t
BuPc)] in any 
case. Additionally, benzylic amination of monodeuterated substrate 21 provides a KIE of 
4.46±0.08 for [Mn
III
Pc] that is significantly larger than for Rh2(OAc)4 (3.83±0.10), but smaller 
than that for [Fe
III
Pc] (4.79±0.13) (Figure 19). Interestingly, a slightly smaller KIE of 4.23±0.10 
was measured for [Mn(
t
BuPc)] relative to [Mn
III
Pc], suggestive of a further slight attenuation of 
radical character that may contribute to the observed reactivity differences between these 
catalysts with challenging substrates. Taken together, these data support our hypothesis that both  
Figure 19 Kinetic isotope effect (KIE) study. 
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[Fe
III
Pc] and [Mn
III
Pc] proceed through a stepwise mechanism via an electrophilic intermediate 
with a transition structure for [Mn
III
Pc] in which C—H bond breakage is marginally less 
pronounced relative to [Fe
III
Pc]. 
We next sought to evaluate the recombination step for both the Mn and Fe systems. 
Similar to our previous results (see Section 1.2.4, Figure 10B), we observed olefin isomerization 
with both [Fe
III
Pc] and [Mn
III
Pc] in the allylic C—H amination of a Z-olefin substrate 60 (>20:1 
Z/E), affording a 10:1 Z/E mixture of products 49, which is suggestive of a discrete intermediate 
that can be stabilized through resonance (Figure 20A, performed by Jennifer Griffin). 
Importantly, however, C—H amination at a defined stereocenter in 3° aliphatic substrate 61 
proceeds with complete stereoretention for both metals (62, 99% ee, Figure 20B). These data 
support a stepwise mechanism for both Fe and Mn involving a short-lived electrophilic 
intermediate that undergoes rapid rebound to form the aminated product. 
Figure 20 Radical rebound probes. (A) Z-olefin isomerization study. (B) C—H amination of a 
defined 3° C—H center. 
 
 
We next investigated the kinetics of the C—H amination reaction in order to account for 
the role of the metal catalyst in effecting profound differences in overall reaction productivity. 
Analysis of the reaction profile with 2° aliphatic substrate 63 indicated a significant rate 
enhancement with [Mn(
t
BuPc)] relative to [Fe
III
Pc] and even to [Mn
III
Pc], resulting in 
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Figure 21 Comparative reaction profile for C—H amination with [FePc], [MnPc], and 
[Mn(
t
BuPc)]. 
 
 
 
noticeably higher product yields of 64 for [Mn(
t
BuPc)] (Figure 21). Further kinetic analysis of 
the [Mn(
t
BuPc)]-catalyzed C—H amination for deuterated and non-deuterated benzylic substrate 
21 revealed a primary isotope effect in the initial rate of the reaction (kH/kD = 1.6), which is 
similar to the value obtained through intermolecular competition (Figure 22). These results 
indicate that C—H cleavage is part of the rate-determining step, although the moderate value 
observed makes it unlikely to be solely rate-determining.
65
 As further evidence of catalyst 
involvement in the rate-determining step, changing the concentration of [Mn(
t
BuPc)] results in a 
proportional change to the initial rate of the reaction (see Section 2.4 for experimental details). 
This is in stark contrast to rhodium catalysis, where kinetic studies established a zero-order 
dependence on catalyst concentration for intramolecular C—H amination.18 Other 
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complementary studies determined that iminoiodinane formation, which is a reversible process, 
is rate-determining with rhodium catalysts. 
Figure 22 Kinetic studies for [Mn(
t
BuPc)]-catalyzed C—H amination. 
 
Collectively, these data indicate that the metal catalyst is involved in the rate-determining 
step and that there are minor differences in the nature of the transition state for C—H cleavage 
between the catalysts. KIE studies suggest that C—H cleavage is at least partly rate-determining 
in C—H amination with [Mn(tBuPc)], although additional experiments are needed to fully 
establish the rate-determining step for the reaction. The importance of C—H cleavage for the 
reaction rate and attenuation of radical character for the reactive metallonitrene species with 
manganese may significantly contribute to the improved reactivity observed under these 
conditions.
60
 At this point, we have not identified the fundamental molecular properties of 
[Mn(
t
BuPc)] that are responsible for its improved productivity relative to [Fe
III
Pc]. 
 
2.2.5 Complex Molecule Diversification 
By allowing for functionalization at late stages in chemical synthesis, C—H activation-
based synthetic strategies can be extremely enabling for the preparation and diversification of 
molecules of biological interest. The high efficiency, broad substrate scope, and good functional 
group tolerance of C—H amination with [Mn(tBuPc)] make this methodology readily amenable 
to complex molecule settings. Applying this method to natural product derivatives revealed that 
C—H amination in functionally and topologically complex natural product derivatives generally 
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occurs with equal efficiency and often magnified selectivity relative to their simple substructural 
units. 
Picrotoxin, which occurs naturally as a mixture of picrotoxinin (the biologically active 
component) and picrotin in the fruit of climbing plant Anamirta cocculus, has potent 
neurological activity, primarily acting as a non-competitive chloride channel blocker for GABAA 
receptors.
66
 Picrotoxinin and its derivatives have attracted synthetic interest due to its long 
history as a stimulant and one-time role as an antidote for barbiturate overdose.
67
 Our group 
previously demonstrated the ability of Fe(PDP)-catalyzed directed C—H lactonization to 
functionally modify the structure at the exocyclic isopropyl unit, affording lactone 65 in 38% 
yield, with an additional 39% of hydroxylactone (Figure 23).
26g
 Here, we prepared a similar 
derivative, diverting the alcohol to sulfamate ester 66. C—H amination of this functionally dense 
picrotoxinin derivative, which contains an unprotected 3° alcohol, proceeded smoothly under 
standard reaction conditions at a 3° C—H bond to produce fused bicycle 67 in 57% yield. 
Figure 23 Derivatization of picrotoxinin via C—H functionalization. 
 
Stevia rebaudiana, also known as sweetleaf, is the plant from which the popular 
alternative sweetener stevia is derived. The active compound in this plant, stevioside, is a 
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glycoside-bound diterpene. Its direct metabolite is steviol, but mineral acid-mediated hydrolysis 
with concomitant Wagner-Meerwein rearrangement instead affords isosteviol,
68
 which has a 
greater bioavailability than its non-rearranged counterpart. Isosteviol and its derivatives have 
been found to have potent and varied beneficial biological effects, including 
antihyperglycemic,
69
 anticancer,
70
 anti-inflammatory,
71
 and antihypertensive
72
 activity. Due to its 
promising bioactivity, there is continued synthetic interest in the preparation of isosteviol 
derivatives, although thus far modifications of the structure have been limited to acetylation 
strategies and skeletal rearrangements.
73
 C—H amination would allow for the direct 
incorporation of new functionality into the molecular scaffold, creating novel oxidation patterns 
that would typically require lengthy de novo synthesis to achieve. With [Mn(
t
BuPc)], isosteviol 
derivative 68 is functionalized exclusively at the C3-2° aliphatic C—H bond to furnish 69 in 
92% yield as a single diastereomer (Figure 24). Importantly, this reaction scales readily using 
reduced catalyst (2.5 mol% versus 5 mol%) and oxidant (1.5 equiv versus 2.0 equiv) loadings 
with no reduction in efficiency (75% yield – identical to 0.2 mmol scale under same conditions). 
Figure 24 C—H amination of an isosteviol derivative. 
 
The versatile sulfamidate that is formed through intramolecular C—H amination is a 
valuable synthetic handle that can be further diversified in a number of ways, allowing rapid 
access to broad libraries of compounds (Figure 25A).
74
 In particular, the α-oxygen position of the  
heterocycle is a good leaving group that is susceptible to displacement by a variety of oxygen,
75
 
nitrogen,
76
 sulfur,
77
 and carbon
78
 nuclophiles. Phenolic oxygens can be displaced via a nickel-
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catalyzed Kumada coupling reaction.
79
 In addition, the sulfate can be extruded with strong base 
to form azetidines
80
 or with hydridic reducing agents to directly generate unprotected 
aminoalcohols.
81
 As a further demonstration of the synthetic utility of this C—H amination 
approach, a N-CBz- protected oxathiazinane was reacted with both nitrogen- and oxygen-based 
nucleophiles (Figure 25B). Addition of NaN3 affords 70 in 56% yield, which can be readily 
reduced to a 1,3-diamine via a Staudinger reaction or reacted with alkyne dipolarophiles to 
generate a series of pharmacophoric triazoles. Alternatively, KOAc can be added to reveal 
protected 1,3-amino alcohol motif 71 in 76% yield. Together these results establish that alcohols, 
which are present in a wide range of readily available natural products, can now serve as 
valuable handles to install nitrogen into a range of sp
3
 C—H bonds in predictable 1,3- or 1,2-
relationships. 
Figure 25 Elaboration of C—H amination products. (A) Methods for diversification of 
sulfamidate heterocycles. (B) Addition of small nucleophiles to an isosteviol derivative. 
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2.3 Conclusion 
We have successfully developed the first truly general catalyst for C(sp
3
)—H amination. 
[Mn(
t
BuPc)] is capable of catalyzing the C—H amination of all types of C(sp3)—H bonds, 
including very strong 1° and 2° aliphatic C—H bonds, in preparative yields (>50%), while 
maintaining excellent chemoselectivity in the presence of olefins. Manganese’s intermediacy 
between the concerted asynchronous C—H insertion mechanism of rhodium and the homolytic 
C—H abstraction/rebound mechanism of iron may in part allow for this unprecedented enzyme-
like balance of reactivity and selectivity. We anticipate that the non-toxic nature and relative 
abundance of this first–row metal catalyst, coupled to its broad reactivity and high site- and 
chemoselectivity, will render this general C—H amination method highly useful for the 
incorporation of nitrogen in both target and diversity-oriented chemical synthesis. 
 
2.4 Experimental Information 
General Information 
The following commercially obtained reagents were used as received: iron(III) phthalocyanine 
chloride ([FePc]Cl, Sigma-Aldrich), manganese(III) phthalocyanine chloride ([MnPc]Cl, Sigma-
Aldrich), 5,10,15,20-Tetraphenyl-21H,23H-porphine iron(III) chloride (Fe(TPP)Cl, Strem), 
5,10,15,20-Tetraphenyl-21H,23H-porphine manganese(III) chloride (Mn(TPP)Cl, Strem), 
Mn(R,R-salen)Cl (Sigma-Aldrich), silver hexafluoroantimonate (AgSbF6, Strem), and bis(tert-
butylcarbonyloxy)iodobenzene
82
 (PhI(OPiv)2, Sigma-Aldrich). All reactions were run in flame- 
or oven-dried glassware under an atmosphere of N2 or Ar gas with dry solvents unless otherwise 
stated. All products were filtered through a glass wool plug prior to obtaining a final weight. 
Solid reagents were stored in a dessicator or glovebox, and anhydrous solvents were purified by 
passage through a bed of activated alumina immediately prior to use (Glass Countour, Laguna 
107 
 
Beach, California). Chloroform-d was stored over 3Å molecular sieves in a secondary container 
with drierite. Fe(R,R-PDP)(SbF6)2, Mn(R,R-PDP)(SbF6)2, and Fe(R,R-salen)Cl were prepared 
according to methods described in the literature
26e,36
 and stored at 4
o
C. Chlorosulfonyl isocyanate 
(ClSO2NCO, Sigma-Aldrich or TCI America) was transferred to a Schlenk-type flask and stored 
at 4
o
C under an inert atmosphere.
37
 4Å MS beads were crushed with a mortar and pestle until 
fine, then activated in a 180°C oven for at least 48h and stored in a dessicator. Thin-layer 
chromatography (TLC) was conducted with E. Merck silica gel 60 F254 pre-coated plates (0.25 
mm) and visualized with UV and ethanolic anisaldehyde or potassium permanganate stains. 
Flash chromatography was performed as described by Still
38
 using American International 
ZEOprep 60 ECO silica gel (230-400 mesh). Achiral gas chromatographic (GC) analysis was 
performed on an Agilent 6890N Series instrument equipped with FID detectors using a HP-5 
(5%-Phenyl)-methylpolysiloxane column (30m, 0.32mm, 0.25mm), and chiral GC analysis using 
a CycloSil-B column (30m, 0.25mm, 0.25mm). 
1
H-NMR spectra were recorded on a Varian Inova-500 (500 MHz) or Varian Unity-500 
(500 MHz) spectrometer and are reported in ppm using solvent as an internal standard (CDCl3 at 
7.26 ppm). Data reported as: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sxt = 
sextet, spt = septet, m = multiplet, br = broad, app = apparent; coupling constant(s) in Hz; 
integration. Proton-decoupled 
13
C-NMR spectra were recorded on a Varian Unity-500 (125 
MHz) spectrometer and are reported in ppm using solvent as an internal standard (CDCl3 at 
77.16 ppm). Kinetic isotope effect analyses were recorded on a Varian Inova-600 (600 MHz) 
spectrometer. IR spectra were recorded as thin films on NaCl plates or using ATR on a Perkin 
Elmer Frontier FTIR and are reported in frequency of absorption (cm
-1
). Optical rotations were 
measured using a 1 mL cell with a 50 mm path length on a Jasco P-1020 polarimeter. Optical 
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rotations were obtained with a sodium lamp and are reported as follows: [α]λT
o
C (c = g/100 mL, 
solvent). High-resolution mass spectra were obtained at the University of Illinois Mass 
Spectrometry Laboratory. Electrospray ionization (ESI) spectra were performed on a Waters Q-
Tof Ultima spectrometer, and electron ionization (EI) and field desorption (FD) spectra were 
performed on a Micromass 70-VSE spectrometer. Elemental analysis was performed by 
Robertson Microlit Laboratories. 
 
Preparation of [Mn
III
(
t
BuPc)] 
 
[Mn(
t
BuPc)]Cl from ligand: The following procedure was adapted from a literature 
preparation.
83
 2,9,16,23-Tetra-tert-butyl-29H,31H-phthalocyanine (250 mg, 0.338 mmol, 1.0 
equiv, Sigma Aldrich) was taken up in degassed DMF (16 mL) in a 50 mL round-bottom flask 
equipped with stir bar and septum (the flask and stir bar should be free of trace metal impurities). 
Mn(OAc)2 (58.5 mg, 0.338 mmol, 1.0 equiv, Sigma-Aldrich) was added under a stream of N2, 
then reaction was warmed to 60°C and stirred for 12h. Upon completion, the reaction cooled to 
rt, then was diluted with water (10 mL), transferred to a separatory funnel, and the aqueous layer 
was washed with hexanes (20 mL) to remove unreacted ligand. Brine (15 mL) was added, and 
then complex was extracted with chloroform (3x30 mL). The combined organic layers were 
dried over Na2SO4 and filtered. Neutral alumina (15 mL) was added to the solution of crude 
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complex and concentrated to dryness. The adsorbed catalyst-alumina powder was then applied to 
a flash column with unwetted neutral alumina (45 mm column, 100 mm Al2O3). Remaining 
uncomplexed ligand, which is a bright turquoise color, was eluted with 9:1 hex/EtOAc (ca. 
1.5L). Once ligand fully eluted, [Mn(
t
BuPc)]Cl, which is a dark evergreen color, was eluted with 
neat EtOAc (ca. 1L). Pure product was isolated as a flaky dark green solid in 89% yield. 
 
 
[Mn(
t
BuPc)]Cl from phthalonitrile: A flame dried 100 mL round-bottom flask equipped with a 
stir bar and reflux condenser (the flask and stir bar should be free of trace metal impurities) was 
sequentially charged with 4-tert-butyl-phthalonitrile (2.211g, 12.0 mmol, 4.0 equiv, TCI 
America), 1-hexanol (24 mL, freshly distilled over MgSO4 and degassed), Mn(OAc)2 (519 mg, 
3.00 mmol, 1.0 equiv, Sigma-Aldrich) and DBU (3.59 mL, 24.0 mmol, 8.0 equiv, Sigma-
Aldrich). Reaction flask was evacuated under vacuum and refilled with N2 3 times, then heated 
to 155ºC. The reaction mixture changed from colorless to turquoise green over 10 minutes. After 
stirring at 155ºC overnight, the heat was ceased and the condenser was removed. Brine (15 mL) 
was cautiously added into the reaction dropwise via a pasteur pipette while the reaction 
temperature was maintained over 100ºC, then the reaction was stirred open to air while cooling 
to room temperature for 1 hour. Brine and chloroform were added to the flask and the mixture 
was extracted with chloroform 3 times. The combined organic layer was dried over Na2SO4, 
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filtered, and concentrated by rotatory evaporation. The remaining solution was transferred to a 
round-bottom flask equipped with stir bar and short path distillation head, placed under high vac, 
and then heated to ~60-80ºC until crude material was a sticky solid (~2-3 days). The crude 
catalyst was taken up in CH2Cl2 with 50 mL neutral alumina (Brockmann Type I, Alfa Aesar), 
then concentrated to dryness and applied to a plug of 200 mL neutral Al2O3 (50 mm fritted glass 
column) pre-wetted with 5% EtOAc/hexanes. Nonpolar impurities were eluted with 10% 
EtOAc/hexanes  20% EtOAc/hexanes (~2L) until eluting solution turned green. 
[Mn(
t
BuPc)]Cl was eluted as a separate dark green fraction by flushing with EtOAc (~2-4L). The 
solution was concentrated by rotatory evaporation and was dried under high vac overnight to 
afford 971 mg (1.17 mmol) of [Mn(
t
BuPc)]Cl as a dark green powder (39% yield). Catalyst 
obtained by this method contains a minor unknown impurity (visible in IR at 1711 cm
-1
), which 
has no observable impact on reactivity for any of the substrate classes examined. Due to the 
convenience and economy of this procedure, this was the standard method for preparing the 
catalyst used in this report. [Mn(
t
BuPc)]Cl prepared in this way can be made analytically pure by 
column chromatography on silica using a gradient of 10%  20%  30%  50%  100% 
EtOAc/hexanes. 
 
UV-Vis (CHCl3, max = nm, ε = M
-1
cm
-1
): 729 (ε = 73400), 662 (ε = 15900), 531 (ε = 10100), 
369 (ε = 32400), 280 (ε = 39200); IR (ATR, cm-1) 2955, 2865, 1612, 1506, 1482, 1459, 1394, 
1363, 1328, 1280, 1255, 1199, 1147, 1075, 932, 893, 828, 763, 746; HRMS (ESI) m/z calculated 
for C48H48MnN8 [M-Cl]
+
: 791.3382, found 791.3380. LRMS (FD) m/z 792.9 (Mn(
t
BuPc)+H), 
827.8 (M
+
). Anal. calculated for C48H48ClMnN8 (FW = 827.36), C 69.68, H 5.85, N 13.54, Mn 
6.64; found C 70.07, H 6.05, N 13.21, Mn 6.62. 
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UV-Vis Studies: 4.2 mg (0.005 mmol) of [Mn
III
(
t
BuPc)] was taken up in CHCl3 to 5 mL 
solution (1.0 mM). 100 µL of this solution was diluted to 10 mL (10.0 µM). UV-Vis was taken 
from 850-250 nm in a quartz cuvette (path length = 1 cm). 
 
 
Preparation of Sulfamate Ester Starting Materials 
General procedure for preparation of sulfamate ester substrates
17a,34
 
Method A: 
Preparation of ClSO2NH2 solution (2M in MeCN): A round-bottom flask equipped with stir bar 
and rubber septum was charged with ClSO2NCO (1.5 equiv) and MeCN (2M relative to 
isocyanate). The flask was cooled to 0
o
C, and then neat formic acid (1.5 equiv) was added 
dropwise. The reaction stirred vigorously at 0
o
C (1 h) then room temp (~23
o
C) overnight.  
Sulfamate ester formation: A 50 mL round-bottom flask equipped with stir bar and rubber 
septum was charged with 95% NaH (1.1 equiv) and 5 mL DMF (1M relative to starting material) 
and cooled to 0
o
C. The alcohol starting material (1.0 equiv) in DMF was slowly added. The 
reaction was stirred at room temp. for 1 h, after which it was cooled again to 0
o
C. The freshly 
prepared 2M MeCN solution of ClSO2NH2 (vide supra) was then added dropwise via syringe, 
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and the reaction stirred at room temp. for 2-4 h. Upon complete consumption of starting material 
as monitored by TLC, the reaction was quenched with H2O until the mixture turned clear (~8 
mL). The reaction mixture was partitioned between H2O (15 mL) and Et2O (60 mL) and 
separated. The aqueous layer was then extracted with Et2O (2x30 mL). The organic layers were 
combined, dried over MgSO4, filtered, and concentrated under reduced pressure. Although the 
sulfamate esters were generally pure by NMR after a single column, as a precaution they were 
subjected to a second column to remove minor NMR-silent impurities that have been shown to 
inhibit the amination reaction. Following purification, sulfamate esters were thrice dissolved in 
benzene and concentrated under reduced pressure to remove trace H2O, then stored in a 
dessicator until use. 
Method B: 
A round-bottom flask equipped with stir bar and rubber septum was charged with ClSO2NCO 
(2.0 equiv) and CH2Cl2 (2M relative to isocyanate). The flask was cooled to 0
o
C, and then neat 
formic acid (2.0 equiv) was added dropwise. The reaction stirred vigorously at 0
o
C (1 h) then 
room temp (~23
o
C) overnight. After cooling the reaction flask back to 0
o
C, the alcohol starting 
material (1.0 equiv) with Et3N (2.0 equiv) in CH2Cl2 (0.75M relative to starting material) was 
slowly added via syringe. After complete addition, the reaction warmed back to room temp. and 
stirred for 4-6 h. If conversion is low after 3-4 h, additional Et3N (1-2 equiv) can be added. Upon 
complete consumption of starting material as monitored by TLC, the reaction was quenched with 
H2O until the mixture turned clear (~8 mL). The reaction mixture was partitioned between H2O 
(15 mL) and CH2Cl2 (30 mL) and separated. The aqueous layer was then extracted with CH2Cl2 
(2x30 mL). The organic layers were combined, dried over MgSO4, filtered, and concentrated 
under reduced pressure. Although the sulfamate esters were generally pure by NMR after a 
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single column, as a precaution they were subjected to a second column to remove minor NMR-
silent impurities that have been shown to inhibit the amination reaction. Following purification, 
sulfamate esters were thrice dissolved in benzene and concentrated under reduced pressure to 
remove trace H2O, then stored in a dessicator until use. 
NOTE: Some sulfamate esters exhibited suboptimal reactivity after storing for more than a 
month (although some are bench stable for much longer); repurification by column 
chromatography usually restored reactivity in these cases. 
 
(±)-3,7-dimethyloctyl sulfamate [31]. 
Prepared according to method A. 4.75 g (30.0 mmol) of (±)-3,7-
dimethyloctanol were used, along with NaH (834 mg, 33.0 mmol, 1.1 equiv), DMF (30 + 15 
mL), ClSO2NCO (3.92 mL, 45.0 mmol, 1.5 equiv), formic acid (1.70 mL, 45.0 mmol, 1.5 equiv) 
and MeCN (23 mL). Flash column chromatography on silica (45 mm fritted glass column, 200 
mm SiO2) using 4:1 hexanes/EtOAc as eluent gave 5.835 g (24.6 mmol) of pure product as a 
colorless oil (82% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.71 (br. s, 2H), 4.29-4.22 (m, 2H), 1.82-1.76 (m, 1H), 1.64-1.48 
(m, 3H), 1.34-1.22 (m, 3H), 1.20-1.10 (m, 3H), 0.92 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 6.5 Hz, 
6H); 
13
C-NMR (125 MHz, CDCl3) δ 70.3, 39.3, 37.1, 35.8, 29.5, 28.1, 24.7, 22.8, 22.7, 19.4; IR 
(film, cm
-1
) 3392, 3294, 2953, 2870, 1556, 1468, 1367, 1180, 1034, 953, 766; HRMS (ESI) m/z 
calculated for C10H23NO3SNa [M+Na]
+
: 260.1296, found 260.1297. 
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(±)-1-(1,3-dioxoisoindolin-2-yl)-4-methylpentan-2-yl sulfamate. 
Prepared according to method B. 1.446 g (5.85 mmol) of (±)-2-(2-hydroxy-4-
methylpentyl)isoindoline-1,3-dione were used, along with Et3N (1.63 mL, 
11.7 mmol, 2.0 equiv), ClSO2NCO (1.02 mL, 11.7 mmol, 2.0 equiv), formic acid (2441 μL, 11.7 
mmol, 2.0 equiv) and CH2Cl2 (6 mL + 8 mL). Flash column chromatography on silica (35 mm 
fritted glass column, 150 mm SiO2) using 2:1 hexanes/EtOAc  1:1 hexanes/EtOAc as eluent 
gave 976 mg (2.99 mmol) of pure product as a white solid (51% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.89-7.85 (m, 2H), 7.77-7.73 (m, 2H), 5.03 (br. s, 2H), 4.92-4.88 
(m, 1H), 4.08 (dd, J = 15.0, 3.0 Hz, 1H), 3.91 (dd, J = 15.0, 5.0 Hz, 1H), 1.89-1.81 (m, 1H), 1.68 
(ddd, J = 14.5, 9.5, 5.0 Hz, 1H), 1.47 (ddd, J = 13.5, 8.5, 4.5 Hz, 1H), 0.98 (d, J = 6.5 Hz, 3H), 
0.97 (d, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 168.8, 134.4, 132.0, 123.7, 79.8, 41.7, 
41.5, 24.3, 23.1, 21.9; IR (ATR, cm
-1
) 3381, 3279, 2964, 2936, 2877, 1770, 1705, 1552, 1466, 
1428, 1402, 1360, 1314, 1180, 1070, 987, 976, 866, 796, 770, 747, 722, 713, 694; HRMS (ESI) 
m/z calculated for C14H19N2O5S [M+H]
+
: 327.1015, found 327.1014. 
 
(-)-(2S,3R)-2-((tert-butyldiphenylsilyl)oxy)-5-methylhexan-3-yl sulfamate. 
Prepared according to method B. 518 mg (1.40 mmol) of (2S,3R)-2-((tert-
butyldiphenylsilyl)oxy)-5-methylhexan-3-ol were used, along with Et3N (391 µL, 
2.80 mmol, 2.0 equiv), ClSO2NCO (244 µL, 2.80 mmol, 2.0 equiv), formic acid 
(106 μL, 2.80 mmol, 2.0 equiv) and CH2Cl2 (1.4 mL + 2.8 mL). Flash column chromatography 
on silica (35 mm fritted glass column, 130 mm SiO2) using 9:1 hexanes/EtOAc  4:1 
hexanes/EtOAc as eluent gave 204 mg (0.454 mmol) of pure product as a white solid (32% 
yield). 
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1
H-NMR (500 MHz, CDCl3) δ 7.73-7.66 (m, 4H), 7.48-7.39 (m, 6H), 4.53 (dt, J = 9.0, 4.0 Hz, 
1H), 4.17 (dq, J = 6.5, 4.0 Hz, 1H), 4.09 (br. s, 2H), 1.79-1.71 (m, 1H), 1.66-1.56 (m, 2H), 1.15 
(d, J = 6.5 Hz, 3H), 1.07 (s, 9H), 0.95 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 6.0 Hz, 3H); 
13
C-NMR 
(125 MHz, CDCl3) δ 136.2, 136.0, 133.8 (2 peaks), 130.2, 130.0, 128.0, 127.8, 83.6, 68.6, 36.6, 
27.1, 23.9 (d, JC-Si = 10.9 Hz), 21.7, 19.3, 16.9; IR (ATR, cm
-1
) 3289, 2959, 2859, 1472, 1428, 
1367, 1187, 1112, 1078, 923, 822, 740, 702; [α]25D = -19.3
o
 (c = 1.1, CHCl3); HRMS (ESI) m/z 
calculated for C23H35NO4SSiNa [M+Na]
+
: 472.1954, found 472.1956. 
 
2-cyclohexylethyl sulfamate. 
Prepared according to method A. 1.145 g (8.93 mmol) of cyclohexylethanol 
were used, along with NaH (248 mg, 9.82 mmol, 1.1 equiv), DMF (9 + 7 mL), 
ClSO2NCO (1.17 mL, 13.4 mmol, 1.5 equiv), formic acid (505 μL, 13.4 mmol, 1.5 equiv) and 
MeCN (7 mL). Flash column chromatography on silica (35 mm fritted glass column, 150 mm 
SiO2) using 3:1 hexanes/EtOAc as eluent gave 1.702 g (8.21 mmol) of pure product as a 
colorless oil (91% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.88 (br. s, 2H), 4.25 (t, J = 6.5 Hz, 2H), 1.74-1.66 (m, 5H), 1.64 
(app. q, J = 7.0 Hz, 2H), 1.48-1.39 (m, 1H), 1.29-1.10 (m, 3H), 0.93 (app. dq, J = 12.0, 3.0 Hz, 
2H); 
13
C-NMR (125 MHz, CDCl3) δ 69.9, 36.1, 34.0, 33.1, 26.5, 26.2; IR (ATR, cm
-1
) 3369, 
3289, 2916, 2844, 1539, 1450, 1376, 1353, 1189, 1097, 1028, 999, 966, 917, 888, 849, 787, 746; 
HRMS (ESI) m/z calculated for C8H17NO3SNa [M+Na]
+
: 230.0827, found 230.0835. 
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(-)-(1R,2S,5R)-menthyl sulfamate. 
Prepared according to method A. 1.563 g (10.0 mmol) of (-)-menthol were used, 
along with NaH (278 mg, 11.0 mmol, 1.1 equiv), DMF (10 + 8 mL), ClSO2NCO 
(1.31 mL, 15.0 mmol, 1.5 equiv), formic acid (566 μL, 15.0 mmol, 1.5 equiv) and MeCN (7.5 
mL). Flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 
4:1 hexanes/EtOAc as eluent, followed by recrystallization from CH2Cl2 layered with hexanes, 
gave 1.821 g (7.70 mmol) of pure product as a crystalline white solid (77% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.71 (br. s, 2H), 4.43 (dt, J = 11.0, 4.5 Hz, 1H), 2.38-2.34 (m, 
1H), 2.12 (ddt, J = 14.0, 7.0, 2.0 Hz, 1H), 1.74-1.66 (m, 2H), 1.51-1.38 (m, 2H), 1.26 (app. q, J = 
11.8 Hz, 1H), 1.04 (dq, J = 13.0, 3.5 Hz, 1H), 0.94 (d, J = 7.0 Hz, 3H), 0.92 (d, J = 7.5 Hz, 3H), 
0.89-0.86 (m, 1H), 0.83 (d, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 84.9, 47.7, 41.6, 
33.9, 31.8, 25.7, 23.2, 22.1, 21.0, 15.9; IR (film, cm
-1
) 3361, 3253, 2945, 2872, 1560, 1454, 
1358, 1186, 1169, 916; [α]25D = -82.1
o
 (c = 1.0, CHCl3); HRMS (ESI) m/z calculated for 
C10H21NO3SNa [M+Na]
+
: 258.1140, found 258.1139. 
 
(-)-(1S,2S,3S,5R)-isopinocampheyl sulfamate. 
Prepared according to method B. 1.543 g (10.0 mmol) of (+)-isopinocampheol 
were used, along with Et3N (2.79 mL, 20.0 mmol, 2.0 equiv), ClSO2NCO (1.74 
mL, 20.0 mmol, 2.0 equiv), formic acid (755 μL, 20.0 mmol, 2.0 equiv) and CH2Cl2 (10 + 10 
mL). Flash column chromatography on silica (45 mm fritted glass column, 170 mm SiO2) using 
4:1 hexanes/EtOAc as eluent gave 580 mg (2.49 mmol) of pure product as a white solid (25% 
yield). 
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1
H-NMR (500 MHz, CDCl3) δ 4.90 (ddd, J = 9.5, 5.5, 4.5 Hz, 1H), 4.72 (s, 2H), 2.70 – 2.60 (m, 
1H), 2.40 (dtd, J = 10.0, 6.0, 2.5 Hz, 1H), 2.28 (qdd, J = 7.5, 5.5, 2.0 Hz, 1H), 2.11 (ddd, J = 
14.5, 4.5, 3.0 Hz, 1H), 1.98 (tt, J = 6.0, 3.0 Hz, 1H), 1.85 (td, J = 6.0, 2.0 Hz, 1H), 1.23 (s, 3H), 
1.18 (d, J = 7.5 Hz, 3H), 1.08 (d, J = 10.0 Hz, 1H), 0.94 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 
84.3, 47.6, 44.2, 44.1, 38.4, 36.2, 33.8, 27.4, 24.1, 20.2; IR (ATR, cm
-1); [α]26D = -24.1
o
 (c = 0.5, 
CHCl3); HRMS (EI) m/z calculated for C10H19NO3S [M]
+
: 233.1086, found 233.1087. 
 
Methyl 6-(sulfamoyloxy)hexanoate. 
Prepared according to method B. 1.385 g (9.47 mmol) of methyl 6-
hydroxyhexanoate
84
 were used, along with Et3N (2.64 mL, 18.9 mmol, 
2.0 equiv), ClSO2NCO (1.65 mL, 18.9 mmol, 2.0 equiv), formic acid (713 μL, 18.9 mmol, 2.0 
equiv) and CH2Cl2 (9 mL + 10 mL). Flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 3:2 hexanes/EtOAc as eluent gave 1.520 g (6.75 mmol) of pure 
product as a white solid (71% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.84 (br. s, 2H), 4.22 (t, J = 6.5 Hz, 2H), 3.67 (s, 3H), 2.34 (t, J = 
7.0 Hz, 2H), 1.77 (dt, J = 13.5, 7.0 Hz, 2H), 1.70-1.64 (m, 2H), 1.49-1.43 (m, 2H); 
13
C-NMR 
(125 MHz, CDCl3) δ 174.4, 71.0, 51.8, 33.8, 28.4, 25.0, 24.2; IR (ATR, cm
-1
) 3352, 3328, 3268, 
3226, 2955, 2875, 1735, 1712, 1547, 1475, 1435, 1414, 1399, 1359, 1305, 1242, 1108, 1040, 
970, 924, 820, 735; HRMS (ESI) m/z calculated for C7H16NO5S [M+H]
+
: 226.0749, found 
226.0748. 
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Methyl 7-(sulfamoyloxy)heptanoate. 
Prepared according to method B. 1.556 g (9.71 mmol) of methyl 7-
hydroxyheptanoate
85
 were used, along with Et3N (2.71 mL, 19.4 
mmol, 2.0 equiv), ClSO2NCO (1.69 mL, 19.4 mmol, 2.0 equiv), formic acid (732 μL, 19.4 
mmol, 2.0 equiv) and CH2Cl2 (10 mL + 10 mL). Flash column chromatography on silica (35 mm 
fritted glass column, 150 mm SiO2) using 3:2 hexanes/EtOAc as eluent gave 1.655 g (6.91 
mmol) of pure product as a colorless oil (71% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.96 (br. s, 2H), 4.21 (t, J = 6.5 Hz, 2H), 3.67 (s, 3H), 2.32 (t, J = 
7.3 Hz, 2H), 1.75 (dt, J = 15.0, 5.5 Hz, 2H), 1.64 (dt, J = 17.0, 5.5 Hz, 2H), 1.47-1.33 (m, 4H); 
13
C-NMR (125 MHz, CDCl3) δ 174.5, 71.3, 51.7, 33.9, 28.6, 28.5, 25.2, 24.7; IR (ATR, cm
-1
) 
3363, 3283, 2950, 2865, 1738, 1698, 1549, 1472, 1430, 1376, 1339, 1304, 1235, 1099, 1011, 
986, 961, 915, 882, 845, 792, 742, 722; HRMS (ESI) m/z calculated for C8H18NO5S [M+H]
+
: 
240.0906, found 240.0905. 
 
7-(tosyloxy)heptyl sulfamate. 
Prepared according to method B. 1.989 g (6.94 mmol) of 7-
(tosyloxy)heptan-1-ol were used, along with Et3N (1.94 mL, 
13.9 mmol, 2.0 equiv), ClSO2NCO (1.21 mL, 13.9 mmol, 2.0 equiv), formic acid (524 μL, 13.9 
mmol, 2.0 equiv) and CH2Cl2 (7 mL + 8 mL). Flash column chromatography on silica (45 mm 
fritted glass column, 170 mm SiO2) using 3:2 hexanes/EtOAc  1:1 hexanes/EtOAc as eluent 
gave 1.491 g (4.08 mmol) of pure product as a colorless oil (59% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.78 (d, J = 6.5 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 4.83 (br. s, 
2H), 4.19 (t, J = 6.5 Hz, 2H), 4.02 (t, J = 6.3 Hz, 2H), 2.45 (s, 3H), 1.74-1.69 (m, 2H), 1.67-1.62 
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(m, 2H), 1.41-1.27 (m, 6H); 
13
C-NMR (125 MHz, CDCl3) δ 144.9, 133.1, 130.0, 128.0, 71.3, 
70.7, 28.7, 28.6, 28.2, 25.3, 25.2, 21.8; IR (ATR, cm
-1
) 3376, 3285, 2937, 2861, 1598, 1561, 
1465, 1349, 1097, 916, 814, 769, 662; HRMS (ESI) m/z calculated for C14H24NO6S2 [M+H]
+
: 
366.1045, found 366.1037. 
 
(±)-cis-4-(tert-butyl)cyclohexyl sulfamate. 
Prepared according to method A. 1.563 g (10.0 mmol) of cis-4-(tert-
butyl)cyclohexanol were used, along with NaH (278 mg, 11.0 mmol, 1.1 
equiv), DMF (10 + 8 mL), ClSO2NCO (1.31 mL, 15.0 mmol, 1.5 equiv), formic acid (566 μL, 
15.0 mmol, 1.5 equiv) and MeCN (7.5 mL). Flash column chromatography on silica (35 mm 
fritted glass column, 150 mm SiO2) using 4:1 hexanes/EtOAc as eluent, followed by 
recrystallization from CH2Cl2 layered with hexanes, gave 1.821 g (7.70 mmol) of pure product as 
a crystalline white solid (77% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.89-4.88 (m, 1H), 4.67 (br. s, 2H), 2.21-2.18 (m, 2H), 1.64-1.61 
(m, 2H), 1.57-1.51 (m, 2H), 1.37 (app. dq, J = 13.0, 3.5 Hz, 2H), 1.03 (tt, J = 12.0, 3.0 Hz, 1H), 
0.86 (s, 9H); 
13
C-NMR (125 MHz, CDCl3) δ 84.3, 43.3, 34.3, 26.9, 23.0, 22.7, 22.5, 14.1; IR 
(ATR, cm
-1
) 3386, 3293, 2952, 2868, 1560, 1440, 1373, 1358, 1347, 1305, 1237, 1193, 1176, 
1161, 1106, 1031, 875, 808, 756; HRMS (ESI) m/z calculated for C10H21NO3SNa [M+Na]
+
: 
258.1140, found 258.1143. 
 
(-)-(1S,2R,4S)-borneyl sulfamate. 
Prepared according to method A. 1.543 g (10.0 mmol) of (-)-borneol were used, 
along with NaH (278 mg, 11.0 mmol, 1.1 equiv), DMF (10 + 8 mL), ClSO2NCO 
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(1.31 mL, 15.0 mmol, 1.5 equiv), formic acid (566 μL, 15.0 mmol, 1.5 equiv) and MeCN (7.5 
mL). Flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 
3:1 hexanes/EtOAc as eluent, followed by recrystallization from Et2O layered with hexanes, 
gave 1.353 g (5.80 mmol) of pure product as a crystalline white solid (58% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.73 (ddd, J = 10.0, 3.4, 2.1 Hz, 1H), 4.64 (br. s, 2H), 2.37 (ddt, J 
= 14.0, 10.1, 4.0 Hz, 1H), 1.91 (ddd, J = 14.6, 9.9, 4.4 Hz, 1H), 1.80-1.72 (m, 2H), 1.55 (s, 1H), 
1.40 (dd, J = 14.0, 3.5 Hz, 1H), 1.36-1.25 (m, 2H), 0.93 (s, 3H), 0.89 (s, 6H); 
13
C-NMR (125 
MHz, CDCl3) δ 89.1, 76.9, 49.7, 47.9, 44.8, 36.3, 28.0, 26.7, 19.8, 18.9, 13.3; IR (ATR, cm
-1
) 
3344, 3274, 2961, 2887, 1562, 1459, 1394, 1350, 1326, 1184, 1141, 1113, 1007, 989, 974, 956, 
941, 906, 871, 838, 809, 784, 744; [α]26D = -27.9° (c = 1.0, CHCl3); HRMS (ESI) m/z calculated 
for C10H19NO3SNa [M+Na]
+
: 256.0983, found 256.0992. 
 
Neopentyl sulfamate. 
Prepared according to method B. 2,2-dimethylpropan-1-ol (440 mg, 5.00 mmol) 
was used, along with ClSO2NCO (653 µL, 7.50 mmol, 1.5 equiv), formic acid 
(283 µL, 7.50 mmol, 1.5 equiv), Et3N (1.05 mL, 7.50 mmol, 1.5 equiv) and CH2Cl2  (3.8 mL + 
7.0 mL). Flash column chromatography on silica (35 mm fritted glass column, 150 mL SiO2) 
using 15% EtOAc/hexanes  40% EtOAc/hexanes as eluent gave 728 mg (4.35 mmol) of pure 
product as a white solid (87% yield).  
1
H-NMR (500 MHz, CDCl3) δ 4.69 (br, s, 2H), 3.88 (s, 2H), 1.00 (s, 9H); 
13
C-NMR (125 MHz, 
CDCl3) δ 80.5, 31.7, 26.2; HRMS (ESI) m/z calculated for C5H13NaNO3S [M+Na]
+
: 190.0514, 
found 190.0510. 
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Hexyl sulfamate. 
Prepared according to method A. 1.88 mL (15.0 mmol) of 1-hexanol were 
used, along with NaH (417 mg, 16.5 mmol, 1.1 equiv), DMF (15 + 12 mL), ClSO2NCO (1.96 
mL, 22.5 mmol, 1.5 equiv), formic acid (849 μL, 22.5 mmol, 1.5 equiv) and MeCN (11 mL). 
Flash column chromatography on silica (45 mm fritted glass column, 170 mm SiO2) using 2:1 
hexanes/EtOAc as eluent gave 2.533 g (14.0 mmol) of pure product as a white solid (93% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.81 (br. s, 2H), 4.21 (t, J = 6.5 Hz, 2H), 1.74 (app. p, J = 7.0 Hz, 
2H), 1.43-1.37 (m, 2H), 1.34-1.28 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, 
CDCl3) δ 71.8, 31.4, 28.9, 25.3, 22.6, 14.1; IR (ATR, cm
-1
) 3263, 2963, 2936, 2875, 1421, 1359, 
1234, 1188, 1137, 1088, 1029, 996, 941, 861, 782; HRMS (ESI) m/z calculated for 
C6H15NO3SNa [M+Na]
+
: 204.0670, found 204.0671. 
 
(E)-hex-4-en-1-yl sulfamate. 
Prepared according to method A. 500 mg (5.0 mmol) of (E)-hex-4-en-1-ol 
were used, along with NaH (138 mg, 5.5 mmol, 1.1 equiv), DMF (8.9 mL), ClSO2NCO (651 μL, 
7.5 mmol, 1.5 equiv), formic acid (283 μL, 7.5 mmol, 1.5 equiv) and MeCN (3.8 mL). Flash 
column chromatography on silica (100 mL SiO2) using 4:13:1 hexanes:EtOAc as eluent gave 
613 mg (3.4 mmol) of pure product as a colorless oil (68% yield). 
1
H-NMR (500 MHz, CDCl3) δ
 
5.52-5.45 (m, 1H), 5.42-5.35 (m, 1H), 4.73 (s, 2H), 4.21 (t, J = 
6.5 Hz, 2H), 2.13-2.08 (m, 2H), 1.80 (tt, J = 7.3, 6.6 Hz, 2H), 1.65 (ddd, J = 6.3, 2.3, 1.2 Hz, 
3H); 
13
C-NMR (125 MHz, CDCl3) δ
 
129.3, 126.7, 71.1, 28.7, 28.4, 18.0.  These data are in 
agreement with that previously reported in the literature.
18
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Optimization of Mn-catalyzed Intramolecular C—H Amination 
General procedure for catalyst and optimization studies (entries 1-15) 
Into a 10 mL round-bottom flask was added AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), catalyst 
(0.040 mmol, 0.10 equiv), crushed 4Å MS (100 mg, if using) and a stir bar in a glovebox. The 
flask was then sealed with a rubber septum, covered in aluminum foil (when AgSbF6 was used), 
and taken out of the box. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv) 
dissolved in 9:1 C6H6/MeCN (800 µL, 0.5M) was added via syringe, followed by PhI(OPiv)2 
(325 mg, 0.800 mmol, 2.0 equiv) in a single portion. The reaction stirred for 8h at room temp 
(~23
o
C), and then was applied directly to a silica column (35 mm fritted glass column, 150 mm 
SiO2). The product and starting material were eluted with 5:1 hexanes/EtOAc and isolated 
separately. 
 
(±)-4-methyl-4-(4-methylpentyl)-1,2,3-oxathiazinane 2,2-dioxide [32]. 
Isolated as a colorless oil. 
1
H-NMR (500 MHz, CDCl3) δ 4.71-4.61 (m, 2H), 
4.29 (br. s, 1H), 1.82-1.67 (m, 3H), 1.54 (app. spt, J = 7.0 Hz, 1H), 1.45-1.41 
(m, 2H), 1.38 (s, 3H), 1.30-1.24 (m, 1H), 1.20-1.15 (m, 2H), 0.87 (d, J = 6.5 Hz, 6H); 
13
C-NMR 
(125 MHz, CDCl3) δ 69.1, 59.1, 41.3, 39.1, 34.7, 27.3, 24.7, 22.7, 22.6, 20.8; IR (film, cm
-1
) 
3271, 2954, 2872, 1466, 1421, 1360, 1252, 1188, 1155, 1113, 1070, 1014, 987, 933, 870, 783; 
HRMS (ESI) m/z calculated for C10H22NO3S [M+H]
+
: 236.1320, found 236.1315. 
 
Entry 1. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24 mg, 
0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv) and 9:1 C6H6/MeCN (800 µL, 0.5M) were used.  
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Run 1: (27.1 mg, 0.115 mmol, 29%), (12.3 mg alcohol, 0.078 mmol, 19%), (24.9 mg rsm, 0.262 
mmol, 26%). Run 2: (28.0 mg, 0.119 mmol, 30%), (32.8 mg rsm, 0.138 mmol, 35%). Run 3: 
(26.6 mg, 0.113 mmol, 28%), (33.7 mg rsm, 0.142 mmol, 36%).  Average: 29% yield ± 0.8, 
32% rsm ± 4.5. 
 
Entry 2. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [MnPc]Cl (24 mg, 
0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv) and 9:1 C6H6/MeCN (800 µL, 0.5M) were used.  
Run 1: (39.2 mg, 0.167 mmol, 42%), (22.3 mg rsm, 0.094 mmol, 23%). Run 2: (39.4 mg, 0.167 
mmol, 42%), (27.1 mg rsm, 0.114 mmol, 29%). Run 3: (41.8 mg, 0.178 mmol, 44%), (26.7 mg 
rsm, 0.113 mmol, 28%).  Average: 43% yield ± 0.9, 27% rsm ± 2.6. 
 
Entry 3. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), Fe(TPP)Cl (28.2 
mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv) and 9:1 C6H6/MeCN (800 µL, 0.5M) were used.  
Run 1: (4.0 mg, 0.017 mmol, 4%), (80.1 mg rsm, 0.338 mmol, 84%). Run 2: (2.9 mg, 0.012 
mmol, 3%), (82.3 mg rsm, 0.347 mmol, 87%). Run 3: (3.5 mg, 0.015 mmol, 4%), (79.5 mg rsm, 
0.335 mmol, 84%).  Average: 4% yield ± 0.5, 85% rsm ± 1.4. 
 
Entry 4. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), Mn(TPP)Cl (28.2 
mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv) and 9:1 C6H6/MeCN (800 µL, 0.5M) were used.  
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Run 1: (15.6 mg, 0.066 mmol, 17%), (51.8 mg rsm, 0.218 mmol, 55%). Run 2: (16.8 mg, 0.072 
mmol, 18%), (63.1 mg rsm, 0.266 mmol, 67%). Run 3: (17.4 mg, 0.074 mmol, 18%), (61.4 mg 
rsm, 0.259 mmol, 65%).  Average: 18% yield ± 0.5, 62% rsm ± 5.3. 
 
Entry 5. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), Fe(R,R-salen)Cl 
(22.8 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv) and 9:1 C6H6/MeCN (800 µL, 0.5M) were used.  
Run 1: <1% yield, (784.6 mg rsm, 0.357 mmol, 89%). Run 2: <1% yield, (77.9 mg rsm, 0.328 
mmol, 82%). Run 3: <1% yield, (79.1 mg rsm, 0.333 mmol, 83%).  Average: <1% yield, 85% 
rsm ± 3.1. 
 
Entry 6. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), Mn(R,R-salen)Cl 
(22.8 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv) and 9:1 C6H6/MeCN (800 µL, 0.5M) were used.  
Run 1: (4.0 mg, 0.016 mmol, 4%), (72.5 mg rsm, 0.306 mmol, 76%). Run 2: (4.1 mg, 0.017 
mmol, 4%), (78.0 mg rsm, 0.329 mmol, 82%). Run 3: (5.1 mg, 0.022 mmol, 5%), (73.2 mg rsm, 
0.309 mmol, 77%).  Average: 4% yield ± 0.5, 78% rsm ± 2.6. 
 
Entry 7. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), Fe(R,R-
PDP)(SbF6)2 (33.6 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) 
and 9:1 C6H6/MeCN (800 µL, 0.5M) were used.  
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Run 1: <1% yield, (87.9 mg rsm, 0.370 mmol, 93%). Run 2: <1% yield, (87.7 mg rsm, 0.370 
mmol, 92%). Run 3: <1% yield, (84.7 mg rsm, 0.357 mmol, 89%).  Average: <1% yield, 91% 
rsm ± 1.7. 
 
Entry 8. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), Mn(R,R-
PDP)(SbF6)2 (33.6 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) 
and 9:1 C6H6/MeCN (800 µL, 0.5M) were used.  
Run 1: (7.0 mg, 0.030 mmol, 7%), (78.3 mg rsm, 0.330 mmol, 83%). Run 2: (6.2 mg, 0.026 
mmol, 7%), (73.7 mg rsm, 0.311 mmol, 78%). Run 3: (6.7 mg, 0.028 mmol, 7%), (79.4 mg rsm, 
0.335 mmol, 84%).  Average: 7% yield ± 0.0, 82% rsm ± 2.2. 
 
Entry 9. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [MnPc]Cl (24.0 mg, 
0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used.  
Run 1: (56.1 mg, 0.238 mmol, 60%), (10.6 mg rsm, 0.045 mmol, 11%). Run 2: (54.3 mg, 0.231 
mmol, 58%), (10.5 mg rsm, 0.044 mmol, 11%). Run 3: (58.2 mg, 0.247 mmol, 62%), (10.9 mg 
rsm, 0.046 mmol, 11%).  Average: 60% yield ± 1.6, 11% rsm ± 0.1. 
 
Entry 10. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [MnPc]Cl (12.0 
mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used.  
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Run 1: (56.3 mg, 0.239 mmol, 60%), (21.6 mg rsm, 0.091 mmol, 23%). Run 2: (51.3 mg, 0.218 
mmol, 55%), (15.0 mg rsm, 0.063 mmol, 16%). Run 3: (56.0 mg, 0.238 mmol, 59%), (20.3 mg 
rsm, 0.086 mmol, 21%).  Average: 58% yield ± 2.2, 20% rsm ± 2.9. 
 
Entry 11. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl 
(33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used.  
Run 1: (71.3 mg, 0.303 mmol, 76%), <5% rsm. Run 2: (70.4 mg, 0.299 mmol, 75%), <5% rsm. 
Run 3: (70.1 mg, 0.298 mmol, 74%), <5% rsm.  Average: 75% yield ± 0.8, <5% rsm. 
 
Entry 12. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [Fe(
t
BuPc)]Cl 
(33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used.  
Run 1: (26.0 mg, 0.111 mmol, 28%), (26.3 mg rsm, 0.111 mmol, 28%). Run 2: (28.0 mg, 0.119 
mmol, 30%), (29.2 mg rsm, 0.123 mmol, 31%). Run 3: (26.2 mg, 0.111 mmol, 28%), (41.2 mg 
rsm, 0.174 mmol, 43%).  Average: 29% yield ± 0.9, 34% rsm ± 6.6. 
 
Entry 13. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl 
(16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used.  
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Run 1: (68.1 mg, 0.289 mmol, 72%), (12.2 mg rsm, 0.051 mmol, 12%). Run 2: (68.8 mg, 0.292 
mmol, 73%), (16.6 mg rsm, 0.070 mmol, 17%). Run 3: (67.8 mg, 0.288 mmol, 72%), (13.1 mg 
rsm, 0.055 mmol, 14%).  Average: 72% yield ± 0.5, 14% rsm ± 2.1. 
 
Entry 14. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl 
(8.3 mg, 0.010 mmol, 0.025 equiv), AgSbF6 (3.4 mg, 0.010 mmol, 0.025 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used. Note: reactions run at these low catalyst loadings were less reproducible at 0.400 mmol 
scale, likely due to increased effect of balance error in weighing catalysts. 
Run 1: (65.6 mg, 0.279 mmol, 70%), (16.5 mg rsm, 0.070 mmol, 17%). Run 2: (67.0 mg, 0.284 
mmol, 71%), (11.8 mg rsm, 0.050 mmol, 12%). Run 3: (66.6 mg, 0.283 mmol, 71%), (10.1 mg 
rsm, 0.043 mmol, 11%).  Average: 71% yield ± 0.5, 13% rsm ± 2.6. 
 
Entry 15. (±)-3,7-dimethyloctyl sulfamate (94.9 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl 
(16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), PhI(OPiv)2 (195 
mg, 0.480 mmol, 1.2 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used.  
Run 1: (64.2 mg, 0.273 mmol, 68%), (12.9 mg rsm, 0.054 mmol, 14%). Run 2: (64.1 mg, 0.272 
mmol, 68%), (15.9 mg rsm, 0.067 mmol, 17%). Run 3: (63.8 mg, 0.271 mmol, 68%), (16.8 mg 
rsm, 0.071 mmol, 18%).  Average: 68% yield ± 0.2, 16% rsm ± 1.7. 
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Substrate Scope for Mn-catalyzed Intramolecular C—H Amination 
General procedure for [MnPc] and [Mn(
t
BuPc)]-mediated C—H amination 
NOTE: All reactions were run in flame- or oven-dried glassware under an atmosphere of argon 
or nitrogen, taking care to exclude moisture. Into a 10 mL round-bottom flask was added 
AgSbF6 (0.05 equiv or 0.10 equiv), [Mn(
t
BuPc)]Cl (0.05 equiv or 0.10 equiv), crushed 4Å MS, 
and a stir bar in a glovebox. The flask was then sealed with a rubber septum, covered in 
aluminum foil, and taken out of the box. Sulfamate ester (1.0 equiv), 9:1 C6H6/MeCN (0.5M), 
and, lastly, PhI(OPiv)2 (2.0 equiv) were then added under an inert atmosphere; if sulfamate ester 
was an oil, it was taken up in the solvent mixture and added to the flask via syringe. After 
addition of oxidant, the dark red solution gradually turned dark brown. The reaction stirred for 
8h at room temp unless otherwise specified (~20°C). Upon completion, the reaction mixture was 
applied directly to a silica column for purification. Alternatively, the reaction can be 
concentrated under reduced pressure, and the remaining dark brown residue suspended in Et2O 
and filtered through a small pad of Celite. Upon removal of solvent under reduced pressure, the 
brown residue was taken up in minimal CH2Cl2 and applied to a column. Any variation of these 
reaction conditions is noted for individual substrates. 
 
General procedure for [FePc]-mediated intramolecular C—H amination34 
NOTE: All reactions were run in flame- or oven-dried glassware under an atmosphere of argon 
or nitrogen, taking care to exclude moisture. Into a 10 mL round-bottom flask was added 
AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), [FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), and a 
stir bar in a glovebox. The flask was then sealed with a rubber septum, covered in aluminum foil, 
and taken out of the box. 4:1 PhMe/MeCN (800 μL, 0.5M), sulfamate ester (0.400 mmol, 1.0 
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equiv), and lastly PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) were then added sequentially; if 
sulfamate ester was an oil, it was taken up in the solvent mixture and added to the flask via 
syringe. After addition of oxidant, the deep violet solution gradually turned dark brown. The 
reaction stirred for 8h at room temp unless otherwise specified (~20°C). Upon completion, the 
reaction mixture was applied directly to a silica column (35 mm fritted glass column, 150 mm 
SiO2) for purification. Alternatively, the reaction can be concentrated under reduced pressure, 
and the remaining dark brown residue suspended in Et2O and filtered through a small pad of 
Celite. Upon removal of solvent under reduced pressure, the brown residue was taken up in 
minimal CH2Cl2 and applied to a column. Any variation of these reaction conditions is noted for 
individual substrates. 
 
(±)-2-((4,4-dimethyl-2,2-dioxido-1,2,3-oxathiazinan-6-yl)methyl)isoindoline-1,3-dione [33]. 
(±)-1-(1,3-dioxoisoindolin-2-yl)-4-methylpentan-2-yl sulfamate (131.0 mg, 
0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.05 equiv), 
AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg 
crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were used. Product was purified via flash 
column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 3:2 
hexanes/EtOAc. Pure product was isolated as a white solid. 
Run 1: (104.0 mg, 0.320 mmol, 80%), 0% rsm. Run 2: (100.1 mg, 0.308 mmol, 77%), 0% rsm. 
Run 3: (103.7 mg, 0.319 mmol, 80%), 0% rsm.  Average: 79% yield ± 1.4, 0% rsm. 
1
H-NMR (500 MHz, acetone-d6) δ 7.91-7.86 (m, 4H), 6.01 (br. s, 1H), 5.13 (dddd, J = 12.0, 7.0, 
5.0, 2.0 Hz, 1H), 4.02 (dd, J = 14.5, 7.0 Hz, 1H), 3.88 (dd, J = 14.5, 5.0 Hz, 1H), 2.01 (dd, J = 
14.5, 2.0 Hz, 1H), 1.72 (dd, J = 14.5, 12.0 Hz, 1H), 1.46 (s, 3H), 1.36 (s, 3H); 
13
C-NMR (125 
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MHz, acetone-d6) δ 168.6, 135.4, 133.1, 124.2, 78.3, 56.5, 42.2, 39.4, 31.6, 25.6; IR (thin film, 
cm
-1
) 3228, 2981, 2950, 1713, 1468, 1433, 1393, 1360, 1272, 1193, 1160, 1061, 1026, 995, 943, 
869; HRMS (ESI) m/z calculated for C14H17N2O5S [M+H]
+
: 325.0858, found 325.0859. 
 
(-)-(R)-6-((S)-1-((tert-butyldiphenylsilyl)oxy)ethyl)-4,4-dimethyl-1,2,3-oxathiazinane 2,2-
dioxide [34]. 
(-)-(2S,3R)-2-((tert-butyldiphenylsilyl)oxy)-5-methylhexan-3-yl sulfamate (89.9 
mg, 0.200 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.10 equiv), 
AgSbF6 (6.9 mg, 0.020 mmol, 0.10 equiv), PhI(OPiv)2 (163 mg, 0.400 mmol, 2.0 
equiv), 50 mg crushed 4Å MS, and 9:1 C6H6/MeCN (400 µL, 0.5M) were used. Product was 
purified via flash column chromatography on silica (35 mm fritted glass column, 100 mm SiO2) 
using 9:1 hexanes/EtOAc. Pure product was isolated as a white solid. 
Run 1: (58.7 mg, 0.131 mmol, 66%), <10% rsm. Run 2: (66.5 mg, 0.149 mmol, 74%), <10% 
rsm. Run 3: (65.4 mg, 0.146 mmol, 73%), <10% rsm.  Average: 71% yield ± 3.6, <10% rsm. 
1
H-NMR (500 MHz, CDCl3) δ 7.68-7.65 (m, 4H), 7.47-7.43 (m, 2H), 7.41-7.38 (m, 4H), 4.68 
(ddd, J = 12.0, 4.5, 2.0 Hz, 1H), 3.96 (qd, J = 12.5, 4.5 Hz, 1H), 3.91 (s, 1H), 1.70 (dd, J = 14.5, 
12.5 Hz, 1H), 1.57 (dd, J = 14.0, 2.0 Hz, 1H), 1.44 (s, 3H), 1.28 (s, 3H), 1.13 (d, J = 6.5 Hz, 3H), 
1.07 (s, 9H); 
13
C-NMR (125 MHz, CDCl3) δ 136.0, 133.7, 133.2, 130.2, 130.0, 127.9, 127.8, 
82.8, 69.7, 55.8, 36.0, 32.3, 27.1, 25.0, 19.4, 18.3; IR (ATR, cm
-1
) 3269, 3072, 2962, 2933, 2859, 
1473, 1428, 1390, 1375, 1353, 1266, 1196, 1141, 1111, 1029, 934, 875, 822, 740, 703; [α]25D = -
23.2
o
 (c = 1.1, CHCl3); HRMS (ESI) m/z calculated for C23H33NO4SSiNa [M+Na]
+
: 470.1797, 
found 470.1798. 
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3-oxa-2-thia-1-azaspiro[5.5]undecane 2,2-dioxide [35]. 
2-cyclohexylethyl sulfamate (82.9 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (33.2 
mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 
(325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) 
were used. Reaction stirred for 20h. Product was purified via flash column chromatography on 
silica (35 mm fritted glass column, 150 mm SiO2) using CH2Cl2  2% Et2O/CH2Cl2  5% 
Et2O/CH2Cl2. Pure product was isolated as a white solid. 
Run 1: (41.0 mg, 0.200 mmol, 50%), (13.1 mg rsm, 0.063 mmol, 16%). Run 2: (41.1 mg, 0.200 
mmol, 50%), (17.6 mg rsm, 0.085 mmol, 21%). Run 3: (45.2 mg, 0.220 mmol, 55%), (13.8 mg 
rsm, 0.067 mmol, 17%).  Average: 52% yield ± 2.4, 18% rsm ± 2.2. 
1
H-NMR (500 MHz, CDCl3) δ 4.64 (t, J = 5.5 Hz, 2H), 4.26 (s, 1H), 2.01 (d, J = 13.0 Hz, 2H), 
1.75 (t, J = 5.5 Hz, 2H), 1.69-1.59 (m, 3H), 1.49-1.42 (m, 4H), 1.33-1.24 (m, 1H); 
13
C-NMR 
(125 MHz, CDCl3) δ 68.7, 58.6, 36.3, 34.9, 25.7, 20.9; IR (ATR, cm
-1
) 3247, 2930, 2860, 1466, 
1445, 1417, 1357, 1341, 1279, 1186, 1153, 1111, 1023, 996, 945, 933, 926, 900, 871, 849, 739; 
HRMS (ESI) m/z calculated for C8H16NO3S [M+H]
+
: 206.0851, found 206.0850. 
 
(+)-(4R,7S,8S)-4,4,7-trimethyloctahydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide [36]. 
(-)-(1R,2S,5R)-menthyl sulfamate (94.1 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl 
(16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 
C6H6/MeCN (800 µL, 0.5M) were used. Product was purified via flash column chromatography 
on silica (35 mm fritted glass column, 150 mm SiO2) using 4:1 hexanes/EtOAc. Pure product 
was isolated as a white solid. 
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Run 1: (81.9 mg, 0.351 mmol, 88%), 0% rsm. Run 2: (79.9 mg, 0.342 mmol, 86%), 0% rsm. Run 
3: (79.0 mg, 0.339 mmol, 85%), 0% rsm.  Average: 86% yield ± 1.2, 0% rsm. 
1
H-NMR (500 MHz, CDCl3) δ 4.58 (dt, J = 10.5, 4.5 Hz, 1H), 4.54 (br. s, 1H), 2.10-2.07 (m, 
1H), 1.79-1.73 (m, 2H), 1.59-1.51 (m, 1H), 1.47 (dt, J = 11.3, 3.0 Hz, 1H), 1.36 (s, 3H), 1.24 (s, 
3H), 1.08-1.00 (m, 1H), 0.96 (d, J = 6.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 82.4, 59.1, 
48.7, 40.4, 34.1, 31.4, 29.4, 25.2, 21.9, 21.2; IR (film, cm
-1
) 3280, 2958, 2922, 2862, 1460, 1410, 
1389, 1373, 1336, 1225, 1200, 1184, 1161, 1137, 1086, 1012, 991, 920, 903, 885, 860, 818; 
[α]25D = +23.5
o
 (c = 1.0, CHCl3); HRMS (ESI) m/z calculated for C10H20NO3S [M+H]
+
: 
234.1164, found 234.1164. 
 
(-)-(3R,4R,6R,7S)-3,5,5-trimethylhexahydro-3H-4,6-methanobenzo[d][1,2,3]oxathiazole 2,2-
dioxide [37]. 
(-)-(1S,2S,3S,5R)-isopinocampheyl sulfamate (93.3 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (6.9 mg, 0.040 mmol, 
0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, 
and 9:1 C6H6/MeCN (800 µL, 0.5M) were used. By crude 
1
H NMR, ratio of 3° to other products 
(most likely 2° and 1° C—H amination products, but could not be isolated pure to confirm 
assignment) was >10:1. Product was purified via flash column chromatography on silica (35 mm 
fritted glass column, 150 mm SiO2) using 7:1 hexanes/EtOAc  4:1 hexanes/EtOAc. Pure 
product was isolated as a white solid. 
Run 1: (57.1 mg, 0.247 mmol, 62%), <5% rsm. Run 2: (59.1 mg, 0.256 mmol, 64%), <5% rsm. 
Run 3: (57.5 mg, 0.249 mmol, 62%), <5%.  Average: 63% yield ± 0.9, <5% rsm. 
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1
H-NMR (500 MHz, CDCl3) δ 4.67 (dd, J = 8.5, 2.0 Hz, 1H), 4.24 (s 1H), 2.49-2.43 (m, 1H), 
2.34 (dtd, J = 11.0, 6.0, 2.0 Hz, 1H), 2.16-2.11 (m, 1H), 2.06 (dd, J = 6.0, 1.5 Hz, 2H), 1.63 (s, 
3H), 1.47 (d, J = 11.0 Hz, 1H), 1.33 (s, 3H), 0.94 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 82.1, 
66.0, 51.1, 39.6, 39.0, 32.7, 28.2, 27.3, 26.1, 24.4; IR (ATR, cm
-1
) 3244, 3005, 2985, 2959, 2941, 
2926, 2912, 1479, 1450, 1393, 1381, 1318, 1281, 1181, 1131, 1085, 1062, 1029, 972, 959, 944, 
893, 865, 852, 815, 753; [α]26D = -48.7
o
 (c = 1.0, CHCl3); HRMS (ESI) m/z calculated for 
C10H17NO3SNa [M+Na]
+
: 254.0827, found 254.0830. 
 
(±)-methyl 3-(2,2-dioxido-1,2,3-oxathiazinan-4-yl)propanoate [38]. 
Methyl 6-(sulfamoyloxy)hexanoate (90.1 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 
mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 
9:1 C6H6/MeCN (800 µL, 0.5M) were used. Reaction stirred at rt for 17h. Material was purified 
via flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 2:1 
hexanes/EtOAc. Starting material and product were isolated as a mixture; yields were 
determined based on 
1
H NMR ratios. Pure product could be isolated by eluting with 5% 
Et2O/CH2Cl2  10% Et2O/CH2Cl2. Pure product was isolated as a white solid. 
Run 1: (26.0 mg, 0.116 mmol, 29%), (37.1 mg rsm, 0.165 mmol, 41%). Run 2: (24.6 mg, 0.110 
mmol, 28%), (42.2 mg rsm, 0.187 mmol, 47%). Run 3: (26.3 mg, 0.118 mmol, 30%), (32.0 mg 
rsm, 0.142 mmol, 36%).  Average: 29% yield ± 0.8, 41% rsm ± 4.1. 
1
H-NMR (500 MHz, CDCl3) δ 4.74-4.68 (m, 1H), 4.54 (dt, J = 11.0, 3.0 Hz, 1H), 4.22 (d, J = 
10.7 Hz, 1H), 3.78-3.71 (m, 1H), 3.69 (s, 3H), 2.49 (td, J = 7.1, 1.5 Hz, 2H), 1.94 (dtd, J = 14.5, 
7.2, 4.5 Hz, 1H), 1.86-1.73 (m, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 173.6, 71.8, 55.9, 52.1, 
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30.2, 29.8, 29.7; IR (ATR, cm
-1
) 3273, 2960, 2942, 1735, 1433, 1386, 1355, 1337, 1319, 1269, 
1252, 1228, 1203, 1170, 1104, 1081, 1056, 1009, 982, 937, 906, 895, 856, 775; HRMS (ESI) m/z 
calculated for C7H14NO5S [M+H]
+
: 224.0593, found 224.0592. 
 
(±)-methyl 4-(2,2-dioxido-1,2,3-oxathiazinan-4-yl)butanoate [39]. 
Methyl 7-(sulfamoyloxy)heptanoate (95.7 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 
mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 
9:1 C6H6/MeCN (800 µL, 0.5M) were used. Reaction stirred at rt for 17h. Product was purified 
via flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 5% 
Et2O/CH2Cl2  10% Et2O/CH2Cl2. Pure product was isolated as a colorless oil with a minor 
amount (~6%) of an unidentified product-like impurity; reported yields are corrected to reflect 
amount of desired product isolated. 
Run 1: (53.9 mg, 0.227 mmol, 57%), (20.4 mg rsm, 0.085 mmol, 21%). Run 2: (54.2 mg, 0.228 
mmol, 57%), (17.1 mg rsm, 0.071 mmol, 18%). Run 3: (53.9 mg, 0.227 mmol, 57%), (17.9 mg 
rsm, 0.075 mmol, 19%).  Average: 57% yield ± 0.0, 19% rsm ± 1.2. 
1
H-NMR (500 MHz, CDCl3) δ 4.74-4.69 (m, 1H), 4.54 (ddd, J = 11.5, 4.5, 2.0 Hz, 1H), 4.08 (br. 
d, J = 10.5 Hz, 1H), 3.76-3.69 (m, 1H), 3.68 (s, 3H), 2.35 (dt, J = 7.3, 2.0 Hz, 2H), 1.84-1.51 (m, 
6H); 
13
C-NMR (125 MHz, CDCl3) δ 173.8, 72.1, 55.9, 51.8, 34.3, 33.3, 29.9, 20.6; IR (ATR, cm
-
1
) 3249, 2956, 1718, 1422, 1357, 1237, 1084, 1012, 987, 938, 917, 890, 862, 774, 731; HRMS 
(ESI) m/z calculated for C8H16NO5S [M+H]
+
: 238.0749, found 238.0750. 
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(+)-(7S,8αR)-9,9-dimethylhexahydro-5H-4α,7-methanobenzo[e][1,2,3]oxathiazine 2,2-
dioxide [41]. 
(-)-(1S,2R,4S)-borneyl sulfamate (93.3 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl 
(16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 
C6H6/MeCN (800 µL, 0.5M) were used. Product was purified via flash column chromatography 
on silica (35 mm fritted glass column, 150 mm SiO2) using 4:1 hexanes/EtOAc. Both 1° and 2° 
products were isolated separately as white solids. 
Run 1: (47.3 mg 1°, 0.204 mmol, 51%), (25.4 mg 2°, 0.110 mmol, 27%), (15.4 mg rsm, 0.065 
mmol, 17%). Run 2: (48.9 mg 1°, 0.211 mmol, 53%), (27.2 mg 2°, 0.118 mmol, 29%), (12.1 mg 
rsm, 0.052 mmol, 13%). Run 3: (49.5 mg 1°, 0.214 mmol, 54%), (24.4 mg 2°, 0.105 mmol, 
26%), (12.6 mg rsm, 0.054 mmol, 14%).  Average: 53% yield 1° ± 1.2, 27% yield 2° ± 1.2, 
14% rsm ± 1.2. 
1
H-NMR (500 MHz, CDCl3) δ 5.13 (ddd, J = 11.0, 5.0, 2.5 Hz, 1H), 4.41 (dd, J = 10.5, 5.0 Hz, 
1H), 3.58 (dd, J = 14.0, 11.0 Hz, 1H), 3.08 (dd, J = 14.0, 5.0 Hz, 1H), 2.34-2.27 (m, 2H), 1.86-
1.80 (m, 2H), 1.51-1.45 (m, 1H), 1.41-1.36 (m, 1H), 1.26 (dd, J = 14.0, 5.0 Hz, 1H), 0.97 (s, 
3H), 0.95 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 87.5, 47.6, 46.4, 45.8, 45.8, 32.6, 27.9, 24.0, 
20.0, 18.9; IR (ATR, cm
-1
) 3312, 2967, 2893, 1463, 1446, 1428, 1349, 1306, 1180, 1137, 1073, 
1019, 989, 968, 922, 873, 840, 815, 797, 753; [α]26D = +37.9
o
 (c = 1.0, CHCl3); HRMS (ESI) m/z 
calculated for C10H18NO3S [M+H]
+
: 232.1007, found 232.1008. 
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(-)-(3αR,4R,7R,7αS)-7,8,8-trimethylhexahydro-3H-4,7-methanobenzo[d][1,2,3]oxathiazole 
2,2-dioxide. 
1
H-NMR (500 MHz, CDCl3) δ 4.72 (dd, J = 9.0, 2.0 Hz, 1H), 4.28 (br. s, 1H), 4.26-
4.21 (m, 1H), 1.99 (dd, J = 4.5, 4.0 Hz, 1H), 1.87 (ddd, J = 14.0, 9.0, 5.0 Hz, 1H), 
1.74-1.63 (m, 2H), 1.39 (dddd, J = 13.5, 11.5, 6.0, 2.0 Hz, 1H), 1.01 (s, 3H), 1.00 
(s, 3H), 0.96 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 88.4, 56.4, 49.6, 48.5, 48.4, 26.5, 20.5, 
19.4, 18.3, 14.3; IR (ATR, cm
-1
) 3325, 2967, 2923, 1475, 1388, 1378, 1342, 1327, 1283, 1262, 
1125, 1075, 1024, 1001, 982, 964, 906, 883, 853, 823, 759, 709; [α]26D = -38.7
o
 (c = 1.6, CHCl3); 
HRMS (ESI) m/z calculated for C10H18NO3S [M+H]
+
: 232.1007, found 232.1007. 
 
 
 
(±)-4-(2,2-dioxido-1,2,3-oxathiazinan-4-yl)butyl 4-methylbenzenesulfonate [42]. 
7-(tosyloxy)heptyl sulfamate (146 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 
0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, 
and 9:1 C6H6/MeCN (800 µL, 0.5M) were used. Reaction stirred for 17h. Product was purified 
via flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 5% 
Et2O/CH2Cl2  10% Et2O/CH2Cl2. Pure product was isolated as a colorless oil. 
Run 1: (78.1 mg, 0.215 mmol, 54%), <10% rsm. Run 2: (79.2 mg, 0.218 mmol, 54%), <10% 
rsm. Run 3: (77.9 mg, 0.214 mmol, 54%), <10% rsm.  Average: 54% yield ± 0.0, <10% rsm. 
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1
H-NMR (500 MHz, CDCl3) δ 7.79 (d, J = 6.5 Hz, 2H), 7.36 (d, J = 6.0 Hz, 2H), 4.70 (dt, J = 
12.0, 3.5 Hz, 1H), 4.53 (ddd, J = 11.5, 4.5, 2.0 Hz, 1H), 4.04 (t, J = 6.0 Hz, 2H), 3.87 (br. d, J = 
10.5 Hz, 1H), 3.70-3.62 (m, 1H), 2.46 (s, 3H), 1.73-1.63 (m, 4H), 1.54-1.40 (m, 4H); 
13
C-NMR 
(125 MHz, CDCl3) δ 145.1, 133.0, 130.1, 128.0, 71.9, 70.0, 56.0, 34.5, 30.2, 28.4, 21.8, 21.3; 
HRMS (ESI) m/z calculated for C14H22NO6S2 [M+H]
+
: 364.0889, found 364.0887. 
(±)-hexahydro-3H-pyrido[1,2-c][1,2,3]oxathiazine 1,1-dioxide [43]. 
Cyclization procedure was modified from a similar procedure reported in the 
literature.
86
 42 (50.0 mg, 0.138 mmol, 1.0 equiv) was taken up in DMF (2.76 mL, 
0.05M) in a 2 dram vial. K2CO3 (28.6 mg, 0.207 mmol, 1.5 equiv) and n-Bu4NI (5.2 mg, 0.014 
mmol, 0.10 equiv) were added, and then vial was capped and reaction stirred vigorously at rt for 
15h (no precautions were taken to remove oxygen or water). Upon completion, reaction was 
quenched with H2O (1 mL), then diluted with EtOAc (15 mL) and H2O (5 mL). After separating, 
the aqueous layer was extracted twice more with EtOAc (2x10 mL). Organic layers were 
combined and washed with H2O (10 mL) and brine (2x10 mL), then dried over MgSO4 and 
filtered. Flash column chromatography on silica (35 mm fritted glass column, 70 mm SiO2) using 
3:1 hexanes/EtOAc as eluent gave 21.1 mg (0.110 mmol) of pure product as a colorless oil (80% 
yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.71 (ddd, J = 13.5, 11.0, 2.5 Hz, 1H), 4.46 (ddd, J = 11.5, 5.5, 
1.5 Hz, 1H), 3.58 (ddt, J = 11.5, 7.0, 3.0 Hz, 1H), 3.47-3.42 (m, 1H), 2.95 (ddd, J = 11.5, 9.0, 4.0 
Hz, 1H), 2.19 (dddd, J = 14.5, 13.5, 12.0, 5.5 Hz, 1H), 1.85-1.80 (m, 1H), 1.75-1.64 (m, 3H), 
1.58-1.44 (m, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 71.9, 57.4, 44.6, 31.2, 28.1, 24.6, 21.5; IR 
(ATR, cm
-1
) 2974, 2957, 2939, 2867, 1468, 1445, 1427, 1360, 1343, 1300, 1282, 1254, 1208, 
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1107, 1089, 1047, 1030, 1011, 985, 959, 900, 872, 862, 799, 704; HRMS (ESI) m/z calculated 
for C7H14NO3S [M+H]
+
: 192.0694, found 192.0699. 
 
(±)-6-(tert-butyl)-2-oxa-3-thia-4-azabicyclo[3.3.1]nonane 3,3-dioxide [46]. 
(±)-cis-4-(tert-butyl)cyclohexyl sulfamate (94.1 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 
0.05 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 
C6H6/MeCN (800 µL, 0.5M) were used. Product was purified via flash column chromatography 
on silica (35 mm fritted glass column, 150 mm SiO2) using 2:1 hexanes/EtOAc. Pure product 
was isolated as a white solid. 
Run 1: (83.0 mg, 0.356 mmol, 89%), 0% rsm. Run 2: (83.6 mg, 0.358 mmol, 90%), 0% rsm. Run 
3: (84.9 mg, 0.364 mmol, 91%), 0% rsm.  Average: 90% yield ± 0.8, 0% rsm. 
1
H-NMR (500 MHz, CDCl3) δ 4.93-4.92 (m, 1H), 4.56 (br. s, 1H), 3.71-3.67 (m, 1H), 2.43-2.39 
(m, 1H), 2.03 (ddd, J = 12.5, 6.0, 3.0 Hz, 1H), 1.71-1.64 (m, 2H), 1.59 (app. q, J = 12.5 Hz, 1H), 
1.33-1.25 (m, 1H), 1.03-0.98 (m, 1H), 0.89 (s, 9H); 
13
C-NMR (125 MHz, CDCl3) δ 84.0, 58.5, 
45.1, 32.5, 29.9, 27.8, 27.4, 20.3; IR (ATR, cm
-1
) 3227, 2955, 2871, 1393, 1376, 1358, 1340, 
1315, 1229, 1181, 1093, 996, 976, 952, 884, 870, 792, 760, 707, 692; HRMS (ESI) m/z 
calculated for C10H20NO3S [M+H]
+
: 234.1164, found 234.1168. 
 
(±)-(E)-4-(prop-1-en-1-yl)-1,2,3-oxathiazinane 2,2-dioxide [49]. 
In all cases, material was purified via flash column chromatography on silica (35 
mm fritted glass column, 150 mm SiO2) using 3:1 hexanes/EtOAc, affording a 
mixture of product and starting material; yields were determined based on 
1
H NMR ratios. Pure 
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product could be obtained by eluting with 10% hexanes/CH2Cl2  CH2Cl2  2% Et2O/CH2Cl2. 
Pure product was isolated as a white solid. 
FePc conditions: (E)-hex-4-en-1-yl sulfamate (71.7 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (12.1 
mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv), and 4:1 PhMe/MeCN (800 µL, 0.5M) were used. 
Run 1: (8.2  mg, 0.046 mmol, 11%), (54.3 mg rsm, 0.303 mmol, 76%). Run 2: (7.6 mg, 0.043 
mmol, 11%), (55.0 mg rsm, 0.307 mmol, 77%). Run 3: (6.7 mg, 0.038 mmol, 9%), (54.8 mg 
rsm, 0.306 mmol, 76%).  Average: 10% yield ± 0.9, 76% rsm ± 0.5. 
MnPc conditions: (E)-hex-4-en-1-yl sulfamate (71.7 mg, 0.400 mmol, 1.0 equiv), [MnPc]Cl 
(12.1 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used.  
Run 1: (43.1 mg, 0.243 mmol, 61%). Run 2: (43.6 mg, 0.246 mmol, 61%). Run 3: (42.7 mg, 
0.241 mmol, 60%) Average: 61% yield ± 0.5. 
Mn(
t
BuPc) conditions: (E)-hex-4-en-1-yl sulfamate (71.7 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used.  
Run 1: (45.0 mg, 0.254 mmol, 63%). Run 2: (40.9 mg, 0.231 mmol, 58%). Run 3: (44.3 mg, 
0.250 mmol, 62%) Average: 61% yield ± 2.2. 
1
H-NMR (500 MHz, CDCl3) δ
 
5.78 (dqd, J = 14.3, 6.5, 1.3 Hz, 1H), 5.45-5.40 (m, 1H), 4.74 (dt, 
J = 12.0, 2.7 Hz, 1H), 4.55 (ddd, J = 11.6, 4.4, 1.3 Hz, 1H), 4.30-4.24 (m, 1H), 4.00 (br. d, J = 
10.0 Hz, 1H), 1.91-1.77 (m, 2H), 1.73 (dd, J = 6.5, 1.4 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ
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129.6, 128.1, 71.8, 56.9, 29.8, 17.9; 
13
C-NMR (125 MHz, CDCl3) δ
 
129.6, 128.1, 71.8, 56.9, 
29.8, 17.9. These data are in agreement with that previously reported in the literature.
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(±)-4-phenyl-1,2,3-oxathiazinane 2,2-dioxide [50].
 
In all cases, material was purified via flash column chromatography on silica (25 
mm fritted glass column, 150 mm SiO2) using 4:1 hexanes/EtOAc as eluent, 
affording oxathiazinane product and starting material separately.  
FePc conditions: 3-phenylpropyl sulfamate (86.5 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (12.0 
mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv), and 4:1 PhMe/MeCN (800 µL, 0.5M) were used. 
Run 1: (18.5 mg, 0.086 mmol, 22%), (54.9 mg rsm, 0.254 mmol, 63%). Run 2: (19.0 mg, 0.089 
mmol, 22%), (58.2 mg rsm, 0.269 mmol, 67%). Run 3: (17.8 mg, 0.083 mmol, 21%), (56.2 mg 
rsm, 0.260 mmol, 65%). Average: 22% yield ± 0.5, 65% rsm ± 1.6.  
MnPc conditions: 3-phenylpropyl sulfamate (86.5 mg, 0.400 mmol, 1.0 equiv), [MnPc]Cl (12.0 
mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used. 
Run 1: (59.1 mg, 0.276 mmol, 69%), (<5% rsm). Run 2: (59.8 mg, 0.279 mmol, 70%), (<5% 
rsm). Run 3: (62.6 mg, 0.292 mmol, 73%), (<5% rsm). Average: 71% yield ± 1.7, <5% rsm.  
Mn(
t
BuPc) conditions: 3-phenylpropyl sulfamate (86.5 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used. 
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Run 1: (63.0 mg, 0.294 mmol, 74%), (<5% rsm). Run 2: (65.2 mg, 0.304 mmol, 76%), (<5% 
rsm). Run 3: (61.5 mg, 0.287 mmol, 72%), (<5% rsm). Average: 74% yield ± 1.6, <5% rsm.  
Pure product was isolated as a white solid. See Section 1.4 for complete characterization. 
 
(±)-4-propyl-1,2,3-oxathiazinane 2,2-dioxide [51]. 
In all cases, material was purified via flash column chromatography on silica (35 
mm fritted glass column, 150 mm SiO2) using 3:1 hexanes/EtOAc, affording a 
mixture of product and starting material; yields were determined based on 
1
H NMR ratios. Pure 
product could be isolated as a white solid by eluting with CH2Cl2  2% Et2O/CH2Cl2. 
FePc conditions: Hexyl sulfamate (72.5 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24.0 mg, 0.040 
mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 
mmol, 2.0 equiv), and 4:1 PhMe/MeCN (800 µL, 0.5M) were used. 
Run 1: (3.7 mg, 0.021 mmol, 5%), (53.3 mg rsm, 0.294 mmol, 74%). Run 2: (3.3 mg, 0.018 
mmol, 5%), (56.2 mg rsm, 0.310 mmol, 77%). Run 3: (2.7 mg, 0.015 mmol, 4%), (55.6 mg rsm, 
0.307 mmol, 77%).  Average: 5% yield ± 0.8, 76% rsm ± 1.4. 
MnPc conditions: Hexyl sulfamate (72.5 mg, 0.400 mmol, 1.0 equiv), [MnPc]Cl (24.0 mg, 
0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used. 
Run 1: (26.1 mg, 0.146 mmol, 36%), (27.2 mg rsm, 0.150 mmol, 38%). Run 2: (29.1 mg, 0.162 
mmol, 41%), (23.9 mg rsm, 0.132 mmol, 33%). Run 3: (28.1 mg, 0.157 mmol, 39%), (23.9 mg 
rsm, 0.132 mmol, 33%).  Average: 39% yield ± 2.1, 35% rsm ± 2.4. 
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Mn(
t
BuPc) conditions: Hexyl sulfamate (72.5 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl 
(33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used. 
Run 1: (40.8 mg, 0.228 mmol, 57%), (14.5 mg rsm, 0.080 mmol, 20%). Run 2: (42.2 mg, 0.235 
mmol, 59%), (11.2 mg rsm, 0.062 mmol, 16%). Run 3: (40.1 mg, 0.224 mmol, 56%), (13.2 mg 
rsm, 0.073 mmol, 18%).  Average: 57% yield ± 1.2, 18% rsm ± 1.6. 
1
H-NMR (500 MHz, CDCl3) δ 4.74-4.66 (m, 1H), 4.52 (dt, J = 11.0, 3.3 Hz, 1H), 4.20 (br. d, J = 
10.5 Hz, 1H), 3.74-3.66 (m, 1H), 1.73-1.69 (m, 2H), 1.53-1.35 (m, 4H), 0.92 (t, J = 7.3 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 72.2, 55.9, 37.2, 29.9, 18.4, 13.7; IR (ATR, cm
-1
) 3367, 3285, 
2919, 2858, 1539, 1470, 1343, 1178, 1063, 1032, 973, 922, 850, 792, 742, 717; HRMS (ESI) m/z 
calculated for C6H14NO3S [M+H]
+
: 180.0694, found 180.0698. 
 
5,5-dimethyl-1,2,3-oxathiazinane 2,2-dioxide [52]. 
In all cases, the reaction was stirred at rt for 24h. The crude reaction mixture was 
purified via flash column chromatography on silica (35 mm fritted glass column, 150 
mm SiO2) using 15% EtOAc/hexanes  20% EtOAc/hexanes with 0.5% AcOH as eluent. 
FePc conditions: Neopentyl sulfamate (66.9 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl (24.2 mg, 
0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 
0.800 mmol, 2.0 equiv) and 4:1 PhMe/MeCN (800 μL) were used. Product and recovered 
starting material were isolated as a mixture after column purification.   
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Run 1: (2.0 mg, 0.012 mmol, 3% yield), (50.2 mg, 0.300 mmol, 75% rsm). Run 2: (2.4 mg, 0.015 
mmol, 4% yield), (48.0 mg, 0.287 mmol, 72% rsm). Run 3: (2.1 mg, 0.013 mmol, 3% yield), 
(52.2 mg, 0.312 mmol, 78% rsm). Average: 3% yield ± 0.6, 75% rsm ± 3.0. 
MnPc conditions: Neopentyl sulfamate (66.9 mg, 0.400 mmol, 1.0 equiv), [MnPc]Cl (24.2 mg, 
0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), crushed 4Å MS (100 mg), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 9:1 C6H6/MeCN (800 μL) were used. Product 
and starting material were isolated separately. 
Run 1: (24.8 mg, 0.150 mmol, 38% yield), (25.9 mg, 0.155 mmol, 39% rsm). Run 2: (22.1 mg, 
0.134 mmol, 33% yield), (27.0 mg, 0.161 mmol, 40% rsm). Run 3: (26.8 mg, 0.162 mmol, 41% 
yield), (29.5 mg, 0.176 mmol, 44% rsm). Average: 37% yield ± 4.0, 41% rsm ± 2.6. 
Mn(
t
BuPc) conditions: Neopentyl sulfamate (66.9 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl 
(33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), crushed 4Å MS 
(100 mg), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 9:1 C6H6/MeCN (800 μL) were 
used. Product and starting material were isolated separately. 
Run 1: (42.6 mg, 0.258 mmol, 64% yield), (6.0 mg, 0.036 mmol, 9% rsm). Run 2: (41.3 mg, 
0.250 mmol, 63% yield), (10.4 mg, 0.062 mmol, 16% rsm). Run 3: (42.6 mg, 0.258 mmol, 64% 
yield), (8.6 mg, 0.051 mmol, 13% rsm). Average: 64% yield ± 0.6, 13% rsm ± 3.5. 
Product was isolated as a white solid. 
1
H-NMR (500 MHz, CDCl3) δ 4.69 (br. s, 1H), 4.27 (s, 
2H), 3.27 (d, J = 7.5 Hz, 2H), 1.07 (s, 6H); 
13
C-NMR (125 MHz, CDCl3) δ 81.7, 55.4, 29.1, 
21.9; HRMS (ESI) m/z calculated for C5H12NO3S [M+H]
+
: 166.0538, found 166.0535. 
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C—H Bond Reactivity Trends 
(±)-5-methyl-1-phenylhexan-3-yl sulfamate [54]. 
Prepared according to method A. 1.600 g (8.56 mmol) of (±)-5-methyl-1-
phenylhexan-3-ol were used, along with NaH (237 mg, 9.4 mmol, 1.1 equiv), 
DMF (8.5 mL + 6.8 mL), ClSO2NCO (1.11 mL, 12.8 mmol, 1.5 equiv), formic acid (483 μL, 
12.8 mmol, 1.5 equiv) and MeCN (6.5 mL). Flash column chromatography on silica (35 mm 
fritted glass column, 150 mm SiO2) using 9:1 hexanes/EtOAc  4:1 hexanes/EtOAc as eluent 
gave 1.720 g (6.34 mmol) of pure product as a white solid (74% yield). 
1
H-NMR (500 MHz, CDCl3) δ 7.31-7.28 (m, 2H), 7.22-7.19 (m, 3H), 4.76-4.69 (m, 3H), 2.75 
(td, J = 8.5, 3.0 Hz, 2H), 2.11-2.00 (m, 2H), 1.79-1.72 (m, 2H), 1.51 (ddd, J = 16.0, 10.0, 5.5 Hz, 
1H), 0.95 (d, J = 6.0 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 141.3, 
128.6, 128.5, 126.2, 83.5, 43.3, 36.2, 31.1, 24.6, 22.9, 22.6. These data are in agreement with that 
previously reported in the literature.
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(±)-2-methyl-8-(trimethylsilyl)oct-7-yn-4-yl sulfamate [55].  
Prepared according to method B. 2.655 g (12.5 mmol) of (±)-2-methyl-8-
(trimethylsilyl)oct-7-yn-4-ol were used, along with Et3N (3.5 mL, 25 
mmol, 2.0 equiv), CH2Cl2 (13 mL + 36 mL), ClSO2NCO (2.18 mL, 25 mmol, 2.0 equiv), formic 
acid (943 μL, 25 mmol, 2.0 equiv). Flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 9:1 hexanes/EtOAc  4:1 hexanes/EtOAc as eluent gave 2.290 g 
(7.85 mmol) of pure product as a white solid (63% yield).  
1
H-NMR (500 MHz, CDCl3) δ 4.84-4.80 (m, 2H), 2.40 (t, J = 6.8 Hz, 2H), 1.92-1.88 (m, 2H), 
1.77-1.71 (m, 2H), 1.53-1.47 (m, 1H), 0.96 (d, J = 6.0 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H), 0.16 (s, 
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9H); 
13
C-NMR (125 MHz, CDCl3) δ 106.0, 86.7, 82.5, 43.6, 33.0, 24.6, 22.7, 22.6, 16.9, 0.2; IR 
(ATR, cm
-1
) 3370, 3284, 2960, 2873, 2175, 1559, 1470, 1359, 1250, 1183, 923, 844, 761; 
HRMS (ESI) m/z calculated for C12H26NO3SSi [M+H]
+
: 292.1403, found 292.1406. 
 
(±)-2-methyloctan-4-yl sulfamate [56]. 
Prepared according to method A. 1.863 g (12.9 mmol) of (±)-2-methyloctan-4-ol 
were used, along with NaH (359 mg, 14.2 mmol, 1.1 equiv), DMF (13 mL + 10 
mL), ClSO2NCO (1.69 mL, 19.4 mmol, 1.5 equiv), formic acid (731 μL, 19.4 mmol, 1.5 equiv) 
and MeCN (10 mL). Flash column chromatography on silica (45 mm fritted glass column, 170 
mm SiO2) using 9:1 hexanes/EtOAc  4:1 hexanes/EtOAc as eluent gave 2.017 g (9.03 mmol) 
of pure product as a colorless oil (70% yield). This sulfamate ester generated precipitate rapidly 
and was repurified if not used within a week. 
1
H-NMR (500 MHz, CDCl3) δ 4.75 (br. s, 2H), 4.67 (app. dq, J = 7.5, 5.5 Hz, 1H), 1.79-1.66 (m, 
4H), 1.47-1.29 (m, 5H), 0.95 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H), 0.91 (t, J = 7.0 Hz, 
3H); 
13
C-NMR (125 MHz, CDCl3) δ 84.3, 43.3, 34.3, 26.9, 24.5, 23.0, 22.7, 22.5, 14.1; HRMS 
(ESI) m/z calculated for C9H21NO3SNa [M+Na]
+
: 246.1140, found 246.1139. 
 
Tertiary C—H versus Allylic C—H [13].  
In all cases, flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) 
using 6:1 hexanes:EtOAc + 1% AcOH as eluent gave pure syn and anti oxathiazinanes 
separately; the olefin maintained a >20:1 E/Z geometry in each case. For data on [FePc]Cl and 
complete characterization of syn and anti allylic oxathiazinanes as well as 3° oxathiazinane and 
aziridine, see Section 1.4. 
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MnPc conditions: (±)-(E)-2-methylnon-7-en-4-yl sulfamate (94.0 mg, 0.400 mmol, 1.0 equiv), 
[MnPc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
μL) were used. By 1H-NMR analysis of the crude product, β:β’ was <1:20, ins./azir. was >20:1, 
and d.r. was 3:1 syn:anti.  
Run 1: (54.6 mg syn + 12.1 mg anti (4.5:1 d.r.), 0.286 mmol, 72%), <5% rsm. Run 2: (56.0 mg 
syn + 11.1 mg anti (5:1 d.r.), 0.288 mmol, 72%), <5% rsm. Run 3: (56.3 mg syn + 11.2 mg anti 
(5:1 d.r.), 0.290 mmol, 73%), <5% rsm. Average: 72% yield allylic ± 0.5 (β:β’ crude = <1:20), 
<5% rsm. 
Mn(
t
BuPc) conditions: (±)-(E)-2-methylnon-7-en-4-yl sulfamate (94.0 mg, 0.400 mmol, 1.0 
equiv), Mn(
t
BuPc)Cl (16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 
equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 
C6H6/MeCN (800 µL, 0.5M) were used. By 
1
H-NMR analysis of the crude product, β:β’ was 
<1:20, ins./azir. was >20:1, and d.r. was 4:1 syn:anti. 
Run 1: (55.0 mg syn + 13.8 mg anti (4:1 d.r.), 0.296 mmol, 74%), 0% rsm. Run 2: (51.9 mg syn 
+ 14.0 mg anti (3.7:1 d.r.), 0.284 mmol, 71%), 0% rsm. Run 3: (55.6 mg syn + 15.9 mg anti 
(3.5:1 d.r.), 0.308 mmol, 77%), 0% rsm. Average: 74% yield allylic ± 2.4 (β:β’ crude = <1:20), 
0% rsm. 
 
Tertiary C—H versus Benzylic C—H. 
In all cases, material was purified via flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using 10% EtOAc/hexanes  15% EtOAc/hexanes  20% 
EtOAc/hexanes, isolating the 3° and benzylic products and starting material separately. 
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FePc conditions: 5-methyl-1-phenylhexan-3-yl sulfamate (109 mg, 0.400 mmol, 1.0 equiv), 
[FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), and 4:1 PhMe/MeCN (800 µL, 0.5M) were used. 
By 
1
H-NMR analysis of the crude product, β:β’ was 1:14. 
Run 1: (56.2 mg benzylic, 0.208 mmol, 52%), (5.5 mg 3° (10:1 benzylic/3°), 0.020 mmol, 5%), 
(14.5 mg rsm, 0.053 mmol, 13% rsm). Run 2: (53.9 mg benzylic, 0.200 mmol, 50%), (5.7 mg 3° 
(10:1 benzylic/3°), 0.021 mmol, 5%), (12.4 mg rsm, 0.046 mmol, 11%). Run 3: (55.5 mg 
benzylic, 0.206 mmol, 51%), (5.8 mg 3° (10:1 benzylic/3°), 0.021 mmol, 5%), (13.4 mg rsm, 
0.049 mmol, 12%). Average: 51% yield benzylic ± 0.8 (β:β’ crude = 1:14), 12% rsm ± 0.8. 
MnPc conditions: 5-methyl-1-phenylhexan-3-yl sulfamate (109 mg, 0.400 mmol, 1.0 equiv), 
[MnPc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used. By 
1
H-NMR analysis of the crude product, β:β’ was 1:3. 
Run 1: (66.8 mg benzylic, 0.247 mmol, 62%), (23.0 mg 3° (2.9:1 benzylic/3°), 0.085 mmol, 
21%), 0% rsm. Run 2: (65.6 mg benzylic, 0.242 mmol, 61%), (19.9 mg 3° (2.8:1 benzylic/3°), 
0.073 mmol, 18%), 0% rsm. Run 3: (64.7 mg benzylic, 0.240 mmol, 60%), (20.5 mg 3° (2.8:1 
benzylic/3°), 0.076 mmol, 19%), 0% rsm. Average: 61% yield benzylic ± 0.8 (β:β’ crude = 
1:3), 0% rsm. 
Mn(
t
BuPc) conditions: 5-methyl-1-phenylhexan-3-yl sulfamate (109 mg, 0.400 mmol, 1.0 
equiv), [Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 
equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 
C6H6/MeCN (800 µL, 0.5M) were used. By 
1
H-NMR analysis of the crude product, β:β’ was 1:3. 
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We also found this catalyst to afford identical product ratios to [MnPc] for all other competition 
substrates. 
Run 1: (66.0 mg benzylic, 0.244 mmol, 61%), (22.8 mg 3° (2.9:1 benzylic/3°), 0.084 mmol, 
21%), 0% rsm. Run 2: (62.6 mg benzylic, 0.232 mmol, 58%), (18.0 mg 3° (2.7:1 benzylic/3°), 
0.067 mmol, 17%), 0% rsm. Run 3: (63.0 mg benzylic, 0.233 mmol, 58%), (20.7 mg 3° (2.8:1 
benzylic/3°), 0.077 mmol, 19%), 0% rsm. Average: 59% yield benzylic ± 1.4 (β:β’ crude = 
1:3), 0% rsm. 
4,4-dimethyl-6-phenethyl-1,2,3-oxathiazinane 2,2-dioxide. 
1
H-NMR (500 
MHz, CDCl3) δ 7.31 (dd, J = 12.5, 7.5 Hz, 2H), 7.23-7.19 (m, 3H), 4.84-4.82 
(m, 1H), 4.34 (br. s, 1H), 2.84 (ddd, J = 15.5, 9.5, 5.0 Hz, 1H), 2.78-2.72 (m, 1H), 2.06 (dtd, J = 
14.5, 9.0, 5.5 Hz, 1H), 1.89 (dddd, J = 13.5, 9.5, 7.5, 4.0 Hz, 1H), 1.68-1.60 (m, 2H), 1.47 (s, 
3H), 1.30 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 140.6, 128.7, 128.6, 126.4, 80.4, 56.0, 41.5, 
37.2, 31.9, 30.9, 25.2. These data agree with that previously reported in the literature.
18
 
6-isobutyl-4-phenyl-1,2,3-oxathiazinane 2,2-dioxide [57]. 
1
H-NMR (500 
MHz, CDCl3) δ 7.42-7.33 (m, 5H), 4.95 (dddd, J = 11.5, 9.0, 4.5, 2.0 Hz, 1H), 
4.81 (ddd, J = 12.0, 9.0, 3.0 Hz, 1H), 4.21 (br. d, J = 9.0 Hz, 1H), 2.04 (dt, J = 14.5, 3.0 Hz, 1H), 
1.94-1.86 (m, 2H), 1.79 (ddd, J = 9.0, 6.0 Hz, 1H), 1.44 (ddd, J = 12.5, 8.5, 4.0 Hz, 1H), 0.97 (d, 
J = 6.5 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 138.2, 129.3, 129.0, 
126.4, 83.9, 58.4, 44.3, 36.8, 23.9, 23.0, 22.0. These data agree with that previously reported in 
the literature.
18
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Tertiary C—H versus Propargylic C—H.  
In all cases, material was purified via flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using 10% EtOAc/hexanes  15% EtOAc/hexanes, isolating 
product and starting material separately. 
FePc conditions: 2-methyl-8-(trimethylsilyl)oct-7-yn-4-yl sulfamate (116.6 mg, 0.400 mmol, 
1.0 equiv), [FePc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 
equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), and 4:1 PhMe/MeCN (800 µL, 0.5M) were 
used. By 
1
H-NMR analysis of the crude product, β:β’ was 1:3. 
Run 1: (61.1 mg propargylic, 0.211 mmol, 53%), (21.7 mg 3°, 0.075 mmol, 19%), 0% rsm. Run 
2: (64.7 mg propargylic, 0.223 mmol, 56%), (23.6 mg 3°, 0.081 mmol, 20%), 0% rsm. Run 3: 
(61.7 mg propargylic, 0.213 mmol, 53%), (26.1 mg 3°, 0.090 mmol, 23%), 0% rsm. Average: 
54% yield ± 1.7 propargylic (β:β’ crude = 1:2.6), 0% rsm. 
MnPc conditions: 2-methyl-8-(trimethylsilyl)oct-7-yn-4-yl sulfamate (116.6 mg, 0.400 mmol, 
1.0 equiv), [MnPc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 
equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 
C6H6/MeCN (800 µL, 0.5M) were used. By 
1
H-NMR analysis of the crude product, β:β’ was 1:2. 
Run 1: (61.0 mg propargylic, 0.210 mmol, 53%), (34.8 mg tertiary, 0.120 mmol, 30%). Run 2: 
(69.9 mg propargylic, 0.241 mmol, 60%), (36.4 mg tertiary, 0.126 mmol, 31%). Run 3: (65.1 mg 
propargylic, 0.225 mmol, 56%), (37.9 mg tertiary, 0.131 mmol, 33%). Average: 56% yield ± 
3.5 propargylic (β:β’ crude = 1:2), 0% rsm. 
Mn(
t
BuPc) conditions: 2-methyl-8-(trimethylsilyl)oct-7-yn-4-yl sulfamate (116.6 mg, 0.400 
mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 
mmol, 0.05 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 
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9:1 C6H6/MeCN (800 µL, 0.5M) were used. By 
1
H-NMR analysis of the crude product, β:β’ was 
1:2. 
Run 1: (81.6 mg propargylic, 0.282 mmol, 70%), (30.8 mg tertiary, 0.106 mmol, 27%). Run 2: 
(78.4 mg propargylic, 0.271 mmol, 68%), (28.7 mg tertiary, 0.099 mmol, 25%). Run 3: (80.0 mg 
propargylic, 0.276 mmol, 69%), (32.5 mg tertiary, 0.112 mmol, 28%). Average: 69% yield ± 
0.8 propargylic (β:β’ crude = 1:2), 0% rsm. 
4,4-dimethyl-6-(4-(trimethylsilyl)but-3-yn-1-yl)-1,2,3-oxathiazinane 2,2-dioxide. 
1
H-NMR (500 MHz, CDCl3) δ 5.00-4.96 (m, 1H), 4.28 (br. s, 1H), 2.40 (t, 
J = 7.0 Hz, 2H), 1.99-1.92 (m, 1H), 1.84-1.77 (m, 1H), 1.70-1.59 (m, 2H), 
1.50 (s, 3H), 1.30 (s, 3H), 0.14 (s, 9H); 
13
C-NMR (125 MHz, CDCl3) δ 134.5, 123.7, 104.9, 86.3, 
79.8, 56.0, 41.2, 33.9, 31.9, 25.2, 15.6, 0.1; (ATR, cm
-1
) 3269, 2960, 1730, 1423, 1389, 1374, 
1354, 1250, 1194, 1164, 944, 908, 844, 873, 760; HRMS (ESI) m/z calculated for C12H24NO3SSi 
[M+H]
+
: 290.1246, found 290.1238. 
6-isobutyl-4-((trimethylsilyl)ethynyl)-1,2,3-oxathiazinane 2,2-dioxide [58]. 
Syn diastereomer: 
 1
H-NMR (500 MHz, CDCl3) δ 4.77 (dddd, J = 11.6, 
9.0, 4.3, 2.1 Hz, 1H), 4.50 (ddd, J = 12.0, 10.4, 3.0 Hz, 1H), 4.12 (d, J = 
10.4 Hz, 1H), 2.02 (dt, J = 14.6, 2.6 Hz, 1H), 1.90-1.81 (m, 1H), 1.82-1.66 (m, 2H), 1.38 (ddd, J 
= 14.2, 8.5, 4.4 Hz, 1H), 0.93 (dd, J = 6.5, 4.7 Hz, 3H), 0.17 (s, 9H); 
13
C-NMR (125 MHz, 
CDCl3) δ 100.4, 91.5, 82.4, 47.6, 44.1, 37.2, 23.9, 23.0, 22.1, -0.2; IR (thin film, cm
-1
): 3278, 
2960, 2873, 2182, 1470, 1422, 1371, 1296, 1251, 1189, 1097, 1059, 1015, 948, 585, 549, 529, 
515;  (ESI) m/z calculated for C12H24NO3SSi [M+H]
+
: 290.1246, found 290.1244. 
Anti diastereomer:  
1
H-NMR (500 MHz, CDCl3) δ 5.19-5.14 (m, 1H), 4.67 
(d, J = 6.0 Hz, 1H), 4.49-4.46 (m, 1H), 2.02-1.77 (m, 4H), 1.44-1.39 (m, 
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1H), 0.97 (d, J = 6.4 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 0.18 (s, 9H); 
13
C-NMR (125 MHz, 
CDCl3) δ 101.1, 91.6, 81.4, 46.1, 43.3, 35.2, 24.1, 22.7, 22.0, 0.0; (ATR, cm
-1
) 3278, 2960, 2874, 
1470, 1422, 1371, 1251, 1189, 1097, 1015, 867, 845, 791, 761; (ESI) m/z calculated for 
C12H24NO3SSi [M+H]
+
: 290.1246, found 290.1252. 
 
Tertiary C—H versus Secondary C—H.  
In all cases, material was purified via flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using 4:1 hexanes/EtOAc, isolating product and starting material 
separately. The 3
°
 + 2
°
 products could not be separated by any column conditions and were thus 
isolated as a mixture. 
FePc conditions: (±)-2-methyloctan-4-yl sulfamate (89.3 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl 
(24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), and 4:1 PhMe/MeCN (800 µL, 0.5M) were used. By 
1
H-NMR 
analysis of the crude product, β:β’ was >20:1. 
Run 1: (26.5 mg 3
°
, 0.120 mmol, 30%), (27.5 mg rsm, 0.123 mmol, 31%). Run 2: (28.3 mg 3
°
, 
0.128 mmol, 32%), (33.6 mg rsm, 0.151 mmol, 38%). Run 3: (27.1 mg 3
°
, 0.122 mmol, 31%), 
(33.4 mg rsm, 0.150 mmol, 37%). Average: 31% yield 3
°
 ± 0.8, 35% rsm ± 3.1. 
MnPc conditions: (±)-2-methyloctan-4-yl sulfamate (89.3 mg, 0.400 mmol, 1.0 equiv), 
[MnPc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used. By 
1
H-NMR analysis of the crude product, β:β’ was 5:1. 
Run 1: (55.8 mg 3
°
, 0.252 mmol, 63%), 0% rsm. Run 2: (57.2 mg 3
°
, 0.259 mmol, 65%), 0% 
rsm. Run 3: (59.0 mg 3
°
, 0.267 mmol, 67%), 0% rsm. Average: 65% yield 3
°
 ± 1.6, 0% rsm. 
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Mn(
t
BuPc) conditions: (±)-2-methyloctan-4-yl sulfamate (89.3 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.05 equiv), AgSbF6 (6.9 mg, 0.020 mmol, 0.05 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used. By 
1
H-NMR analysis of the isolated product, β:β’ was 5:1. 
Run 1: (70.6 mg 3
°
, 0.319 mmol, 80%), 0% rsm. Run 2: (71.1 mg 3
°
, 0.321 mmol, 80%), 0% 
rsm. Run 3: (74.3 mg 3
°
, 0.336 mmol, 84%), 0% rsm. Average: 81% yield 3
°
 ± 1.9, 0% rsm. 
6-butyl-4,4-dimethyl-1,2,3-oxathiazinane 2,2-dioxide [59]. Product was 
isolated as a white solid.
 1
H-NMR (500 MHz, CDCl3) δ 4.84-4.79 (m, 1H), 4.06 
(s, 1H), 1.77-1.71 (m, 1H), 1.66-1.56 (m, 3H), 1.51-1.31 (m, 4H), 1.48 (s, 3H), 1.30 (s, 3H), 0.91 
(t, J = 7.0 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 81.4, 56.0, 41.7, 35.1, 32.1, 26.8, 25.3, 22.4, 
14.0; IR (ATR, cm
-1
) 3264, 2974, 2953, 2931, 2874, 1472, 1456, 1429, 1418, 1388, 1374, 1345, 
1271, 1190, 1179, 1152, 1043, 1008, 988, 952, 890, 822, 766, 728; HRMS (ESI) m/z calculated 
for C9H19NO3SNa [M+Na]
+
: 244.0983, found 244.0982. 
 
Intramolecular Kinetic Isotope Effect Study 
Method for KIE Determination: The column-purified product mixture 22 (ca. 30 mg in 700 μL 
CDCl3) was analyzed by 
13
C-NMR (600 MHz instrument).
34,43
 Cr(acac)3 (15 mg) was added 
directly to the solution in the NMR tube immediately prior to running the NMR study; this helps 
to significantly reduce delay times needed to obtain accurate integrations. The experiment was 
run under inverse-gated decoupling conditions without sample spinning. The following 
parameters were used for the experiment, listed as Varian commands:  
temp=23 
dm=’nny’ (inverse-gated decoupling) 
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d1=5 (initial delay) 
at=0.5 (acquisition time) 
setsw(180,0) (spectral width, in ppm) 
bs=64 (block size for FID) 
nt=2944 (number of scans) 
pw=7.0 (pulse width) 
pw90=7.0 (90° pulse width) 
The KIE was reported as the area of the deuterated peak over that of the protonated peak. Three 
identical NMR experiments were run on the sample and an average value was calculated with 
error reported as a standard deviation. 
[FePc]Cl: kH/kD = 4.79 ± 0.13 (4.95, 4.63, 4.78) 
[MnPc]Cl: kH/kD = 4.46 ± 0.08 (4.57, 4.44, 4.38) 
[Mn(tBuPc)]Cl: kH/kD = 4.23 ± 0.10 (4.20, 4.13, 4.36) 
Rh2(OAc)4: kH/kD = 3.83 ± 0.10 (3.82, 3.96, 3.71) 
 
(±)-4-deuterio-4-phenyl-tetrahydro-1,2,3-oxathiazine-2,2-dioxide [22]. 
MnPc conditons: (±)-3-deuterio-3-phenylprop-1-yl sulfamate 21 (86.5 mg, 0.400 
mmol, 1.0 equiv), [MnPc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 
0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv) and 9:1 C6H6:MeCN (800 
µL) were used. Flash column chromatography on silica (35 mm fritted glass column, 150 mm 
SiO2) using 3:1 hexanes/EtOAc as eluent gave the deuterated and protonated oxathiazinanes as a 
mixture. For complete characterization of sulfamate ester and oxathiazinane, see Section 1.4. 
Run 1: (58.4 mg, 0.1273 mmol, 68%), <5% rsm. Run 2: (55.7 mg, 0.260 mmol, 65%), <5% rsm. 
Run 3: (55.1 mg, 0.257 mmol, 64%), <5% rsm. Average: 66% yield ± 1.7, <5% rsm. 
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Intermolecular Kinetic Isotope Effect Study 
(±)-4-deuterio-4-phenyl-tetrahydro-1,2,3-oxathiazine-2,2-dioxide [65]. 
3-phenylpropyl sulfamate 21 (43.1 mg, 0.200 mmol, 1.0 equiv), 3-phenylpropyl-3,3-d2 sulfamate 
21-d2 (43.5 mg, 0.200 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.10 equiv), 
AgSbF6 (6.9 mg, 0.020 mmol, 0.10 equiv), PhI(OPiv)2 (162.5 mg, 0.400 mmol, 2.0 equiv) and 
9:1 C6H6/MeCN (400 µL) were used. Flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using 3:1 hexanes/EtOAc as eluent gave the deuterated and 
protonated oxathiazinanes as a mixture. KIE value was determined as described above, with 
nt=4416. [Mn(
t
BuPc)]Cl: kH/kD = 1.62 ± 0.06 (1.56, 1.67, 1.64). 
 
Olefin Isomerization Study 
(Z)-hex-4-en-1-yl sulfamate [66]. 
Prepared according to method A. 500 mg (584 μL, 5.00 mmol) of cis-4-
hexene-1-ol were used, along with NaH (138 mg, 5.50 mmol, 1.1 equiv), 
DMF (8.9 mL), ClSO2NCO (651 μL, 7.50 mmol, 1.5 equiv), formic acid (283 μL, 7.50 mmol, 
1.5 equiv) and MeCN (3.8 mL). Flash column chromatography on silica (100 mL SiO2) using 4:1 
hexanes/EtOAc  3:1 hexanes/EtOAc as eluent gave 756 mg (4.20 mmol) of pure product as a 
colorless oil (84% yield). 
1
H-NMR (500 MHz, CDCl3) δ
 
5.56-5.49 (m, 1H), 5.38-5.32 (m, 1H), 4.79 (s, 1H), 4.22 (t, J = 
6.5 Hz, 2H), 2.20-2.15 (m, 2H), 1.82 (tt, J = 7.3, 6.6 Hz, 2H), 1.62 (ddd, J = 6.8, 1.7, 0.9 Hz, 
3H); 
13
C-NMR (125 MHz, CDCl3) δ 128.6, 125.9, 71.2, 28.8, 22.9, 13.0.  These data are in 
agreement with that previously reported in the literature.
18
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Procedure for olefin isomerization experiments: 
In all cases, crude material was purified via flash column chromatography on silica (35 mm 
fritted glass column, 120 mm SiO2) using 9:1 CH2Cl2/hexanes 19:1 CH2Cl2/hexanes as 
eluent, affording pure oxathiazinane as a white solid. 
[FePc] Conditions: (Z)-hex-4-en-1-yl sulfamate (71.7 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl 
(24.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), and 4:1 PhMe/MeCN (800 µL, 0.5M) were used. By 
1
H-NMR 
analysis of the crude product, Z/E was 10:1 (this ratio was confirmed by subjecting column-
purified Z/E mixtures of products to 
1
H-NMR analysis).  
[MnPc] Conditions: (Z)-hex-4-en-1-yl sulfamate (71.7 mg, 0.400 mmol, 1.0 equiv), [MnPcCl 
(24.1 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were 
used. By 
1
H-NMR analysis of the crude product, Z/E was 10:1 (this ratio was confirmed by 
subjecting column-purified Z/E mixtures of products to 
1
H-NMR analysis). 
[Mn(
t
BuPc)] Conditions: (Z)-hex-4-en-1-yl sulfamate (71.7 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used. By 
1
H-NMR analysis of the crude product, Z:E was 10:1 (this ratio was 
confirmed by subjecting column-purified Z/E mixtures of products to 
1
H-NMR analysis). 
(Z)-4-(prop-1-en-1-yl)-1,2,3-oxathiazinane 2,2-dioxide [49]. 
1
H-NMR (500 MHz, CDCl3) δ
 
5.77 (dqd, J = 10.8, 7.0, 1.2 Hz, 1H), 5.27 (ddq, J = 
10.1, 8.1, 1.9 Hz, 1H), 4.81 (ddd, J = 12.8, 11.7, 2.4 Hz, 1H), 4.66-4.60 (m, 1H), 4.57 
(ddd, J = 11.7, 5.0, 1.7 Hz, 1H), 4.01 (br. d, J = 9.3 Hz, 1H), 1.90 (dddd, J = 14.6, 12.8, 11.7, 5.0 
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Hz, 1H), 1.80-1.71 (m, 4H); 
13
C-NMR (125 MHz, CDCl3) δ
 
130.8, 127.1, 71.9, 52.8, 30.1, 13.8. 
These data are in agreement with that previously reported in the literature.
18
  
 
Stereoretention Study 
(+)-(R)-3-methylpentyl sulfamate [61]. 
Prepared according to method A. 1.00 mL (8.12 mmol) of (+)-(R)-3-methyl-
1-pentanol were used, along with NaH (226 mg, 8.93 mmol, 1.1 equiv), DMF 
(8 mL + 6 mL), ClSO2NCO (1.06 mL, 12.2 mmol, 1.5 equiv), formic acid (460 μL, 12.2 mmol, 
1.5 equiv) and MeCN (6 mL). Flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 3:1 hexanes/EtOAc as eluent gave 1.385 g (7.64 mmol) of pure 
product as a colorless oil (94% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.96 (br. s, 2H), 4.28-4.21 (m, 2H), 1.83-1.74 (m, 1H), 1.57-1.49 
(m, 2H), 1.41-1.33 (m, 1H), 1.20 (dp, J = 14.5, 7.0 Hz, 1H), 0.91 (d, J = 6.5 Hz, 3H), 0.88 (t, J = 
7.5 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 70.3, 35.3, 31.0, 29.4, 18.9, 11.3; [α]
25
D = +5.8
o
 (c = 
2.0, CHCl3). These data agree with that previously reported in the literature.
17a
 
 
(+)-(R)-4-ethyl-4-methyl-1,2,3-oxathiazinane 2,2-dioxide [62]. 
In all cases, material was purified via flash column chromatography on silica (35 mm fritted 
glass column, 150 mm SiO2) using CH2Cl2  2% Et2O/CH2Cl2, affording pure product (starting 
material was not collected). Enantiopurity was established by chiral GC analysis using a 
CycloSil-B column with an isocratic method at 160°C.  
Racemic product: tr (R) = 22.51 min, tr (S) = 24.35 min 
Enantioenriched product: tr (R) = 22.51 min 
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FePc conditions: (+)-(R)-3-methylpentyl sulfamate (72.5 mg, 0.400 mmol, 1.0 equiv), [FePc]Cl 
(24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv), and 4:1 PhMe/MeCN (800 µL, 0.5M) were used. By chiral GC 
analysis, product was 99% ee. 
Run 1: (14.2 mg product, 0.079 mmol, 20%). Run 2: (13.7 mg product, 0.076 mmol, 19%). Run 
3: (13.6 mg product, 0.076 mmol, 19%). Average: 19% yield ± 0.5. 
MnPc conditions: (+)-(R)-3-methylpentyl sulfamate (72.5 mg, 0.400 mmol, 1.0 equiv), 
[MnPc]Cl (24.0 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used. By chiral GC analysis, product was 99% ee. 
Run 1: (33.3 mg product, 0.186 mmol, 46%). Run 2: (36.4 mg product, 0.203 mmol, 51%). Run 
3: (34.4 mg product, 0.192 mmol, 48%).  Average: 48% yield ± 2.1. 
Mn(
t
BuPc) conditions: (+)-(R)-3-methylpentyl sulfamate (72.5 mg, 0.400 mmol, 1.0 equiv), 
[Mn(
t
BuPc)]Cl (33.2 mg, 0.040 mmol, 0.10 equiv), AgSbF6 (13.7 mg, 0.040 mmol, 0.10 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used. By chiral GC analysis, product was 99% ee. 
Run 1: (44.3 mg product, 0.247 mmol, 62%). Run 2: (43.2 mg product, 0.241 mmol, 60%). Run 
3: (40.4 mg product, 0.225 mmol, 56%).  Average: 59% yield ± 2.5. 
Pure product is isolated as a white solid. 
1
H-NMR (500 MHz, CDCl3) δ 4.77-4.63 (m, 
2H), 4.10 (br. s, 1H), 1.86 (dq, J = 14.0, 7.5 Hz, 1H), 1.79 (ddd, J = 14.5, 8.0, 4.0 Hz, 
1H), 1.71 (ddd, J = 15.0, 6.5, 4.0 Hz, 1H), 1.52 (dq, J = 14.0, 7.3 Hz, 1H), 1.37 (s, 3H), 0.97 (t, J 
= 7.3 Hz, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 69.1, 59.2, 34.4, 33.7, 24.3, 7.6; [α]
26
D = +7.6
o
 (c 
= 1.8, CHCl3). These data agree with that previously reported in the literature.
17a
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Reaction Kinetics Studies 
Procedure for reaction profile studies:  
Into a 1 dram vial was added AgSbF6 (6.8 mg, 0.020 mmol, 0.10 equiv), catalyst (0.020 mmol, 
0.10 equiv), and a stir bar in a glovebox. The vial was then sealed with a septum-lined cap, 
covered in aluminum foil, taken out of the box, and topped with a balloon of argon. Pentan-2-yl 
sulfamate 63 (33.4 mg, 0.200 mmol, 1.0 equiv) was taken up in 9:1 C6H6/MeCN (400 μL, 0.5M) 
and added via syringe, followed by internal standard (decane, 19.5 µL, 0.500 equiv). After 
stirring for 10-15 min, a 10 µL aliquot was removed (as a t0 timepoint), then PhI(OPiv)2 (325 
mg, 0.800 mmol, 2.0 equiv) was added under an inert atmosphere and reaction stirred at room 
temp (~23
o
C) for 8h. 10 µL aliquots were removed by syringe at 15 min, 30 min, 1h, 1.5h, 2h, 
3h, 4h, 6h, and 8h; aliquots were filtered through a short plug of silica (glass wool lined pipette, 
1-2 mm SiO2) with 1 mL Et2O directly into a GC vial. Yields were established by GC analysis 
based on a standard curve. Each catalyst was run in triplicate; reported values are averages of 
three runs with error bars denoting standard deviation. 
 
Procedure for Initial Rate Analysis 
5 mol% Conditions: In order to obtain accurate initial rate data, all reactions for rate analysis 
were run at room temperature and at 0.25 M concentration. To a 1 dram flame-dried borosilicate 
vial containing a Teflon stir bar was added catalyst  (0.010 mmol, 0.05 equiv) and AgSbF6 (3.4 
mg, 0.010 mmol, 0.05 equiv). Pentan-2-yl sulfamate 63 (33.4 mg, 0.2 mmol, 1.0 equiv) and 
internal standard decane (0.08 mmol, 40 mol%), were dissolved in 9:1 C6H6/MeCN (400 µL, 
0.5M) and added to the 1 dram vial. PhI(OPiv)2 (163 mg, 0.400 mmol, 2.0 equiv) was dissolved 
in 9:1 C6H6/MeCN (400 µL, 0.5M), and added directly to the reaction. The vial was then sealed 
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and placed to stir at rt. Aliquots (10 μL) were taken at the corresponding times from the reaction 
flask, and filtered through a silica pad with 600 μL of diethyl ether for GC analysis. The yield 
was determined by integration of the product peaks relative to the decane internal standard. 
Yields are reported as the average of three runs with error bars denoting standard deviation. 
 
 
10 mol% Conditions: In order to obtain accurate initial rate data, all reactions for rate 
analysis were run at room temperature and 0.25 M concentration. To a 1 dram flame-dried 
borosilicate vial containing a Teflon stir bar were added catalyst  (0.020 mmol, 0.10 equiv) and 
AgSbF6 (6.8 mg, 0.020 mmol, 0.10 equiv). Pentan-2-yl sulfamate 63 (33.4 mg, 0.2 mmol, 1.0 
equiv) and internal standard decane (0.08 mmol, 40 mol%), were dissolved in 9:1 C6H6/MeCN 
(400 µL, 0.5M) and added to the 1 dram vial. PhI(OPiv)2 (163 mg, 0.400 mmol, 2.0 equiv) was 
dissolved in 9:1 C6H6:MeCN (400 µL, 0.5M), and added directly to the reaction. The vial was 
then sealed and placed to stir at room temperature. Aliquots (10 μL) were taken at the 
corresponding times from the reaction flask, and filtered through a silica pad with 600 μL of 
diethyl ether for GC analysis. The yield was determined by integration of the product peaks 
relative to the decane internal standard. Yields are reported as the average of three runs with 
error bars denoting standard deviation. 
y = 0.0000279x + 0.0010532 
R² = 0.9987839 
0
0.005
0.01
0.015
0.02
0 100 200 300 400 500 600
[P
ro
d
u
ct
] 
Time (s) 
5 mol% [MntBuPc] 
160 
 
 
 
(±)-pentan-2-yl sulfamate [63].
 
Prepared according to method A. 1.30 g (1.63 mL, 15.0 mmol) of pentan-2-ol were 
used, along with NaH (417 mg, 16.5 mmol, 1.1 equiv), DMF (27 mL), ClSO2NCO 
(1.95 mL, 22.5 mmol, 1.5 equiv), formic acid (850 μL, 22.5 mmol, 1.5 equiv) and MeCN (11.3 
mL). Flash column chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 
4:1 hexanes/EtOAc as eluent gave 2.00 g (11.7 mmol) of pure product as a colorless oil (80% 
yield).
  
1
H-NMR (500 MHz, CDCl3) δ 4.76-4.70 (m, 3H), 1.79-1.71 (m, 1H), 1.60 (ddt, J = 13.9, 9.7, 5.8 
Hz, 1H), 1.51-1.38 (m, 1H), 1.44 (d, J = 6.2 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H); 
13
C NMR (125 
MHz, CDCl3) δ 81.7, 38.7, 20.7, 18.5, 13.9.  These data are in agreement with that previously 
reported in the literature.
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(±)-4,6-dimethyl-1,2,3-oxathiazinane 2,2-dioxide [64]. 
Syn diastereomer:  Isolated as a white sold. 
1
H-NMR (500 MHz, CDCl3) δ 4.89 
(dqd, J = 12.5, 6.3, 2.2 Hz, 1H), 3.87-3.78 (m, 1H), 3.65 (br. d, J = 10.6 Hz, 1H), 
1.84 (dt, J = 14.3, 2.5 Hz, 1H), 1.44 (d, J = 6.2 Hz, 2H), 1.38 (dt, J = 14.4, 11.8 Hz, 1H), 1.29 (d, 
y = 0.0000422x + 0.0014767 
R² = 0.9996988 
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J = 6.4 Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ 81.0, 51.2, 38.8, 21.1, 20.7. These data are in 
agreement with that previously reported in the literature.
87
  
Anti diastereomer: Isolated as a white solid with ~20% of syn diastereomer.
 1
H-
NMR (500 MHz, CDCl3) δ 5.04 (dqd, J = 9.8, 6.4, 3.3 Hz, 1H), 4.37 (d, J = 7.8 Hz, 
1H), 3.84 (dtd, J = 14.5, 7.3, 4.7 Hz, 1H), 1.87-1.78 (m, 1H), 1.71-1.66 (m, 1H), 1.50 (d, J = 6.5 
Hz, 2H), 1.46 (d, J = 7.1 Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ 78.8, 77.4, 77.2, 76.9, 49.4, 
36.0, 20.8, 19.7. These data are in agreement with that previously reported in the literature.
87  
 
Determination of Kinetic Isotope Effect via Initial Rates  
General Procedure for Initial Rate Analysis:  In order to obtain accurate initial rate data, all 
reactions for rate analysis were run at room temperature and at 0.25 M concentration. To a 1 
dram flame-dried borosilicate vial containing a Teflon stir bar was added [Mn(
t
BuPc)]Cl (0.010 
mmol, 0.05 equiv) and AgSbF6 (3.4 mg, 0.010 mmol, 0.05 equiv). 3-phenylpropyl sulfamate 21-
h2 or 3-phenylpropyl-3,3-d2 sulfamate 21-d2 (33.4 mg, 0.2 mmol, 1.0 equiv) and internal 
standard 1-fluoro-2-nitrobenzene (0.08 mmol, 40 mol%), were dissolved in 9:1 C6H6/MeCN 
(400 µL, 0.5M) and added to the 1 dram vial. PhI(OPiv)2 (163 mg, 0.400 mmol, 2.0 equiv) was 
dissolved in 9:1 C6H6/MeCN (400 µL, 0.5M), and added directly to the reaction. The vial was 
then sealed and placed to stir at rt. Aliquots (10 μL) were taken at the corresponding times from 
the reaction flask, and filtered through a silica pad with 600 μL of isopropanol for HPLC (Zorbax 
CN, 4.6 x 250 nm) analysis. The yield was determined by integration of the product peaks 
relative to the 1-fluoro-2-nitrobenzene internal standard and comparison to a standard curve. 
Yields are reported as the average of three runs with error bars denoting standard deviation.  
Initial rates were determined for formation of 22 (Figure 1).  Error for kinetic isotopes was 
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calculated via propagation of the standard error of the mean for each set of rates, with an average 
value of kH/kD= 0.0052 / 0.0030= 1.7 ± 0.1. 
 
(±)-3-phenylpropyl-3,3-d2 sulfamate [21-d2]. 
1
H-NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.5 Hz, 2H), 7.23-7.19 (m, 3H), 
4.75 (br s, 2H), 4.22 (t, J = 6.5 Hz, 2H), 2.08 (dt, J = 7.5, 7.0 Hz, 2H). 
 
 
 
Diversification of Complex Molecules 
(+)-tetrahydropicrotoxin-(3-sulfamoyloxy)-15-methyl ester [66].  
Prepared according to method B. 1.328 g (4.25 mmol) of (+)-
tetrahydropicrotoxin-(3-hydroxy)-15-methyl ester
26g
 were used, along with 
Et3N (1.48 mL, 10.6 mmol, 2.5 equiv), ClSO2NCO (923 µL, 10.6 mmol, 2.5 
equiv), formic acid (400 μL, 10.6 mmol, 2.5 equiv) and CH2Cl2 (6 mL + 6 mL). Flash column 
chromatography on silica (35 mm fritted glass column, 150 mm SiO2) using 30% 
acetone/hexanes  40% acetone/hexanes as eluent gave 590 mg (1.50 mmol) of pure product as 
a white solid (35% yield). 
y = 0.0052x + 0.6775 
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1
H-NMR (500 MHz, CDCl3) δ 4.95 (br. s, 2H), 4.80 (d, J = 3.5 Hz, 1H), 4.71 (dd, J = 10.0, 4.0 
Hz, 1H), 3.75 (s, 3H), 2.79 (d, J = 7.5 Hz, 1H), 2.65 (d, J = 12.5 Hz, 1H), 2.36 (ddd, J = 12.5, 
11.0, 2.0 Hz, 1H), 2.22 – 2.07 (m, 3H), 1.95 (td, J = 14.0, 6.5 Hz, 1H), 1.86-1.80 (m, 1H), 1.58 
(dd, J = 14.0, 5.5 Hz, 1H), 1.34 (s, 3H), 1.10 (d, J = 7.0 Hz, 3H), 1.00 (d, J = 7.0 Hz, 3H); 
13
C-
NMR (125 MHz, CDCl3) δ 179.5, 172.3, 83.2, 81.3, 78.7, 54.9, 53.1, 52.3, 52.1, 39.3, 37.7, 29.1, 
27.6, 21.3, 19.7, 16.8; IR (ATR, cm
-1
) 3254, 2960, 1760, 1720, 1566, 1438, 1371, 1236, 1015, 
965, 931, 825, 796; [α]25D = +78.1
o
 (c = 1.0, CHCl3); HRMS (ESI) m/z calculated for 
C16H26NO8S [M+H]
+
: 392.1379, found 392.1383. 
 
(+)-tetrahydropicrotoxin-3-(2,2-dioxido-1,2,3-oxathiazinan-3-yl)-15-methyl ester [67]. 
(+)-tetrahydropicrotoxin-(3-sulfamoyloxy)-15-methyl ester (78.3 mg, 0.200 
mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (16.6 mg, 0.020 mmol, 0.10 equiv), AgSbF6 
(6.9 mg, 0.020 mmol, 0.10 equiv), PhI(OPiv)2 (163 mg, 0.400 mmol, 2.0 
equiv), 50 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were used. Reaction stirred 
for 17h. Product was purified via flash column chromatography on silica (35 mm fritted glass 
column, 150 mm SiO2) using 35% acetone/hexanes. Pure product was isolated as a white solid. 
Run 1: (47.6 mg, 0.122 mmol, 61%), <10% rsm. Run 2: (44.6 mg, 0.115 mmol, 57%), <10% 
rsm. Run 3: (42.9 mg, 0.110 mmol, 55%), <10% rsm.  Average: 57% yield ± 2.1, <10% rsm. 
1
H-NMR (500 MHz, acetone-d6) δ 6.28 (s, 1H), 4.96 (dd, J = 11.5, 3.5 Hz, 1H), 4.69 (d, J = 3.5 
Hz, 1H), 4.15 (s, 1H), 3.71 (s, 3H), 2.86 (d, J = 7.5 Hz, 1H), 2.76 (d, J = 12.0 Hz, 1H), 2.31 (t, J 
= 12.0 Hz, 1H), 2.21-2.13 (m, 1H), 1.92-1.81 (m, 3H), 1.51 (s, 3H), 1.46 (s, 3H), 1.24 (s, 3H); 
13
C-NMR (125 MHz, acetone-d6) δ 179.2, 173.0, 83.8, 82.3, 79.0, 59.5, 55.3, 52.4, 52.2, 51.6, 
40.5, 38.3, 30.9, 27.8, 21.3, 19.2; IR (ATR, cm
-1
) 3582, 3190, 2954, 1777, 1711, 1443, 1397, 
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1363, 1289, 1224, 1196, 1154, 1092, 1049, 993, 975, 938, 920, 903, 865, 839, 732, 707; [α]23D = 
+66.7
o
 (c = 0.5, acetone); HRMS (ESI) m/z calculated for C16H24NO8S [M+H]
+
: 390.1223, found 
390.1218. 
 
(-)-18-hydroxy-13-methyl-17-norkauran-16-one. 
(-)-Isosteviol (2.229 g, 7.00 mmol, 1.0 equiv) was suspended in benzene (6 mL, 
~1.2M) in a 25 mL round-bottom flask equipped with stir bar. Ethylene glycol 
(429 uL, 7.70 mmol, 1.1 equiv) and p-TSA (6.1 mg, 0.035 mmol, 0.005 equiv) 
were added, then flask was fitted with a Dean-Stark trap and condenser. Reaction stirred under 
reflux for 48h. Upon completion, reaction was cooled to rt, diluted with CH2Cl2, and washed 
with H2O (5 times). The organic layer was dried over MgSO4 and concentrated in vacuo. Crude 
material was carried forward without additional purification. 
LiAlH4 (531 mg, 14.0 mmol, 2.0 equiv) was suspended in THF (35 mL) in a 250 mL multineck 
flask equipped with stir bar and reflux condenser. Isosteviol ketal from previous step was 
dissolved in remaining THF (35 mL) and added dropwise. Reaction was then heated to reflux 
and stirred 48h. Upon completion, reaction was cooled to rt, diluted with Et2O (100 mL), 
carefully quenched with dropwise addition of H2O, then poured into a 500 mL Erylenmeyer flask 
containing sat. aq. Rochelle salt solution (150 mL). Once layers became clear, material was 
extracted with 3x50 mL Et2O, then organic layer was dried over MgSO4 and concentrated in 
vacuo. The resulting residue was suspended in acetone (14 mL, 0.5M) in a 50 mL round-bottom 
flask. p-TSA (12.1 mg, 0.070 mmol, 0.01 equiv) was added, then reaction stirred for 48h at room 
temp. Upon completion, reaction was diluted with 50 mL Et2O and washed with 4x15 mL H2O. 
Organic layer was dried over MgSO4 and concentrated in vacuo. Flash column chromatography 
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on silica (35 mm fritted glass column, 150 mm SiO2) using 2:1 hexanes/EtOAc as eluent gave 
1.037 g (3.41 mmol) of pure alcohol as a white solid (49% yield over three steps). 
1
H-NMR (500 MHz, CDCl3) δ 3.74 (d, J = 11.0 Hz, 1H), 3.44 (d, J = 10.5 Hz, 1H), 2.64 (dd, J = 
18.5, 3.8 Hz, 1H), 1.82-1.73 (m, 2H), 1.71-1.61 (m, 5H), 1.57-1.48 (m, 3H), 1.43-1.20 (m, 7H), 
1.07-1.05 (m, 2H), 0.99 (s, 3H), 0.97 (s, 3H), 0.96-0.88 (m, 1H), 0.86 (s, 3H); 
13
C-NMR (125 
MHz, CDCl3) δ 222.9, 65.6, 57.0, 55.6, 54.6, 48.8 (2 peaks), 41.8, 39.6, 39.5, 38.6, 37.7, 37.5, 
35.6, 27.2, 20.4, 20.3, 20.0, 18.1, 15.6; IR (ATR, cm
-1
) 3536, 2927, 2843, 1737, 1715, 1454, 
1400, 1253, 1115, 1090, 1070, 1033, 975, 852; [α]25D = -40.7
o
 (c = 1.0, CHCl3); HRMS (ESI) 
m/z calculated for C20H33O2 [M+H]
+
: 305.2481, found 305.2479. 
 
(-)-18-sulfamoyloxy-13-methyl-17-norkauran-16-one [68]. 
Prepared according to method A. 1.037 g (3.41 mmol) of (-)-18-hydroxy-13-
methyl-17-norkauran-16-one were used, along with NaH (94.6 mg, 3.75 mmol, 
1.1 equiv), DMF (3 mL + 2 mL), ClSO2NCO (445 µL, 5.11 mmol, 1.5 equiv), 
formic acid (193 μL, 5.11 mmol, 1.5 equiv) and MeCN (2.5 mL). Flash column chromatography 
on silica (35 mm fritted glass column, 150 mm SiO2) using 2:1 hexanes/EtOAc as eluent, 
followed by recrystallization from EtOAc layered with hexanes, gave 685 mg (1.79 mmol) of 
pure product as a white solid (52% yield). 
1
H-NMR (500 MHz, CDCl3) δ 4.67 (br. s, 2H), 4.35 (d, J = 9.5 Hz, 1H), 3.97 (d, J = 9.5 Hz, 
1H), 2.63 (dd, J = 18.5, 4.0 Hz, 1H), 1.83-1.62 (m, 7H), 1.59-1.36 (m, 6H), 1.30 (dq, J = 13.0, 
3.5 Hz, 1H), 1.27-1.18 (m, 2H), 1.12 (dd, J = 12.5, 1.5 Hz, 1H), 1.09-1.02 (m, 1H), 1.04 (s, 3H), 
0.98 (s, 3H), 0.94-0.88 (m, 1H), 0.88 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 223.0, 74.3, 56.8, 
55.5, 54.4, 48.9, 48.7, 41.5, 39.5, 39.2, 37.6, 37.4, 37.3, 35.7, 27.4, 20.3 (2 peaks), 20.0, 17.9, 
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15.7; IR (film, cm
-1
) 3363, 3228, 2927, 2873, 2846, 1728, 1568, 1454, 1377, 1367, 1169, 1109, 
1092, 962, 914, 837; [α]25D = -40.9
o
 (c = 1.0, CHCl3); HRMS (ESI) m/z calculated for 
C20H34NO4S [M+H]
+
: 384.2209, found 384.2208. 
 
(-)-3,18-(2,2-dioxido-1,2,3-oxathiazinan-3-yl)-13-methyl-17-norkauran-16-one [69].  
Preparative-scale C—H amination: (-)-18-sulfamoyloxy-13-methyl-17-
norkauran-16-one (76.7 mg, 0.200 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (8.3 
mg, 0.010 mmol, 0.05 equiv), AgSbF6 (3.4 mg, 0.010 mmol, 0.05 equiv), 
PhI(OPiv)2 (325 mg, 0.800 mmol, 2.0 equiv), 100 mg crushed 4Å MS, and 9:1 C6H6/MeCN (800 
µL, 0.5M) were used. Product was purified via flash column chromatography on silica (35 mm 
fritted glass column, 150 mm SiO2) using 2:1 hexanes/EtOAc. Pure product was isolated as a 
white solid. X-ray quality crystals were obtained via diffusion crystallization from EtOAc with 
pentane. 
Run 1: (71.2 mg, 0.187 mmol, 93%), 0% rsm. Run 2: (70.4 mg, 0.185 mmol, 92%), 0% rsm. Run 
3: (70.1 mg, 0.184 mmol, 92%), 0% rsm. Average: 92% yield ± 0.5, 0% rsm. 
Reduced catalyst and oxidant loadings: (-)-18-sulfamoyloxy-13-methyl-17-norkauran-16-one 
(147 mg, 0.400 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (8.3 mg, 0.010 mmol, 0.025 equiv), AgSbF6 
(3.4 mg, 0.010 mmol, 0.025 equiv), PhI(OPiv)2 (244 mg, 0.600 mmol, 1.5 equiv), 100 mg 
crushed 4Å MS, and 9:1 C6H6/MeCN (800 µL, 0.5M) were used. Flash column chromatography 
on silica (35 mm fritted glass column, 150 mm SiO2) using 2% Et2O/CH2Cl2  5% Et2O/CH2Cl2 
 Et2O gave 116.0 mg (0.304 mmol) of pure product as a white solid (76% yield). This yield is 
identical to that obtained when the reaction is run on a larger scale (vide infra). 
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Gram-scale C—H amination: (-)-18-sulfamoyloxy-13-methyl-17-norkauran-16-one (1.00 g, 
2.61 mmol, 1.0 equiv), [Mn(
t
BuPc)]Cl (54.0 mg, 0.065 mmol, 0.025 equiv), AgSbF6 (22.1 mg, 
0.065 mmol, 0.025 equiv), PhI(OPiv)2 (1.590 mg, 3.92 mmol, 1.5 equiv), 650 mg crushed 4Å 
MS, and 9:1 C6H6/MeCN (5.2 mL, 0.5M) were used. Product was purified via flash column 
chromatography on silica (45 mm fritted glass column, 200 mm SiO2) using 5% Et2O/CH2Cl2  
Et2O. Pure product was isolated as a white solid. 
Run 1: (768 mg, 2.01 mmol, 77%), (155 mg rsm, 0.404 mmol, 16%). Run 2: (730 mg, 1.91 
mmol, 73%), (145 mg rsm, 0.378 mmol, 15%). Run 3: (738 mg, 1.93 mmol, 74%), (130 mg rsm, 
0.339 mmol, 13%).  Average: 75% yield ± 1.7, 15% rsm ± 0.9. 
1
H-NMR (500 MHz, CDCl3) δ 5.31 (d, J = 3.5 Hz, 1H), 5.02 (d, J = 11.5 Hz, 1H), 3.95 (d, J = 
12.0 Hz, 1H), 2.96 (d, J = 12.0 Hz, 1H), 2.60 (dd, J = 19.0, 3.5 Hz, 1H), 2.53 (app. q, J = 12.8 
Hz, 1H), 1.79-1.50 (m, 9H), 1.41-1.33 (m, 2H), 1.33 (s, 3H), 1.27-1.12 (m, 5H), 0.96 (s, 3H), 
0.94 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 222.2, 75.4, 63.7, 55.2, 54.9, 54.2, 48.8, 48.6, 41.1, 
39.2, 37.5, 37.1 (2 peaks), 35.8, 24.5, 23.6, 20.2, 19.9, 19.8, 15.5; IR (film, cm
-1
) 3242, 2949, 
2929, 2850, 1726, 1454, 1437, 1371, 1360, 1180, 947, 785, 773; [α]25D = -4.5
o
 (c = 1.0, CHCl3); 
HRMS (ESI) m/z calculated for C20H32NO4S [M+H]
+
: 382.2052, found 382.2055. 
 
Scheme 1 Crystal structure of (-)-(18,18-dioxido-1,2,3-oxathiazinan-3-yl)-13-methyl-17-
norkauran-16-one (69) 
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Table 10 Crystal data and structure refinement for 69. 
Identification code  cm72isa 
Empirical formula  C20 H31 N O4 S 
Formula weight  381.52 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 12.1565(17) Å  
 b = 13.8036(19) Å  
 c = 34.595(4) Å  
Volume 5805.0(13) Å3 
Z 12 
Density (calculated) 1.310 Mg/m3 
Absorption coefficient 0.192 mm-1 
F(000) 2472 
Crystal size 0.685 x 0.536 x 0.12 mm3 
Theta range for data collection 1.588 to 25.460°. 
Index ranges -14<=h<=14, -16<=k<=16, -41<=l<=27 
Reflections collected 93497 
Independent reflections 21440 [R(int) = 0.0637] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Integration 
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Table 10 (cont.) 
Max. and min. transmission 0.98024 and 0.89778 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 21440 / 38 / 1441 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0429, wR2 = 0.0996 
R indices (all data) R1 = 0.0537, wR2 = 0.1060 
Absolute structure parameter -0.01(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.472 and -0.465 e.Å-3 
 
(-)-N-benzylcarbamoyl-3,18-(2,2-dioxido-1,2,3-oxathiazinan-3-yl)-13-methyl-17-norkauran-
16-one [72]. 
(-)-3,18-(2,2-dioxido-1,2,3-oxathiazinan-3-yl)-13-methyl-17-
norkauran-16-one 69 (76.2 mg, 0.200 mmol, 1.0 equiv) was taken up 
in THF (870 µL). 4-dimethylaminopyridine (24.0 mg, 0.200 mmol, 
1.0 equiv), Et3N (557 µL, 4 mmol, 20 equiv), and benzyl chloroformate (275 µL, 1.9 mmol, 9.5 
equiv) were added and reaction was stirred for 2h. Flash column chromatography on silica (35 
mm fritted glass column, 150 mm SiO2) using 4:1 hexanes/EtOAc  2:1 hexanes/EtOAc as 
eluent gave 85.3 mg (0.170 mmol) of pure product as a white solid (83% yield).  
1
H-NMR (500 MHz, CDCl3) δ 7.44-7.42 (m, 2H), 7.37 (t, J = 7.3 Hz, 2H), 7.34-7.32 (m, 1H), 
5.33 (dd, J = 12.5, 17.5 Hz, 2H), 4.85 (d, J = 12.0 Hz, 1H), 4.13 (d, J = 11.9 Hz, 2H), 2.64 (dd, J 
= 18.5, 3.8 Hz, 1H), 2.24 (qd, J = 13.6, 13.1, 3.2 Hz, 1H), 1.83-1.54 (m, 9H), 1.404-1.39 (m, 
170 
 
2H), 1.31 (s, 3H), 1.29-1.17 (m, 4H), 1.03 (dd, J = 13.9, 3.9 Hz, 1H), 0.99 (s, 3H), 0.97 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 221.6, 152.4, 134.9, 128.8, 128.5, 127.7, 75.9, 69.5, 67.2, 55.2, 
54.6, 54.2, 48.8, 48.7, 40.9, 39.2, 38.1, 37.2, 37.1 (2 peaks), 26.9, 23.7, 20.3, 20.2, 19.9, 14.3; IR 
(thin film, cm
-1) 2935, 2852, 1736, 1456, 1392, 1290, 1174, 976, 813, 751; [α]25D = -50.7
o
 (c = 
1.2, CHCl3);  HRMS (ESI) m/z calculated for C28H38NO6S [M+H]+: 516.2420, found 516.2421. 
 
(-)-3-(benzylcarbamoyl)-18-azido-13-methyl-17-norkauran-16-one [70]. 
CBz-protected (-)-3,18-(2,2-dioxido-1,2,3-oxathiazinan-3-yl)-13-
methyl-17-norkauran-16-one 72 (103 mg, 0.200 mmol, 1.0 equiv) 
was taken up in DMF (500 µL) in a 1-dram vial. Sodium azide (26.0 
mg, 0.400 mmol, 2.0 equiv) was added, then vial was sealed with a Teflon-lined cap and reaction 
stirred at 40°C for 48h. After cooling to rt, reaction was diluted with Et2O (1.5 mL) and 10% aq. 
HCl (0.5 mL), then stirred for 30 min. This mixture was poured into brine (15 mL), then 
extracted with Et2O (3x15 mL). The combined organic layers were washed with brine and dried 
over MgSO4. Purification via flash column chromatography on silica (35 mm fritted glass 
column, 120 mm SiO2) using 4:1 hexanes/EtOAc as eluent afforded 53.3 mg (0.111 mmol) of 
product as a white solid in 56% yield. 
1
H-NMR (500 MHz, CDCl3) δ 7.36-7.29 (m, 5H), 5.68 (d, J = 9.0 Hz, 1H), 5.12 (d, J = 12.5 Hz, 
1H), 5.05 (d, J = 12.5 Hz, 1H), 3.71 (d, J = 13.0 Hz, 1H), 3.36 (ddd, J = 12.5, 8.5, 4.0 Hz, 1H), 
3.22 (d, J = 13.0 Hz, 1H), 2.59 (dd, J = 18.8, 3.8 Hz, 1H), 1.80-1.06 (m, 17H), 1.14 (s, 3H), 0.97 
(s, 3H), 0.83 (s, 3H); 
13
C-NMR (125 MHz, CDCl3) δ 222.2, 156.3, 136.8, 128.6, 128.2, 128.1, 
66.6, 59.6, 57.2, 55.4, 54.4, 54.0, 48.8, 48.5, 41.8, 41.3, 39.3, 38.3, 37.3 (2 peaks), 37.2, 25.3, 
23.6, 20.5, 20.2, 19.9, 15.8; IR (thin film, cm
-1
) 3408, 2935, 2850, 2101, 1733, 1512, 1455, 1246, 
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1072, 1047, 1016, 755; [α]25D = -28.0
o
 (c = 2.3, CHCl3); HRMS (ESI) m/z calculated for 
C28H39N4O3 [M+H]
+
: 479.3026, found 479.3022. 
 
(-)-3-(benzylcarbamoyl)-18-acetoxy-13-methyl-17-norkauran-16-one [71]. 
CBz-protected (-)-3,18-(2,2-dioxido-1,2,3-oxathiazinan-3-yl)-13-
methyl-17-norkauran-16-one 72 (103 mg, 0.200 mmol, 1.0 equiv) 
was taken up in DMF (500 µL) in a 1-dram vial. Potassium acetate 
(58.9 mg, 0.600 mmol, 3.0 equiv) was added and reaction was stirred at 80
o
 C for 48h. 
Additional KOAc (9.8 mg, 0.100 mmol, 0.5 equiv) was added at this point, then reaction 
continued to stir at 80
o
 C for 24h more. After cooling to rt, reaction was diluted with Et2O (1.5 
mL) and 10% aq. HCl (0.5 mL), then stirred for 30 min. This mixture was poured into brine (15 
mL), then extracted with Et2O (3x15 mL). The combined organic layers were washed with brine 
and dried over MgSO4. Flash column chromatography on silica (35 mm fritted glass column, 150 
mm SiO2) using 5% Et2O in DCM as eluent gave 74.9 mg (0.15 mmol) of pure product as a 
white solid (76% yield). 
1
H NMR (500 MHz, CDCl3) δ 7.35-7.28 (m, 5H), 5.33 (d, J = 9.3 Hz, 1H), 5.09 (s, 2H), 4.21-
4.09 (m, 2H), 3.39 (ddd, J = 13.0, 9.3, 4.1 Hz, 1H), 2.59 (dd, J = 18.5, 3.7 Hz, 1H), 2.01 (s, 3H), 
1.77-1.49 (m, 10H), 1.42-1.31 (m, 3H), 1.25-1.08 (m, 4H), 1.05 (s, 3H), 0.96 (s, 3H), 0.82 (s, 
3H); 
13
C NMR (126 MHz, CDCl3) δ 222.2, 170.8, 156.3, 136.9, 128.5, 128.1, 127.9, 66.5, 65.2, 
59.0, 57.2, 55.2, 54.2, 48.8, 48.5, 41.5, 41.3, 39.3, 38.4, 37.2, 37.2, 25.5, 22.7, 21.1, 20.5, 20.3, 
19.9, 15.5; IR (thin film, cm
-1
): 3445, 3349, 2936, 2850, 1737, 1520, 1455, 1399, 1375, 1317, 
1246, 1126, 1072, 1047, 1017, 754; [α]25D = -25.5
o
 (c = 1.6, CHCl3); HRMS (ESI) m/z 
calculated for C30H42NO5 [M+H]+: 496.3063, found 496.3070.  
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